

GIP/GLP1/GCG TRI-RECEPTOR AGONISTS AND USES THEREOF

Field of Invention

This disclosure relates to polypeptides having activity at each of a glucose-
5 dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and
glucagon (GCG) receptors. The polypeptides described herein have structural features that
provide appropriate activity levels and extended duration of action at each of these
receptors. Furthermore, the present invention relates to compounds that may be
administered orally or subcutaneously. Such polypeptides may be useful for treating
10 disorders or conditions such as obesity, chronic weight management, type 2 diabetes
mellitus (T2DM), dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease
(NAFLD), non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD),
osteoarthritis (OA), obesity-related sleep apnea (OSA) and/or polycystic ovary syndrome
(PCOS).

15

Background

Over the past several decades, the prevalence of diabetes has continued to rise.
T2DM is the most common form of diabetes accounting for about 90% of all diabetes.
T2DM is characterized by high blood glucose levels caused by insulin resistance. The
20 current standard of care for T2DM includes diet and exercise, as well as treatment with oral
medications and injectable glucose-lowering drugs including incretin-based therapies, such
as GLP-1 receptor agonists. A variety of GLP-1 analogs are currently available for treating
T2DM, including dulaglutide, exenatide and liraglutide. Many currently marketed GLP-1
receptor agonists, however, are dose-limited by gastrointestinal side effects, such as nausea
25 and vomiting. Subcutaneous injection is the typical route of administration for the available
GLP-1 receptor agonists. When treatment with available oral medications and incretin-
based therapies is insufficient, insulin is considered. Despite the treatment options
available, significant numbers of individuals receiving approved therapies are not reaching
glycemic control goals (*see, e.g., Casagrande et al. (2013) Diabetes Care 36:2271-2279*).
30 Uncontrolled diabetes can lead to one or more conditions that impact morbidity and
mortality of such individuals.

One of the main risk factors for T2DM is obesity, and a majority of individuals with T2DM (~90%) are overweight or obese. Obesity is a complex medical disorder resulting in excessive accumulation of adipose tissue mass. Today obesity is a global public health concern that is associated with undesired health outcomes and morbidities. Desired treatments for patients with obesity strive to reduce excess body weight, improve obesity-related co-morbidities, and maintain long-term weight reduction. Available treatments for obesity are particularly unsatisfactory for patients with severe obesity. There is a need for alternative treatment options to induce therapeutic weight loss in patients in need of such treatment.

10 In view thereof, new therapies being studied include compounds having not only activity at a GLP-1 receptor but also activity at one or more other receptors, such as the GIP and/or glucagon receptors.

For example, Int'l Patent Application Publication No. WO2013/164483 and WO2016/111971 describe polypeptides stated to have GLP-1 and GIP receptor activity. 15 WO2011/075393, WO2012/177444, and WO2016/209707 describe polypeptides stated to have GCG and GIP receptor activity.

Furthermore, certain compounds have been described as having triple agonist activity (*i.e.*, activity at each of the GIP, GLP-1 and glucagon receptors). For example, WO2015/067716 describes glucagon analogs having triple agonist activity. Similarly, 20 WO2016/198624 describes analogs of exendin-4, itself a GLP-1 analog, having triple agonist activity. Likewise, WO2014/049610 and WO2017/116204 each describe a variety of analogs having triple agonist activity. Moreover, Int'l Patent Application No. WO2017/153375 describes glucagon and GLP-1 co-agonists that also are stated to have GIP activity. Furthermore, WO2019/125938, WO2019/125929 and WO2021/126695 each 25 describe a variety of polypeptides having triple agonist activity.

Nevertheless, a need remains for compounds that are capable of providing effective glucose control with weight loss benefits and a favorable side effect profile. There is also a need for alternate treatment options to provide therapeutic weight loss or chronic weight management in a patient in need of such treatment. There also is a need for therapeutic agents available for use with sufficiently extended duration of action to allow for dosing as 30 infrequently as once a day, thrice-weekly, twice-weekly, or once a week. Furthermore, there is a desire and need for compounds that are amenable to convenient modes of

administration, such as subcutaneous or oral route. In particular, there is a desire for compounds that exhibit sufficient efficacy with a favorable side effect profile, and/or stability and bioavailability so that they can be administered orally.

5 Summary

The polypeptides described herein seek to meet one or more of the needs above. Accordingly, this disclosure describes polypeptides with activity at each of the GIP, GLP-1 and glucagon receptors. The polypeptides described herein allow for administration of doses that provide sufficient activity at each receptor to provide the benefits of agonism of that receptor while avoiding unwanted side effects associated with too much activity. Moreover, the polypeptides described herein have extended duration of action at the GIP, GLP-1 and glucagon receptors allowing for dosing as infrequently as once-a-day, thrice-weekly, twice-weekly, or once-a-week. In this manner, the polypeptides result in enhanced glucose control, metabolic benefits such as body weight lowering and/or improved body composition, lipid benefits, and/or other benefits such as an increase in bone mass or bone formation or a decrease in bone resorption. Furthermore, the polypeptides described herein are suitable for subcutaneous or oral administration. This disclosure also describes effective treatments for disorders or conditions, including obesity, chronic weight management, type 2 diabetes mellitus, NAFLD, NASH, dyslipidemia, metabolic disorder, CKD, OA, OSA and PCOS.

In one embodiment, a polypeptide is provided that includes the formula I (SEQ ID NO:4):

$X_1X_2QGT X_6TSDX_{10}X_{11}X_{12}X_{13}LDX_{16}X_{17}AX_{19}X_{20}X_{21}FX_{23}X_{24}X_{25}LX_{27}X_{28}X_{29}X_{30}$
 $X_{31}SSX_{34}X_{35}X_{36}X_{37}X_{38}X_{39}X_{40}X_{41}X_{42},$

25 wherein:

X_1 is Y, NMeY or H,

X_2 is Aib,

X_6 is F, α MeF or α MeF(2F),

X_{10} is F, 4-Pal, F(4CN), 3-Pal, F(4NO₂) or Y,

30 X_{11} is S or α MeS,

X_{12} is Orn, K, R, Q, Dap, Dab, S, E or I,

X_{13} is α MeL, I or L,

- X₁₆ is K, Orn, A or E,
X₁₇ is any amino acid with a functional group available for conjugation to a fatty acid, A, I or Q,
X₁₉ is Q or A,
5 X₂₀ is any amino acid with a functional group available for conjugation to a fatty acid, Aib, α Me-4-Pal, Q or R,
X₂₁ is A, Q, Orn, Aad, Aib, S, N, E or T,
X₂₃ is I or V,
X₂₄ is any amino acid with a functional group available for conjugation to a fatty acid, E, Q, D-Glu or N,
10 X₂₅ is W, Y, F, 4-Pal, α MeY or α Me-4-Pal,
X₂₇ is L, I, E, V, A, Q or S,
X₂₈ is any amino acid with a functional group available for conjugation to a fatty acid, E or A,
15 X₂₉ is G, D-Ala, Aib, T or A,
X₃₀ is A or G,
X₃₁ is P, H, S, 4-Pal, E, T, K(Ac) or Hyp (hydroxyproline),
X₃₄ is G or Aib,
X₃₅ is A, Aib, E, H or 4-Pal,
20 X₃₆ is P or Hyp,
X₃₇ is P, Hyp or E,
X₃₈ is P or Hyp,
X₃₉ is E, S, G, T, H, 4-Pal, γ E or A,
X₄₀ is absent or G, E, S, A or T,
25 wherein if X₄₀ is G, E, S, A or T, then X₄₁ is absent or E, S, T, 4-Pal, D, G, Q or H,
wherein if X₄₁ is E, S, T, 4-Pal, D, G, Q or H, then X₄₂ is absent or G, E or γ E,
wherein if X₄₀ is absent, then X₄₁ and X₄₂ are also absent,
30 wherein if X₄₁ is absent, then X₄₂ is also absent,
wherein at least one of X₁₇, X₂₀, X₂₄ and X₂₈ is an amino acid with a functional group available for conjugation to a fatty acid,

wherein the C-terminal amino acid is optionally amidated;
or a pharmaceutically acceptable salt thereof.

In some embodiments, the amino acid at position X_{17} , X_{20} , X_{24} or X_{28} with a functional group available for conjugation to a fatty acid is K, C, E or D. In some
5 embodiments, the amino acid at position X_{17} , X_{20} , X_{24} or X_{28} with a functional group available for conjugation to a fatty acid is K. In some embodiments, X_{10} is F or 4-Pal. In some embodiments, X_{12} is Orn, K, R or Q.

In some embodiments, only one of X_{17} , X_{20} , X_{24} and X_{28} is an amino acid with a functional group available for conjugation to a fatty acid.

10 In some embodiments, only one of X_{17} , X_{20} , X_{24} , or X_{28} is conjugated to a fatty acid, via a direct bond or via a linker between the amino acid and the fatty acid. In some embodiments, only one of X_{17} , X_{20} , X_{24} , or X_{28} is conjugated to a fatty acid via a linker between the amino acid and the fatty acid. In some embodiments, the fatty acid is a C_{16} - C_{22} fatty acid.

15 In one embodiment, a polypeptide is provided that includes the formula I' (SEQ ID NO:1243):

$X_1X_2QX_4TX_6TSDX_{10}X_{11}X_{12}X_{13}LX_{15}X_{16}X_{17}AX_{19}X_{20}X_{21}FX_{23}X_{24}X_{25}LX_{27}X_{28}X_{29}X_{30}X_{31}X_{32}SX_{34}X_{35}X_{36}X_{37}X_{38}X_{39}X_{40}X_{41}X_{42}X_{43}X_{44}X_{45}X_{46}$, wherein:

X_1 is Y, NMeY or H,
20 X_2 is Aib,
 X_4 is G or D-Ala,
 X_6 is F, α MeF or α MeF(2F),
 X_{10} is F, 4-Pal, F(4CN), 3-Pal, F(4NO₂) or Y,
 X_{11} is S or α MeS,
25 X_{12} is Orn, K, R, Q, Dap, Dab, S, E or I,
 X_{13} is α MeL, I or L,
 X_{15} is D or E,
 X_{16} is K, Orn, A or E,
 X_{17} is any amino acid with a functional group available for conjugation to a fatty
30 acid, A, I, Q or Orn,
 X_{19} is Q or A,

- X₂₀ is any amino acid with a functional group available for conjugation to a fatty acid, Aib, αMe-4-Pal, Q, R or L-Iva,
- X₂₁ is A, Q, Orn, Aad, Aib, S, N, E or T,
- X₂₃ is I or V,
- 5 X₂₄ is any amino acid with a functional group available for conjugation to a fatty acid, E, Q, D-Glu, N or D-Gln,
- X₂₅ is W, Y, F, 4-Pal, αMeY or αMe-4-Pal,
- X₂₇ is L, I, E, V, A, Q, S, T or Aad,
- X₂₈ is any amino acid with a functional group available for conjugation to a fatty
- 10 acid, E, Q or A,
- X₂₉ is G, D-Ala, Aib, T or A,
- X₃₀ is A, S or G,
- X₃₁ is P, H, S, 4-Pal, E, T, K(Ac) or Hyp (hydroxyproline),
- X₃₂ is S or P
- 15 X₃₄ is G or Aib,
- X₃₅ is A, Aib, E, D, H or 4-Pal or Orn,
- X₃₆ is P or Hyp,
- X₃₇ is P, Hyp or E,
- X₃₈ is P or Hyp,
- 20 X₃₉ is E, S, G, T, H, 4-Pal, γE or A or Orn,
- X₄₀ is absent or G, E, S, A, T, or D-Glu,
- wherein if X₄₀ is G, E, S, A, T or D-Glu, then X₄₁ is absent or A, E, S, T, 4-Pal, D, G, γE, D-Glu(e), Q or H,
- wherein if X₄₁ is A, E, S, T, 4-Pal, D, G, γE, D-Glu, Q or H, then X₄₂ is absent or
- 25 G, E, γE, D-Glu, or AEEA,
- wherein if X₄₂ is G, E, γE, D-Glu(e), or AEEA, then X₄₃ is absent or E, γE, or D-Glu,
- wherein if X₄₃ is E, γE, or D-Glu, then X₄₄ is absent or E, wherein if X₄₄ is E then X₄₅ is absent or E, wherein if X₄₅ is E then X₄₆ is absent or E,
- 30 wherein if X₄₀ is absent, then X₄₁ through X₄₆ are also absent,
- wherein if X₄₁ is absent, then X₄₂, through X₄₆ are also absent,
- wherein if X₄₂ is absent, then X₄₃ through X₄₆ are also absent,

wherein if X_{43} is absent, then X_{44} through X_{46} are also absent, wherein if X_{44} is absent, then X_{45} and X_{46} are also absent; wherein if X_{45} is absent then X_{46} is also absent,

wherein at least one of X_{17} , X_{20} , X_{24} and X_{28} is an amino acid with a functional group available for conjugation to a fatty acid,

5 wherein the C-terminal amino acid is optionally amidated; or a pharmaceutically acceptable salt thereof.

In some embodiments, the amino acid at position X_{17} , X_{20} , X_{24} or X_{28} with a functional group available for conjugation to a fatty acid is K, C, E, D or Orn. In some embodiments, the amino acid at position X_{17} , X_{20} , X_{24} or X_{28} with a functional group available for conjugation to a fatty acid is K. In some embodiments, the amino acid at position X_{17} , X_{20} , X_{24} or X_{28} with a functional group available for conjugation to a fatty acid is Orn. In some embodiments, X_{10} is F or 4-Pal. In some embodiments, X_{12} is Orn, K, R or Q.

15 In some embodiments, only one of X_{17} , X_{20} , X_{24} and X_{28} is an amino acid with a functional group available for conjugation to a fatty acid.

In some embodiments, one of X_{17} , X_{20} , X_{24} , or X_{28} is conjugated to a fatty acid, via a direct bond or via a linker between the amino acid and the fatty acid. In some embodiments, one of X_{17} , X_{20} , X_{24} , or X_{28} is conjugated to a fatty acid via a linker between the amino acid and the fatty acid. In some embodiments, the fatty acid is a C_{16} - C_{22} fatty acid.

In some embodiments, none of X_{17} , X_{20} , X_{24} , or X_{28} is conjugated to a fatty acid.

In one embodiment, a polypeptide is provided that includes the formula II (SEQ ID NO:5):

25 $YX_2QGTFTSDX_{10}SX_{12}X_{13}LDX_{16}X_{17}AQX_{20}X_{21}FIX_{24}X_{25}LX_{27}X_{28}X_{29}X_{30}X_{31}SSX_{34}$
 $X_{35}X_{36}X_{37}X_{38}X_{39}X_{40}X_{41}X_{42},$

wherein

X_2 is Aib,

X_{10} is F, 4-Pal or F(4CN),

X_{12} is Orn, K, R, Q, Dap or Dab,

30 X_{13} is α MeL,

X_{16} is K or Orn,

X₁₇ is any amino acid with a functional group available for conjugation to a fatty acid,

X₂₀ is Aib, α Me-4-Pal or Q,

X₂₁ is A, Q or Orn,

5 X₂₄ is E or Q,

X₂₅ is W, Y, 4-Pal, α MeY or α Me-4-Pal,

X₂₇ is L or I,

X₂₈ is E or A,

X₂₉ is G, D-Ala or Aib,

10 X₃₀ is A or G,

X₃₁ is P, H, S, 4-Pal, E, T, K(Ac) or Hyp,

X₃₄ is G or Aib,

X₃₅ is A, Aib, E, H or 4-Pal,

X₃₆ is P or Hyp,

15 X₃₇ is P or Hyp,

X₃₈ is P or Hyp,

X₃₉ is E, S, G, T, H, 4-Pal or γ E,

X₄₀ is absent or G, E or S,

wherein if X₄₀ is G, E or S, then X₄₁ is absent or E, S, T, 4-Pal, D, G, Q or

20 H,

wherein if X₄₁ is E, S, T, 4-Pal, D, G, Q or H, then X₄₂ is absent or G, E or γ E,

wherein if X₄₀ is absent, then X₄₁ and X₄₂ are also absent,

wherein if X₄₁ is absent, then X₄₂ is also absent,

25 wherein the C-terminal amino acid is optionally amidated;

or a pharmaceutically acceptable salt thereof.

In some embodiments of polypeptides of formula II, X₁₇ is K, C, E or D. In some embodiments, X₁₇ is K. In some embodiments, X₁₀ is F or 4-Pal. In some embodiments, X₁₂ is Orn, K, R or Q.

30 In some embodiments, X₁₇ is K and is conjugated to a fatty acid via a direct bond or via a linker between the amino acid and the fatty acid. In some embodiments, X₁₇ is K

and is conjugated to a fatty acid via a linker between the amino acid and the fatty acid. In some embodiments, the fatty acid is a C₁₆-C₂₂ fatty acid.

In some embodiments, X₁₇ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a linker between the X₁₇ amino acid and the C₁₆-C₂₂ fatty acid.

5 In one embodiment, a polypeptide is provided that includes the formula II' (SEQ ID NO:1244):

X₁X₂QGTFTSDX₁₀SX₁₂X₁₃LDX₁₆X₁₇AQX₂₀X₂₁FIX₂₄X₂₅LX₂₇X₂₈X₂₉X₃₀X₃₁SSX₃₄X₃₅X₃₆X₃₇X₃₈X₃₉X₄₀X₄₁X₄₂X₄₃X₄₄, wherein

X₁ is Y or NMeY

10 X₂ is Aib,

X₁₀ is F, 4-Pal or F(4CN),

X₁₂ is Orn, K, R, I, Q, Dap or Dab,

X₁₃ is αMeL,

X₁₆ is K or Orn,

15 X₁₇ is any amino acid with a functional group available for conjugation to a fatty acid,

X₂₀ is Aib, αMe-4-Pal, Q or L-Iva,

X₂₁ is A, Q or Orn,

X₂₄ is E or Q,

20 X₂₅ is W, Y, 4-Pal, αMeY or αMe-4-Pal,

X₂₇ is L or I,

X₂₈ is E, Q or A,

X₂₉ is G, D-Ala or Aib,

X₃₀ is A, S or G,

25 X₃₁ is P, H, S, 4-Pal, E, T, K(Ac) or Hyp,

X₃₄ is G or Aib,

X₃₅ is A, Aib, E, H or 4-Pal,

X₃₆ is P or Hyp,

X₃₇ is P or Hyp,

30 X₃₈ is P or Hyp,

X₃₉ is E, S, G, T, H, 4-Pal or γE,

X₄₀ is absent or G, E, S or D-Glu,

wherein if X_{40} is G, E, S or D-Glu, then X_{41} is absent or E, S, T, 4-Pal, D, G, Q or H,

wherein if X_{41} is E, S, T, 4-Pal, D, G, Q or H, then X_{42} is absent or G, E or γ E,

wherein if X_{42} is G, E, or γ E, then X_{43} is absent or E,

5 wherein if X_{43} is E, then X_{44} is absent or E,

wherein if X_{40} is absent, then X_{41} , X_{42} , X_{43} , and X_{44} are also absent,

wherein if X_{41} is absent, then X_{42} , X_{43} and X_{44} are also absent,

wherein if X_{43} is absent then X_{44} is also absent,

wherein the C-terminal amino acid is optionally amidated; or a pharmaceutically acceptable
10 salt thereof.

In some embodiments of polypeptides of formula II', X_{17} is K, C, E or D. In some embodiments, X_{17} is K. In some embodiments, X_{10} is F or 4-Pal. In some embodiments, X_{12} is Orn, K, R or Q.

15 In some embodiments, X_{17} is K and is conjugated to a fatty acid via a direct bond or via a linker between the amino acid and the fatty acid. In some embodiments, X_{17} is K and is conjugated to a fatty acid via a linker between the amino acid and the fatty acid. In some embodiments, the fatty acid is a C_{16} - C_{22} fatty acid.

In some embodiments, X_{17} is K and is conjugated to a C_{16} - C_{22} fatty acid via a linker between the X_{17} amino acid and the C_{16} - C_{22} fatty acid.

20 In some embodiments, none of X_{17} , X_{20} , X_{24} , or X_{28} is conjugated to a fatty acid.

In one embodiment, a polypeptide is provided that includes the formula III (SEQ ID NO:6):

$X_1X_2QGT X_6TSDX_{10}X_{11}X_{12}X_{13}LDX_{16}X_{17}AX_{19}X_{20}X_{21}FX_{23}X_{24}X_{25}LX_{27}X_{28}X_{29}GX_{31}SSX_{34}X_{35}X_{36}X_{37}X_{38}X_{39}X_{40}X_{41}$,

25 wherein

X_1 is Y, NMeY or H,

X_2 is Aib,

X_6 is F, α MeF or α MeF(2F),

X_{10} is F, 3-Pal, 4-Pal, F(4CN), F(4NO₂) or Y,

30 X_{11} is S or α MeS,

X_{12} is Orn, K, R, Q, Dap, S, E or I,

X_{13} is α MeL, I or L,

- X₁₆ is K, Orn, A or E,
X₁₇ is any amino acid with a functional group available for conjugation to a fatty acid, A, I or Q,
X₁₉ is A or Q,
5 X₂₀ is any amino acid with a functional group available for conjugation to a fatty acid Aib, Q, R or α Me-4-Pal,
X₂₁ is A, Aad, Aib, S, N, Q, E, T or Orn,
X₂₃ is I or V,
X₂₄ is any amino acid with a functional group available for conjugation to a fatty
10 acid E, D-Glu, Q or N,
X₂₅ is W, Y, F, 4-Pal, α MeY or α Me-4-Pal,
X₂₇ is L, I, E, V, A, Q or S,
X₂₈ is any amino acid with a functional group available for conjugation to a fatty acid, E or A,
15 X₂₉ is G, Aib, T, D-Ala or A,
X₃₁ is P or E,
X₃₄ is G or Aib,
X₃₅ is A or E,
X₃₆ is P,
20 X₃₇ is P or E,
X₃₈ is P,
X₃₉ is E, S, G or A,
X₄₀ is absent or G, E, S, A or T,
wherein if X₄₀ is G, E, S, A or T, then X₄₁ is absent or is E, S, D or G,
25 wherein if X₄₁ is E, S, D or G, then X₄₂ is absent or G, E or γ E,
wherein if X₄₀ is absent, then X₄₁ and X₄₂ are also absent,
wherein if X₄₁ is absent, then X₄₂ is also absent,
wherein if X₁₀ is F, 3-Pal, 4-Pal, F(4CN), F(4NO₂), then X₁₂ is I,
wherein at least one of X₁₇, X₂₀, X₂₄ or X₂₈ is an amino acid with a functional group
30 available for conjugation to a fatty acid,
wherein the C-terminal amino acid is optionally amidated;
or a pharmaceutically acceptable salt thereof.

In some embodiments of Formula III, the amino acid at position X_{17} , X_{20} , X_{24} or X_{28} with a functional group available for conjugation to a fatty acid is K, C, E or D. In some embodiments, the amino acid at position X_{17} , X_{20} , X_{24} or X_{28} with a functional group available for conjugation to a fatty acid is K. In some embodiments, X_{10} is F, 3-Pal, 4-Pal, F(4CN) or F(4NO₂) and X_{12} is I. In some embodiments, X_{10} is Y and X_{12} is Orn, K, R, Q, Dap, S, E or I.

In some embodiments, only one of X_{17} , X_{20} , X_{24} and X_{28} is an amino acid with a functional group available for conjugation to a fatty acid.

In some embodiments, only one of X_{17} , X_{20} , X_{24} , or X_{28} is conjugated to a fatty acid, via a direct bond or via a linker between the amino acid and the fatty acid. In some embodiments, only one of X_{17} , X_{20} , X_{24} , or X_{28} is conjugated to a fatty acid via a linker between the amino acid and the fatty acid. In some embodiments, the fatty acid is a C₁₆-C₂₂ fatty acid.

In some embodiments, only one of X_{17} , X_{20} , X_{24} , or X_{28} is K and is conjugated to a C₁₆-C₂₂ fatty acid via a linker between the amino acid and the C₁₆-C₂₂ fatty acid.

In one embodiment, a polypeptide is provided that includes the formula III' (SEQ ID NO:1245):

$X_1X_2QX_4TX_6TSDX_{10}X_{11}X_{12}X_{13}LX_{15}X_{16}X_{17}AX_{19}X_{20}X_{21}FX_{23}X_{24}X_{25}LX_{27}X_{28}X_{29}GX_{31}X_{32}SX_{34}X_{35}PX_{37}PX_{39}X_{40}X_{41}X_{42}X_{43}X_{44}X_{45}X_{46}$,

wherein

X_1 is Y, NMeY or H,

X_2 is Aib,

X_4 is G or D-Ala,

X_6 is F, α MeF or α MeF(2F),

X_{10} is F, 3-Pal, 4-Pal, F(4CN), F(4NO₂) or Y,

X_{11} is S or α MeS,

X_{12} is Orn, K, R, Q, Dap, S, E or I,

X_{13} is α MeL, I or L,

X_{15} is D or E,

X_{16} is K, Orn, A or E,

X_{17} is any amino acid with a functional group available for conjugation to a fatty acid, A, I or Q or Orn,

X_{19} is A or Q,

X_{20} is any amino acid with a functional group available for conjugation to a fatty acid, Aib, Q, R or α Me-4-Pal,

X_{21} is A, Aad, Aib, S, N, Q, E, T or Orn,

X_{23} is I or V, X_{24} is any amino acid with a functional group available for conjugation to a fatty acid E, D-Glu, Q, N or D-Gln,

X_{25} is W, Y, F, 4-Pal, α MeY or α Me-4-Pal,

X_{27} is L, I, E, V, A, Aad, T, Q or S,

X_{28} is any amino acid with a functional group available for conjugation to a fatty acid, E or A,

X_{29} is G, Aib, T, D-Ala or A,

X_{31} is P or E,

X_{32} is S or P,

X_{34} is G or Aib,

X_{35} is A, D or E,

X_{37} is P or E,

X_{39} is E, S, G, A, T or Orn,

X_{40} is absent or G, E, S, A or T,

wherein if X_{40} is G, E, S, A, T or D-Glu, then X_{41} is absent or is E, S, D, G, Q, T, A, γ E or D-Glu,

wherein if X_{41} is E, S, D, G, Q, T, A, γ E or D-Glu, then X_{42} is absent or G, E, D-Glu or γ E,

wherein if X_{42} is G, E, D-Glu or γ E, then X_{43} is absent or E, γ E, or D-Glu,

wherein if X_{43} is E, γ E, or D-Glu, then X_{44} is absent or E,

wherein if X_{44} is E then X_{45} is absent or E,

wherein if X_{45} is E then X_{46} is absent or E,

wherein if X_{40} is absent, then X_{41} through X_{46} are also absent,

wherein if X_{41} is absent, then X_{42} through X_{46} are also absent,

wherein if X_{42} is absent, then X_{43} through X_{46} are also absent,

wherein if X_{43} is absent, then X_{44} through X_{46} are also absent,

wherein if X_{44} is absent, then X_{45} and X_{46} are also absent,

5 wherein if X_{45} is absent then X_{46} is also absent,

wherein the polypeptide comprises at least one of the following: X_6 is α MeF or α MeF(2F); X_{10} is F, 3-Pal, 4-Pal, F(4CN) or F(4NO₂); X_{11} is α MeS; X_{13} is α MeL; X_{24} is D-Glu; and/or X_{25} is α MeY,

wherein if X_{10} is F, 3-Pal, 4-Pal, F(4CN), or F(4NO₂), then X_{12} is I,

10 and wherein at least one of X_{17} , X_{20} , X_{24} or X_{28} is an amino acid with a functional group available for conjugation to a fatty acid,

wherein the C-terminal amino acid is optionally amidated; or a pharmaceutically acceptable salt thereof.

In some embodiments of Formula III', the amino acid at position X_{17} , X_{20} , X_{24} or X_{28} with a functional group available for conjugation to a fatty acid is K, C, E, D or Orn. In some embodiments, the amino acid at position X_{17} , X_{20} , X_{24} or X_{28} with a functional group available for conjugation to a fatty acid is K. In some embodiments, the amino acid at position X_{17} , X_{20} , X_{24} or X_{28} with a functional group available for conjugation to a fatty acid is Orn. In some embodiments, X_{10} is F, 3-Pal, 4-Pal, F(4CN) or F(4NO₂) and X_{12} is I.

15 In some embodiments, X_{10} is Y and X_{12} is Orn, K, R, Q, Dap, S, E or I.

In some embodiments, only one of X_{17} , X_{20} , X_{24} and X_{28} is an amino acid with a functional group available for conjugation to a fatty acid.

In some embodiments, one of X_{17} , X_{20} , X_{24} , or X_{28} is conjugated to a fatty acid, via a direct bond or via a linker between the amino acid and the fatty acid. In some

25 embodiments, one of X_{17} , X_{20} , X_{24} , or X_{28} is conjugated to a fatty acid via a linker between the amino acid and the fatty acid. In some embodiments, the fatty acid is a C₁₆-C₂₂ fatty acid.

In some embodiments, only one of X_{17} , X_{20} , X_{24} , or X_{28} is K and is conjugated to a C₁₆-C₂₂ fatty acid via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In some

30 embodiments, none of X_{17} , X_{20} , X_{24} , or X_{28} is conjugated to a fatty acid.

In another embodiment, provided herein is a pharmaceutical composition that comprises a polypeptide described herein or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, diluent, or excipient. In some embodiments, the pharmaceutical composition is formulated for subcutaneous administration. In some embodiments, the pharmaceutical composition is formulated for oral administration.

In another embodiment, a method is provided for treating a disease or disorder including obesity, chronic weight management, type 2 diabetes mellitus, NAFLD, NASH, dyslipidemia, metabolic disorder, CKD, OA, OSA and PCOS. Another embodiment provides a method for providing non-therapeutic weight loss comprising administering to a subject in need thereof, an effective amount of a polypeptide described herein or a pharmaceutically acceptable salt thereof. Such methods can include at least a step of administering to an individual in need thereof an effective amount of a polypeptide a pharmaceutically acceptable salt thereof described herein.

In another embodiment, a polypeptide as described herein is provided for use in therapy. For example, a polypeptide as described herein is provided for use in treating a disease or disorder including obesity, chronic weight management, type 2 diabetes mellitus, NAFLD, NASH, dyslipidemia, metabolic disorder, CKD, OA, OSA and/or PCOS.

In another embodiment, there is provided the use of a polypeptide as described herein in the manufacture of a medicament for treating a disease or disorder including obesity, chronic weight management, type 2 diabetes mellitus, NAFLD, NASH, dyslipidemia, metabolic disorder, CKD, OA, OSA and/or PCOS.

Detailed Description

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of skill in the art to which the disclosure pertains. Although any methods and materials similar to or equivalent to those described herein can be used in the practice or testing of the polypeptides, pharmaceutical compositions, and methods, the preferred methods and materials are described herein.

Moreover, reference to an element by the indefinite article “a” or “an” does not exclude the possibility that more than one element is present, unless the context clearly requires that there be one and only one element. The indefinite article “a” or “an” thus usually means “at least one.”

GIP is a 42-amino acid peptide (SEQ ID NO:1) and is an incretin, which plays a physiological role in glucose homeostasis by stimulating insulin secretion from pancreatic beta cells in the presence of glucose.

5 GLP-1 is a 36-amino acid peptide and also is an incretin, which stimulates glucose-dependent insulin secretion and which has been shown to prevent hyperglycemia in diabetics. The major biologically active fragment of GLP-1 is produced as a 30-amino acid, C-terminal amidated peptide (GLP-1₇₋₃₆) (SEQ ID NO:2).

10 Glucagon is a 29-amino acid peptide (SEQ ID NO:3) that helps maintain blood glucose by binding to and activating glucagon receptors on hepatocytes, causing the liver to release glucose – stored in the form of glycogen – through a process called glycogenolysis.

In addition to T2DM, incretins and analogs thereof having activity at one or more of the GIP, GLP-1 and/or glucagon receptors have been described as having a potential for therapeutic value in a number of other conditions, diseases or disorders, including, for
15 example, obesity, NAFLD and NASH, dyslipidemia, metabolic syndrome, bone-related disorders, and neurodegenerative and/or cognitive disorders such as Alzheimer's disease and Parkinson's disease. *See, e.g., Jall et al. (2017) Mol. Metab. 6:440-446; Carbone et al. (2016) J. Gastroenterol. Hepatol. 31:23-31; Finan et al. (2016) Trends Mol. Med. 22:359-376; Choi et al. (2017) Potent body weight loss and efficacy in a NASH animal model by a novel long-acting GLP-1/Glucagon/GIP triple-agonist (HM15211), ADA Poster 1139-P; Ding (2008) J. Bone Miner. Res. 23:536-543; Tai et al. (2018) Brain Res. 1678:64-74; Müller et al. (2017) Physiol. Rev. 97:721-766; Finan et al. (2013) Sci. Transl. Med. 5:209; Hölscher (2014) Biochem. Soc. Trans. 42:593-600.*
20

As used herein, "about" means within a statistically meaningful range of a value or
25 values such as, for example, a stated concentration, length, molecular weight, pH, sequence identity, time frame, temperature or volume. Such a value or range can be within an order of magnitude typically within 20%, more typically within 10%, and even more typically within 5% of a given value or range. The allowable variation encompassed by "about" will depend upon the particular system under study, and can be readily appreciated by one of
30 skill in the art.

As used herein, and in reference to one or more of the GIP, GLP-1 or glucagon receptors, "activity," "activate," "activating" and the like means a capacity of a compound,

such as the polypeptides described herein, to bind to and induce a response at the receptor(s), as measured using assays known in the art, such as the *in vitro* assays described below.

As used herein, “amino acid with a functional group available for conjugation” means any natural (coded) or non-natural (non-coded) amino acid with a functional group that may be conjugated to fatty acid directly or by way of, for example, a linker. Examples of such functional groups include, but are not limited to, alkynyl, alkenyl, amino, azido, bromo, carboxyl, chloro, iodo, and thiol groups. Examples of natural amino acids including such functional groups include K (amino), C (thiol), E (carboxyl) and D (carboxyl).

As used herein, “conservative amino acid substitution” means substitution of an amino acid with an amino acid having similar characteristics (e.g., charge, side-chain size, hydrophobicity/hydrophilicity, backbone conformation and rigidity, etc.) and having minimal impact on the biological activity of the resulting substituted peptide or polypeptide. Conservative substitutions of functionally similar amino acids are well known in the art and thus need not be exhaustively described herein.

As used herein, “C₁₆-C₂₂ fatty acid” means a carboxylic acid having between 16 and 22 carbon atoms. The C₁₆-C₂₂ fatty acid suitable for use herein can be a saturated monoacid or a saturated diacid. As used herein, “saturated” means the fatty acid contains no carbon-carbon double or triple bonds.

As used herein, “effective amount” means an amount, concentration or dose of one or more polypeptides described herein, or a pharmaceutically acceptable salt thereof which, upon single or multiple dose administration to an individual in need thereof, provides a desired effect in such an individual under diagnosis or treatment. An effective amount can be readily determined by one of skill in the art through the use of known techniques and by observing results obtained under analogous circumstances. In determining the effective amount for an individual, a number of factors are considered including, but not limited to, the species of mammal; its size, age and general health; the specific disease or disorder involved; the degree of or involvement of or the severity of the disease or disorder; the response of the individual patient; the particular polypeptide administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.

As used herein, “extended duration of action” means that binding affinity and activity for a polypeptide continues for a period of time greater than native human GIP, GLP-1 and glucagon peptides, allowing for dosing at least as infrequently as once daily or even thrice-weekly, twice-weekly or once-weekly. The time action profile of the polypeptide may be measured using known pharmacokinetic test methods such as those
5 utilized in the examples below.

As used herein, “polypeptide” or “peptide” means a polymer of amino acid residues. The term applies to polymers comprising naturally occurring amino acids and polymers comprising one or more non-naturally occurring amino acids.

10 As used herein, “individual in need thereof” means a mammal, such as a human, with a condition, disease, disorder or symptom requiring treatment or therapy, including for example, those listed herein.

As used herein, “treat,” “treating,” “to treat” and the like mean restraining, slowing, stopping or reversing the progression or severity of an existing condition, disease, disorder
15 or symptom.

As used herein, and with reference to a polypeptide, “triple agonist activity” means a polypeptide with activity at each of the GIP, GLP-1 and glucagon receptors, especially a polypeptide having sufficient activity at each receptor to provide the benefits of agonism of that receptor while avoiding unwanted side effects associated with too much activity.
20 The polypeptides having triple agonist activity (Also referred herein as “GGG polypeptides”) have extended duration of action at the GIP, GLP-1 and glucagon receptors, which advantageously allows for dosing as infrequently as once-a-day, thrice-weekly, twice-weekly or once-a-week.

As used herein, the term “Sequence identity” refers to the degree of similarity
25 between two sequences. The degree of sequence identity between two polypeptides may be expressed as a percent, calculated as follows:

% Sequence identity = 100%*(number of identical amino acids)/(length of the shortest common sequence).

The structural features of the polypeptides described herein result in them having
30 appropriate activity at each of the GIP, GLP-1 and glucagon receptors to obtain the favorable effects of activity at each receptor (*i.e.*, triple agonist activity), but not so much activity at any one receptor to either overwhelm the activity at the other two receptors or

result in undesirable side effects when administered at a dose sufficient to result in activity at all three receptors. In some embodiments, the polypeptides described herein are partial agonists at the GLP-1 receptor showing agonism of 80% or less compared to the native GLP-1₇₋₃₆ (SEQ ID NO:2) as demonstrated by the HEK293 cell GLP-1 receptor internalization assay described herein. In other embodiments, the polypeptides described herein are full agonists at the GLP-1 receptor showing agonism of $\geq 80\%$ compared to the native GLP-1₇₋₃₆ (SEQ ID NO:2) as demonstrated by the HEK293 cell GLP-1 receptor internalization assay described herein. In some embodiments, the polypeptides described herein have greater potency at each of the glucagon, GIP and GLP-1 receptors as compared to native glucagon (SEQ ID NO:3), GIP (SEQ ID NO:1) and GLP-1₇₋₃₆ (SEQ ID NO:2).

The structural features of the polypeptides described herein also result in polypeptides having many other beneficial attributes relevant to their developability as therapeutic treatments, including for improving solubility of the analogs in near neutral pH aqueous solutions, improving chemical and physical formulation stability, improving peptide membrane permeability in the presence of a permeation enhancer, extending the pharmacokinetic profile, and minimizing potential for injection site reaction or immunogenicity.

It should be noted that the combination of beneficial characteristics of exemplary analogs described herein is not the result of any single modification in isolation but is instead achieved through the novel combinations of the structural features described herein.

Polypeptide sequences

In one embodiment, provided herein is a polypeptide that comprises formula I (SEQ ID NO:4):

X₁X₂QGTX₆TSDX₁₀X₁₁X₁₂X₁₃LDX₁₆X₁₇AX₁₉X₂₀X₂₁FX₂₃X₂₄X₂₅LX₂₇X₂₈X₂₉X₃₀
X₃₁SSX₃₄X₃₅X₃₆X₃₇X₃₈X₃₉X₄₀X₄₁X₄₂, wherein

X₁ is Y, NMeY or H,

X₂ is Aib,

X₆ is F, α MeF or α MeF(2F),

X₁₀ is F, 4-Pal, F(4CN), 3-Pal, F(4NO₂) or Y,

X₁₁ is S or α MeS,

X₁₂ is Orn, K, R, Q, Dap, Dab, S, E or I,

- X₁₃ is αMeL, I or L,
X₁₆ is K, Orn, A or E,
X₁₇ is any amino acid with a functional group available for conjugation to a fatty acid, A, I or Q,
- 5 X₁₉ is Q or A,
X₂₀ is any amino acid with a functional group available for conjugation to a fatty acid, Aib, αMe-4-pal, Q or R,
X₂₁ is A, Q, Orn, Aad, Aib, S, N, E or T,
X₂₃ is I or V,
- 10 X₂₄ is any amino acid with a functional group available for conjugation to a fatty acid, E, Q, D-Glu or N,
X₂₅ is W, Y, F, 4-Pal, αMeY or αMe-4-pal,
X₂₇ is L, I, E, V, A, Q or S,
X₂₈ is any amino acid with a functional group available for conjugation to a fatty acid, E or A,
- 15 X₂₉ is G, D-Ala, Aib, T or A,
X₃₀ is A or G,
X₃₁ is P, H, S, 4-Pal, E, T, K(Ac) or Hyp,
X₃₄ is G or Aib,
- 20 X₃₅ is A, Aib, E, H or 4-Pal,
X₃₆ is P or Hyp,
X₃₇ is P, Hyp or E,
X₃₈ is P or Hyp,
X₃₉ is E, S, G, T, H, 4-Pal, γE or A,
- 25 X₄₀ is absent or G, E, S, A or T,
wherein if X₄₀ is G, E, S, A or T, then X₄₁ is absent or E, S, T, 4-Pal, D, G, Q or H,
wherein if X₄₁ is E, S, T, 4-Pal, D, G, Q or H, then X₄₂ is absent or G, E or γE,
wherein if X₄₀ is absent, then X₄₁ and X₄₂ are also absent,
wherein if X₄₁ is absent, then X₄₂ is also absent,
- 30 wherein at least one of X₁₇, X₂₀, X₂₄ and X₂₈ is an amino acid with a functional group available for conjugation to a fatty acid,

and wherein the C-terminal amino acid is optionally amidated; or a pharmaceutically acceptable salt thereof.

If X₄₀ absent, then X₄₁ and X₄₂ are also absent and the polypeptide comprises a 39 amino acid sequence. If X₄₁ absent, then X₄₂ is also absent and the polypeptide comprises
5 a 40 amino acid sequence. If X₄₂ is absent, then the polypeptide comprises a 41 amino acid sequence. If none of X₄₀, X₄₁ and X₄₂ are absent (in other words all of X₄₀, X₄₁ and X₄₂ are present), the polypeptide comprises a 42 amino acid sequence.

In one embodiment, X₄₀ is G, E, S, A or T, X₄₁ is absent, and X₄₂ is absent. In such embodiments, the polypeptide comprises a 40 amino acid sequence. In one embodiment,
10 X₄₀ is G, E, S, A or T, X₄₁ is E, S, T, 4-Pal, D, G, Q or H, and X₄₂ is absent. In such embodiments, the polypeptide comprises a 41 amino acid sequence. In one embodiment, X₄₀ is G, E, S, A or T, X₄₁ is E, S, T, 4-Pal, D, G, Q or H, and X₄₂ is G, E or γE. In such embodiments, the polypeptide comprises a 42 amino acid sequence.

In some embodiments, polypeptides of the present invention include at position X₁₇,
15 X₂₀, X₂₄ or X₂₈ any amino acid (natural or non-natural) with a functional group available for conjugation to a fatty acid. In certain embodiments, the amino acid with a functional group available for conjugation to a fatty acid is K, C, E or D. In particularly preferred embodiments the amino acid is K and the conjugation is to the epsilon-amino group of the K side-chain.

Thus, in some embodiments, the amino acid at position X₁₇, X₂₀, X₂₄ or X₂₈ with a
20 functional group available for conjugation to a fatty acid is K, C, E or D. In some embodiments, the amino acid at position X₁₇, X₂₀, X₂₄ or X₂₈ with a functional group available for conjugation to a fatty acid is K.

In some embodiments, X₁₀ is F or 4-Pal. In some embodiments, X₁₀ is F. In some
25 embodiments, X₁₀ is 4-Pal. In some embodiments, X₁₂ is Orn, K, R or Q. In some embodiments, X₁₂ is Orn. In some embodiments, X₁₂ is K. In some embodiments, X₁₂ is R. In some embodiments, X₁₂ is Q.

In one embodiment, only one of X₁₇, X₂₀, X₂₄ and X₂₈ is an amino acid with a
functional group available for conjugation to a fatty acid. In one embodiment, the
30 conjugation is an acylation.

In some embodiments, only one of X₁₇, X₂₀, X₂₄ and X₂₈ is conjugated to a fatty acid. In some embodiments, only one of X₁₇, X₂₀, X₂₄ and X₂₈ is conjugated to a fatty acid

optionally via a linker between the amino acid and the fatty acid. Thus, in some embodiments, only one of X₁₇, X₂₀, X₂₄ and X₂₈ is conjugated to a fatty acid via a direct bond between the amino acid and the fatty acid or via a linker between the amino acid and the fatty acid. In some embodiments, the fatty acid is a C₁₆-C₂₂ fatty acid.

5 Thus, in one embodiment, X₁₇ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one embodiment, X₁₇ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In such embodiments, X₂₀ is Aib, αMe-4-pal, Q or R, X₂₄ is E, Q, D-Glu or N, and X₂₈ is E or A. In an embodiment, the conjugation is to the
10 epsilon-amino group of the K side-chain.

In one embodiment, X₂₀ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one embodiment, X₂₀ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In such embodiments, X₁₇ is A, I or Q, X₂₄ is E, Q, D-Glu or N, and
15 X₂₈ is E or A. In an embodiment, the conjugation is to the epsilon-amino group of the K side-chain.

In one embodiment, X₂₄ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one embodiment, X₂₄ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In such embodiments, X₁₇ is A, I or Q, X₂₀ is Aib, αMe-4-pal, Q or R, and X₂₈ is E or A. In an embodiment, the conjugation is to the epsilon-amino group of the K side-chain.
20

In one embodiment, X₂₈ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one embodiment, X₂₈ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In such embodiments, X₁₇ is A, I or Q, X₂₀ is Aib, αMe-4-pal, Q or R, and X₂₄ is E, Q, D-Glu or N. In an embodiment, the conjugation is to the epsilon-amino group of the K side-chain.
25

In one embodiment, provided herein is a polypeptide that comprises Formula I' (SEQ ID NO:1243):
30

X₁X₂QX₄TX₆TSDX₁₀X₁₁X₁₂X₁₃LX₁₅X₁₆X₁₇AX₁₉X₂₀X₂₁FX₂₃X₂₄X₂₅LX₂₇X₂₈X₂₉X₃₀X₃₁X₃₂SX₃₄X₃₅X₃₆X₃₇X₃₈X₃₉X₄₀X₄₁X₄₂X₄₃X₄₄X₄₅X₄₆, wherein:

- X₁ is Y, NMeY or H,
X₂ is Aib,
X₄ is G or D-Ala,
X₆ is F, αMeF or αMeF(2F),
5 X₁₀ is F, 4-Pal, F(4CN), 3-Pal, F(4NO₂) or Y,
X₁₁ is S or αMeS,
X₁₂ is Orn, K, R, Q, Dap, Dab, S, E or I,
X₁₃ is αMeL, I or L,
X₁₅ is D or E,
10 X₁₆ is K, Orn, A or E,
X₁₇ is any amino acid with a functional group available for conjugation to a fatty acid, A, I, Q or Orn,
X₁₉ is Q or A,
X₂₀ is any amino acid with a functional group available for conjugation to a fatty acid, Aib, αMe-4-Pal, Q, R or L-Iva,
15 X₂₁ is A, Q, Orn, Aad, Aib, S, N, E or T,
X₂₃ is I or V,
X₂₄ is any amino acid with a functional group available for conjugation to a fatty acid, E, Q, D-Glu, N or D-Gln,
20 X₂₅ is W, Y, F, 4-Pal, αMeY or αMe-4-Pal,
X₂₇ is L, I, E, V, A, Q, S, T or Aad,
X₂₈ is any amino acid with a functional group available for conjugation to a fatty acid, E, Q or A,
X₂₉ is G, D-Ala, Aib, T or A,
25 X₃₀ is A, S or G,
X₃₁ is P, H, S, 4-Pal, E, T, K(Ac) or Hyp (hydroxyproline),
X₃₂ is S or P
X₃₄ is G or Aib,
X₃₅ is A, Aib, E, D, H or 4-Pal or Orn,
30 X₃₆ is P or Hyp,
X₃₇ is P, Hyp or E,
X₃₈ is P or Hyp,

- X₃₉ is E, S, G, T, H, 4-Pal, γE or A or Orn,
X₄₀ is absent or G, E, S, A, T, or D-Glu,
wherein if X₄₀ is G, E, S, A or T, then X₄₁ is absent or A, E, S, T, 4-Pal, D, G, γE, D-Glu, Q or H,
- 5 wherein if X₄₁ is A, E, S, T, 4-Pal, D, G, γE, D-Glu, Q or H, then X₄₂ is absent or G, E, γE, D-Glu, or AEEA,
 wherein if X₄₂ is G, E, γE, D-Glu(e), or AEEA, then X₄₃ is absent or E, γE, or D-Glu,
 wherein if X₄₃ is E, γE, or D-Glu, then X₄₄ is absent or E, wherein if X₄₄ is E then
- 10 X₄₅ is absent or E, wherein if X₄₅ is E then X₄₆ is absent or E,
 wherein if X₄₀ is absent, then X₄₁ through X₄₆ are also absent,
 wherein if X₄₁ is absent, then X₄₂, through X₄₆ are also absent,
 wherein if X₄₂ is absent, then X₄₃ through X₄₆ are also absent,
 wherein if X₄₃ is absent, then X₄₄ through X₄₆ are also absent, wherein if X₄₄ is
- 15 absent, then X₄₅ and X₄₆ are also absent; wherein if X₄₅ is absent then X₄₆ is also absent,
 wherein at least one of X₁₇, X₂₀, X₂₄ and X₂₈ is an amino acid with a functional group available for conjugation to a fatty acid,
 wherein the C-terminal amino acid is optionally amidated; or a pharmaceutically acceptable salt thereof.
- 20 If X₄₀ absent, then X₄₁ through X₄₆ are also absent and the polypeptide comprises a 39 amino acid sequence backbone. If X₄₁ absent, then X₄₂ through X₄₆ are also absent and the polypeptide comprises a 40 amino acid sequence backbone. If X₄₂ is absent, then the polypeptide comprises a 41 amino acid sequence backbone. If X₄₃ is absent, then the polypeptide comprises a 42 amino acid sequence backbone. If X₄₄ is absent, then the
- 25 polypeptide comprises a 43 amino acid sequence backbone. If X₄₅ is absent, then the polypeptide comprises a 44 amino acid sequence backbone. If X₄₆ is absent, then the polypeptide comprises a 45 amino acid sequence backbone. If none of X₄₀ through X₄₆ are absent (in other words all of X₄₀ through X₄₆ are present), the polypeptide comprises a 46 amino acid sequence backbone.
- 30 In one embodiment, X₄₀ is G, E, S, A or T, X₄₁ is absent, and X₄₂ is absent. In such embodiments, the polypeptide comprises a 40 amino acid sequence. In one embodiment, X₄₀ is G, E, S, A or T, X₄₁ is E, S, T, 4-Pal, D, G, Q or H, and X₄₂ is absent. In such

embodiments, the polypeptide comprises a 41 amino acid sequence. In one embodiment, X₄₀ is G, E, S, A or T, X₄₁ is E, S, T, 4-Pal, D, G, Q or H, and X₄₂ is G, E or γE. In such embodiments, the polypeptide comprises a 42 amino acid sequence.

In some embodiments, polypeptides of the present invention include at position X₁₇,
5 X₂₀, X₂₄ or X₂₈ any amino acid (natural or non-natural) with a functional group available for conjugation to a fatty acid. In certain embodiments, the amino acid with a functional group available for conjugation to a fatty acid is K, C, E or D. In certain embodiments the amino acid is K, and a fatty acid is conjugated to the epsilon-amino group of the K side-chain.

10 Thus, in some embodiments, the amino acid at position X₁₇, X₂₀, X₂₄ or X₂₈ with a functional group available for conjugation to a fatty acid is K, C, E or D. In some embodiments, the amino acid at position X₁₇, X₂₀, X₂₄ or X₂₈ with a functional group available for conjugation to a fatty acid is K.

In some embodiments, X₁₀ is F or 4-Pal. In some embodiments, X₁₀ is F. In some
15 embodiments, X₁₀ is 4-Pal. In some embodiments, X₁₂ is Orn, K, R or Q. In some embodiments, X₁₂ is Orn. In some embodiments, X₁₂ is K. In some embodiments, X₁₂ is R. In some embodiments, X₁₂ is Q.

In one embodiment, only one of X₁₇, X₂₀, X₂₄ and X₂₈ is an amino acid with a functional group available for conjugation to a fatty acid. In one embodiment, the
20 conjugation is an acylation.

In some embodiments, only one of X₁₇, X₂₀, X₂₄ and X₂₈ is conjugated to a fatty acid. In some embodiments, only one of X₁₇, X₂₀, X₂₄ and X₂₈ is conjugated to a fatty acid *optionally* via a linker between the amino acid and the fatty acid. Thus, in some
25 embodiments, only one of X₁₇, X₂₀, X₂₄ and X₂₈ is conjugated to a fatty acid via a direct bond between the amino acid and the fatty acid or via a linker between the amino acid and the fatty acid. In some embodiments, the fatty acid is a C₁₆-C₂₂ fatty acid.

Thus, in one embodiment, X₁₇ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one
30 embodiment, X₁₇ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In such embodiments, X₂₀ is Aib, αMe-4-pal, Q or R, X₂₄ is E, Q, D-Glu or N, and X₂₈ is E or A. In an embodiment, the conjugation is to the epsilon-amino group of the K side-chain.

In one embodiment, X₂₀ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one embodiment, X₂₀ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In such embodiments, X₁₇ is A, I or Q, X₂₄ is E, Q, D-Glu or N, and X₂₈ is E or A. In an embodiment, the conjugation is to the epsilon-amino group of the K side-chain.

In one embodiment, X₂₄ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one embodiment, X₂₄ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In such embodiments, X₁₇ is A, I or Q, X₂₀ is Aib, αMe-4-pal, Q or R, and X₂₈ is E or A. In an embodiment, the conjugation is to the epsilon-amino group of the K side-chain.

In one embodiment, X₂₈ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one embodiment, X₂₈ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In such embodiments, X₁₇ is A, I or Q, X₂₀ is Aib, αMe-4-pal, Q or R, and X₂₄ is E, Q, D-Glu or N. In an embodiment, the conjugation is to the epsilon-amino group of the K side-chain.

In some embodiments, none of X₁₇, X₂₀, X₂₄ and X₂₈ is conjugated to a fatty acid.

In one embodiment, provided herein is a polypeptide that includes the formula II (SEQ ID NO:5):

YX₂QGTFTSDX₁₀SX₁₂X₁₃LDX₁₆X₁₇AQX₂₀X₂₁FIX₂₄X₂₅LX₂₇X₂₈X₂₉X₃₀X₃₁SSX₃₄X₃₅X₃₆X₃₇X₃₈X₃₉X₄₀X₄₁X₄₂, wherein:

X₂ is Aib,

X₁₀ is F, 4-Pal, F(4CN),

X₁₂ is Orn, K, R, Q, Dap or Dab,

X₁₃ is αMeL,

X₁₆ is K or Orn,

X₁₇ is any amino acid with a functional group available for conjugation to a fatty acid,

X₂₀ is Aib, αMe-4-pal or Q,

X₂₁ is A, Q or Orn,

- X₂₄ is E or Q,
 X₂₅ is W, Y, 4-Pal, α MeY or α Me-4-Pal,
 X₂₇ is L or I,
 X₂₈ is E or A,
 5 X₂₉ is G, D-Ala or Aib,
 X₃₀ is A or G,
 X₃₁ is P, H, S, 4-Pal, E, T, K(Ac) or Hyp,
 X₃₄ is G or Aib,
 X₃₅ is A, Aib, E, H or 4-Pal,
 10 X₃₆ is P or Hyp,
 X₃₇ is P or Hyp,
 X₃₈ is P or Hyp,
 X₃₉ is E, S, G, T, H, 4-Pal or γ E,
 X₄₀ is absent or G, E or S,
 15 wherein if X₄₀ is G, E or S, then X₄₁ is absent or E, S, T, 4-Pal, D, G, Q or H,
 wherein if X₄₁ is E, S, T, 4-Pal, D, G, Q or H, then X₄₂ is absent or G, E or γ E,
 wherein if X₄₀ is absent, then X₄₁ and X₄₂ are also absent,
 wherein if X₄₁ is absent, then X₄₂ is also absent,
 wherein the C-terminal amino acid is optionally amidated;
 20 or a pharmaceutically acceptable salt thereof.

As noted before, if X₄₀ absent, then X₄₁ and X₄₂ are also absent and the polypeptide comprises a 39 amino acid sequence. If X₄₁ absent, then X₄₂ is also absent and the polypeptide comprises a 40 amino acid sequence. If X₄₂ is absent, then the polypeptide comprises a 41 amino acid sequence. If none of X₄₀, X₄₁ and X₄₂ are absent (in other words
 25 all of X₄₀, X₄₁ and X₄₂ are present), the polypeptide comprises a 42 amino acid sequence.

In one embodiment, X₄₀ is G, E or S, X₄₁ is absent, and X₄₂ is absent. In such embodiments, the polypeptide comprises a 40 amino acid sequence. In one embodiment, X₄₀ is G, E or S, X₄₁ is E, S, T, 4-Pal, D, G, Q or H, and X₄₂ is absent. In such embodiments, the polypeptide comprises a 41 amino acid sequence. In one embodiment, X₄₀ is G, E or S,
 30 X₄₁ is E, S, T, 4-Pal, D, G, Q or H, and X₄₂ is G, E or γ E. In such embodiments, the polypeptide comprises a 42 amino acid sequence.

In some embodiments of polypeptides of formula II, the amino acid at position X₁₇ with a functional group available for conjugation to a fatty acid is K, C, E or D. In preferred embodiments, the amino acid at position X₁₇ with a functional group available for conjugation to a fatty acid is K and the conjugation is to the epsilon-amino group of the K side-chain.

In some embodiments of polypeptides of formula II, X₁₀ is F or 4-Pal. In some embodiments, X₁₀ is F. In some embodiments, X₁₀ is 4-Pal. In some embodiments, X₁₂ is Orn, K, R or Q. In some embodiments, X₁₂ is Orn. In some embodiments, X₁₂ is K. In some embodiments, X₁₂ is R. In some embodiments, X₁₂ is Q. In some embodiments, X₁₀ is F or 4-Pal and X₁₂ is Orn, K, R or Q. In some embodiments, X₁₀ is F and X₁₂ is Q. In some embodiments, X₁₀ is F and X₁₂ is Orn. In some embodiments, X₁₀ is F and X₁₂ is K. In some embodiments, X₁₀ is F and X₁₂ is R. In some embodiments, X₁₀ is 4-Pal and X₁₂ is Q. In some embodiments, X₁₀ is 4-Pal and X₁₂ is Orn. In some embodiments, X₁₀ is 4-Pal and X₁₂ is K. In some embodiments, X₁₀ is 4-Pal and X₁₂ is R.

In further embodiments, X₁₀ is selected from F or 4-Pal. In some embodiments, X₁₂ is selected from Orn, K, R or Q. In some embodiments, X₁₆ is K. In some embodiments, X₁₇ is K. In some embodiments, X₂₀ is selected from Aib or α Me-4-pal. In some embodiments, X₂₄ is E. In some embodiments, X₂₈ is selected from E or A. In some embodiments, X₃₁ is selected from P, H, S, 4-Pal, T or E. In some embodiments, X₃₅ is selected from A, Aib or E. In some embodiments, X₃₆ is P. In some embodiments, X₃₇ is P. In some embodiments, X₃₈ is P. In some embodiments, X₃₉ is selected from E, S or G. In some embodiments, X₄₀ is selected from G, E or S. In some embodiments, X₄₁ is selected from E, S, T, 4-Pal or H.

In some embodiments, X₁₀ is selected from the group consisting of F and 4-Pal. In some embodiments, X₁₂ is selected from the group consisting of Orn, K, R and Q. In some embodiments, X₁₆ is K. In some embodiments, X₁₇ is K. In some embodiments, X₂₀ is selected from the group consisting of Aib and α Me-4-pal. In some embodiments, X₂₄ is E. In some embodiments, X₂₈ is selected from the group consisting of E and A. In some embodiments, X₃₁ is selected from the group consisting of P, H, S, 4-Pal, T and E. In some embodiments, X₃₅ is selected from the group consisting of A, Aib and E. In some embodiments, X₃₆ is P. In some embodiments, X₃₇ is P. In some embodiments, X₃₈ is P. In some embodiments, X₃₉ is selected from the group consisting of E, S and G. In some

embodiments, X₄₀ is selected from the group consisting of G, E and S. In some embodiments, X₄₁ is selected from the group consisting of E, S, T, 4-Pal and H.

In some embodiments, X₁₀ is selected from F or 4-Pal; X₁₂ is Orn, K, R or Q; X₁₆ is K; X₁₇ is K; X₂₀ is selected from Aib or αMe-4-pal; X₂₄ is E; X₂₈ is selected from E or A; X₃₁ is selected from P, H, S, 4-Pal, T or E; X₃₅ is selected from A, Aib or E; X₃₆ is P; X₃₇ is P; X₃₈ is P; X₃₉ is selected from E, S or G; X₄₀ is selected from G, E or S; and X₄₁ is selected from E, S, T, 4-Pal or H.

In some embodiments, X₁₀ is selected from the group consisting of F and 4-Pal; X₁₂ is selected from the group consisting of Orn, K, R and Q; X₁₆ is K; X₁₇ is K; X₂₀ is selected from the group consisting of Aib and αMe-4-pal; X₂₄ is E; X₂₈ is selected from the group consisting of E and A; X₃₁ is selected from the group consisting of P, H, S, 4-Pal, T and E; X₃₅ is selected from the group consisting of A, Aib and E; X₃₆ is P; X₃₇ is P; X₃₈ is P; X₃₉ is selected from the group consisting of E, S and G; X₄₀ is selected from the group consisting of G, E and S; and X₄₁ is selected from the group consisting of E, S, T, 4-Pal and H.

In some embodiments, amino acid X₁₇ is conjugated to a fatty acid. In some embodiments, amino acid X₁₇ is conjugated to a fatty acid *optionally* via a linker between the amino acid and the fatty acid. Thus, in some embodiments, amino acid X₁₇ is conjugated to a fatty acid via a direct bond between the amino acid and the fatty acid or via a linker between the amino acid and the fatty acid. In some embodiments, the fatty acid is a C₁₆-C₂₂ fatty acid.

Thus, in some embodiments, X₁₇ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond between the amino acid and the C₁₆-C₂₂ fatty acid or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one embodiment, X₁₇ K is conjugated to a C₁₆-C₂₂ fatty acid via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In an embodiment, the conjugation is to the epsilon-amino group of the X₁₇ K side-chain.

In one embodiment, provided herein is a polypeptide that includes the formula II' (SEQ ID NO:1244):

X₁X₂QGTFTSDX₁₀SX₁₂X₁₃LDX₁₆X₁₇AQX₂₀X₂₁FIX₂₄X₂₅LX₂₇X₂₈X₂₉X₃₀X₃₁SSX₃₄X₃₅X₃₆X₃₇X₃₈X₃₉X₄₀X₄₁X₄₂X₄₃X₄₄, wherein

X₁ is Y or NMeY

X₂ is Aib,

- X₁₀ is F, 4-Pal or F(4CN),
X₁₂ is Orn, K, R, I, Q, Dap or Dab,
X₁₃ is α MeL,
X₁₆ is K or Orn,
5 X₁₇ is any amino acid with a functional group available for conjugation to a fatty acid,
X₂₀ is Aib, α Me-4-Pal, Q or L-Iva,
X₂₁ is A, Q or Orn,
X₂₄ is E or Q,
10 X₂₅ is W, Y, 4-Pal, α MeY or α Me-4-Pal,
X₂₇ is L or I,
X₂₈ is E, Q or A,
X₂₉ is G, D-Ala or Aib,
X₃₀ is A, S or G,
15 X₃₁ is P, H, S, 4-Pal, E, T, K(Ac) or Hyp,
X₃₄ is G or Aib,
X₃₅ is A, Aib, E, H or 4-Pal,
X₃₆ is P or Hyp,
X₃₇ is P or Hyp,
20 X₃₈ is P or Hyp,
X₃₉ is E, S, G, T, H, 4-Pal or γ E,
X₄₀ is absent or G, E, S or D-Glu,
wherein if X₄₀ is G, E, S or D-Glu, then X₄₁ is absent or E, S, T, 4-Pal, D, G, Q or H,
25 wherein if X₄₁ is E, S, T, 4-Pal, D, G, Q or H, then X₄₂ is absent or G, E or γ E,
wherein if X₄₂ is G, E, or γ E, then X₄₃ is absent or E,
wherein if X₄₃ is E, then X₄₄ is absent or E,
wherein if X₄₀ is absent, then X₄₁, X₄₂, X₄₃, and X₄₄ are also absent,
wherein if X₄₁ is absent, then X₄₂, X₄₃ and X₄₄ are also absent,
30 wherein if X₄₃ is absent then X₄₄ is also absent,
wherein the C-terminal amino acid is optionally amidated; or a pharmaceutically acceptable salt thereof.

As noted before, if X_{40} is absent, then X_{41} through X_{44} are also absent and the polypeptide comprises a 39 amino acid sequence backbone. If X_{41} is absent, then X_{42} through X_{44} are also absent and the polypeptide comprises a 40 amino acid sequence backbone. If X_{42} is absent, then X_{43} through X_{44} are also absent and the polypeptide comprises a 41 amino acid sequence backbone. If X_{43} is absent, then X_{44} is also absent and the polypeptide comprises a 42 amino acid sequence backbone. If none of X_{40} through X_{44} are absent (in other words all of X_{40} through X_{44} are present), the polypeptide comprises a 44 amino acid sequence backbone.

In one embodiment, X_{40} is G, E or S, X_{41} is absent, and X_{42} is absent. In such embodiments, the polypeptide comprises a 40 amino acid sequence. In one embodiment, X_{40} is G, E or S, X_{41} is E, S, T, 4-Pal, D, G, Q or H, and X_{42} is absent. In such embodiments, the polypeptide comprises a 41 amino acid sequence. In one embodiment, X_{40} is G, E or S, X_{41} is E, S, T, 4-Pal, D, G, Q or H, and X_{42} is G, E or γ E. In such embodiments, the polypeptide comprises a 42 amino acid sequence backbone.

In some embodiments of polypeptides of formula II', the amino acid at position X_{17} with a functional group available for conjugation to a fatty acid is K, C, E or D. In some embodiments, the amino acid at position X_{17} with a functional group available for conjugation to a fatty acid is K and the conjugation is to the epsilon-amino group of the K side-chain.

In some embodiments of polypeptides of formula II', X_{10} is F or 4-Pal. In some embodiments, X_{10} is F. In some embodiments, X_{10} is 4-Pal. In some embodiments, X_{12} is Orn, K, R or Q. In some embodiments, X_{12} is Orn. In some embodiments, X_{12} is K. In some embodiments, X_{12} is R. In some embodiments, X_{12} is Q. In some embodiments, X_{10} is F or 4-Pal and X_{12} is Orn, K, R or Q. In some embodiments, X_{10} is F and X_{12} is Q. In some embodiments, X_{10} is F and X_{12} is Orn. In some embodiments, X_{10} is F and X_{12} is K. In some embodiments, X_{10} is F and X_{12} is R. In some embodiments, X_{10} is 4-Pal and X_{12} is Q. In some embodiments, X_{10} is 4-Pal and X_{12} is Orn. In some embodiments, X_{10} is 4-Pal and X_{12} is K. In some embodiments, X_{10} is 4-Pal and X_{12} is R.

In further embodiments, X_{10} is selected from F or 4-Pal. In some embodiments, X_{12} is selected from Orn, K, R or Q. In some embodiments, X_{16} is K. In some embodiments, X_{17} is K. In some embodiments, X_{20} is selected from Aib or α Me-4-pal. In some embodiments, X_{24} is E. In some embodiments, X_{28} is selected from E or A. In some

embodiments, X₃₁ is selected from P, H, S, 4-Pal, T or E. In some embodiments, X₃₅ is selected from A, Aib or E. In some embodiments, X₃₆ is P. In some embodiments, X₃₇ is P. In some embodiments, X₃₈ is P. In some embodiments, X₃₉ is selected from E, S or G. In some embodiments, X₄₀ is selected from G, E or S. In some embodiments, X₄₁ is selected from E, S, T, 4-Pal or H.

In some embodiments, X₁₀ is selected from the group consisting of F and 4-Pal. In some embodiments, X₁₂ is selected from the group consisting of Orn, K, R and Q. In some embodiments, X₁₆ is K. In some embodiments, X₁₇ is K. In some embodiments, X₂₀ is selected from the group consisting of Aib and α Me-4-pal. In some embodiments, X₂₄ is E.

10 In some embodiments, X₂₈ is selected from the group consisting of E and A. In some embodiments, X₃₁ is selected from the group consisting of P, H, S, 4-Pal, T and E. In some embodiments, X₃₅ is selected from the group consisting of A, Aib and E. In some embodiments, X₃₆ is P. In some embodiments, X₃₇ is P. In some embodiments, X₃₈ is P. In some embodiments, X₃₉ is selected from the group consisting of E, S and G. In some

15 embodiments, X₄₀ is selected from the group consisting of G, E and S. In some embodiments, X₄₁ is selected from the group consisting of E, S, T, 4-Pal and H.

In some embodiments, X₁₀ is selected from F or 4-Pal; X₁₂ is Orn, K, R or Q; X₁₆ is K; X₁₇ is K; X₂₀ is selected from Aib or α Me-4-pal; X₂₄ is E; X₂₈ is selected from E or A; X₃₁ is selected from P, H, S, 4-Pal, T or E; X₃₅ is selected from A, Aib or E; X₃₆ is P; X₃₇ is P; X₃₈ is P; X₃₉ is selected from E, S or G; X₄₀ is selected from G, E or S; and X₄₁ is selected from E, S, T, 4-Pal or H.

In some embodiments, X₁₀ is selected from the group consisting of F and 4-Pal; X₁₂ is selected from the group consisting of Orn, K, R and Q; X₁₆ is K; X₁₇ is K; X₂₀ is selected from the group consisting of Aib and α Me-4-pal; X₂₄ is E; X₂₈ is selected from the group consisting of E and A; X₃₁ is selected from the group consisting of P, H, S, 4-Pal, T and E; X₃₅ is selected from the group consisting of A, Aib and E; X₃₆ is P; X₃₇ is P; X₃₈ is P; X₃₉ is selected from the group consisting of E, S and G; X₄₀ is selected from the group consisting of G, E and S; and X₄₁ is selected from the group consisting of E, S, T, 4-Pal and H.

30 In some embodiments, amino acid X₁₇ is conjugated to a fatty acid. In some embodiments, amino acid X₁₇ is conjugated to a fatty acid *optionally* via a linker between the amino acid and the fatty acid. Thus, in some embodiments, amino acid X₁₇ is conjugated

to a fatty acid via a direct bond between the amino acid and the fatty acid or via a linker between the amino acid and the fatty acid. In some embodiments, the fatty acid is a C₁₆-C₂₂ fatty acid.

Thus, in some embodiments, X₁₇ is K and is conjugated to a C₁₆-C₂₂ fatty acid via
5 a direct bond between the amino acid and the C₁₆-C₂₂ fatty acid or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one embodiment, X₁₇ K is conjugated to a C₁₆-C₂₂ fatty acid via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In an embodiment, the conjugation is to the epsilon-amino group of the X₁₇ K side-chain.

In one embodiment, provided herein is a polypeptide that includes the formula III
10 (SEQ ID NO:6):

YX₂QGTFTSDX₁₀SX₁₂X₁₃LDX₁₆X₁₇AQX₂₀X₂₁FIX₂₄X₂₅LX₂₇X₂₈X₂₉X₃₀X₃₁SSX₃₄
X₃₅X₃₆X₃₇X₃₈X₃₉X₄₀X₄₁, wherein

X₁ is Y, NMeY or H,

X₂ is Aib,

15 X₆ is F, αMeF or αMeF(2F),

X₁₀ is F, 3-Pal, 4-Pal, F(4CN), F(4NO₂) or Y,

X₁₁ is S or αMeS,

X₁₂ is Orn, K, R, Q, Dap, S, E or I,

X₁₃ is αMeL, I or L,

20 X₁₆ is K, Orn, A or E,

X₁₇ is any amino acid with a functional group available for conjugation to a fatty acid, A, I or Q,

X₁₉ is A or Q,

25 X₂₀ is any amino acid with a functional group available for conjugation to a fatty acid Aib, Q, R or αMe-4-pal,

X₂₁ is A, Aad, Aib, S, N, Q, E, T or Orn,

X₂₃ is I or V,

X₂₄ is any amino acid with a functional group available for conjugation to a fatty acid E, D-Glu, Q or N,

30 X₂₅ is W, Y, F, 4-Pal, αMeY or αMe-4-pal,

X₂₇ is L, I, E, V, A, Q or S,

X₂₈ is any amino acid with a functional group available for conjugation to a fatty acid, E or A,

X₂₉ is G, Aib, T, D-Ala or A,

X₃₁ is P or E,

5 X₃₄ is G or Aib,

X₃₅ is A or E,

X₃₆ is P,

X₃₇ is P or E,

X₃₈ is P,

10 X₃₉ is E, S, G or A,

X₄₀ is absent or G, E, S, A or T,

wherein if X₄₀ is G, E, S, A or T, then X₄₁ is absent or is E, S, D or G,

wherein if X₄₁ is E, S, D or G, then X₄₂ is absent or G, E or γE,

wherein if X₄₀ is absent, then X₄₁ and X₄₂ are also absent,

15 wherein if X₄₁ is absent, then X₄₂ is also absent, wherein if X₁₀ is F, 3-Pal, 4-Pal, F(4CN), F(4NO₂), then X₁₂ is I and

wherein at least one of X₁₇, X₂₀, X₂₄ or X₂₈ is any amino acid with a functional group available for conjugation to a C₁₆-C₂₂ fatty acid,

wherein the C-terminal amino acid is optionally amidated;

20 or a pharmaceutically acceptable salt thereof.

As noted before, if X₄₀ absent, then X₄₁ and X₄₂ are also absent and the polypeptide comprises a 39 amino acid sequence. If X₄₁ absent, then X₄₂ is also absent and the polypeptide comprises a 40 amino acid sequence. If X₄₂ is absent, then the polypeptide comprises a 41 amino acid sequence. If none of X₄₀, X₄₁ and X₄₂ are absent (in other words
25 all of X₄₀, X₄₁ and X₄₂ are present), the polypeptide comprises a 42 amino acid sequence.

In one embodiment, X₄₀ is G, E, S, A, or T, and X₄₁ is absent. In such embodiment, the polypeptide comprises a 40 amino acid sequence. In one embodiment, X₄₀ is G, E, S, A or T, X₄₁ is E, S, D or G. In such embodiment, the polypeptide comprises a 41 amino acid sequence. In one embodiment, X₄₀ is G, E, S, A or T, X₄₁ is E, S, D or G, and X₄₂ is
30 G, E or γE. In such embodiment, the polypeptide comprises a 42 amino acid sequence.

In some embodiments of polypeptides of formula III, the amino acid at position X₁₇, X₂₀, X₂₄ or X₂₈ with a functional group available for conjugation to a fatty acid is K, C, E

or D. In some embodiments, the amino acid at position X_{17} , X_{20} , X_{24} or X_{28} with a functional group available for conjugation to a fatty acid is K and the conjugation is to the epsilon-amino group of the K side-chain.

In some embodiments, X_{10} is F, 3-Pal, 4-Pal, F(4CN) or F(4NO₂) and X_{12} is I. In
5 some embodiments of the polypeptide of formula III, X_{10} is Y and X_{12} is Orn, K, R, Q, Dap, S, E or I.

In some embodiments, only one of X_{17} , X_{20} , X_{24} and X_{28} is an amino acid with a functional group available for conjugation to a C₁₆-C₂₂ fatty acid.

In some embodiments, only one of X_{17} , X_{20} , X_{24} and X_{28} is conjugated to a fatty
10 acid *optionally* via a linker between the amino acid and the fatty acid. Thus, in some embodiments, only one of X_{17} , X_{20} , X_{24} and X_{28} is conjugated to a fatty acid via a direct bond between the amino acid and the fatty acid or via a linker between the amino acid and the fatty acid. In one embodiment, only one of X_{17} , X_{20} , X_{24} and X_{28} is conjugated to a fatty acid via a linker between the amino acid and the fatty acid. In some embodiments, the fatty
15 acid is a C₁₆-C₂₂ fatty acid.

Thus, in one embodiment, X_{17} is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one embodiment, X_{17} is K and is conjugated to a C₁₆-C₂₂ fatty acid via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In such embodiments, X_{20} is Aib, α Me-4-pal, Q or
20 R, X_{24} is E, Q, D-Glu or N, and X_{28} is E or A. In an embodiment, the conjugation is to the epsilon-amino group of the K side-chain.

In one embodiment, X_{20} is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one embodiment, X_{20} is K and is conjugated to a C₁₆-C₂₂ fatty acid via linker between the amino acid and the
25 C₁₆-C₂₂ fatty acid. In such embodiments, X_{17} is A, I or Q, X_{24} is E, Q, D-Glu or N, and X_{28} is E or A. In an embodiment, the conjugation is to the epsilon-amino group of the K side-chain.

In one embodiment, X_{24} is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one embodiment,
30 X_{24} is K and is conjugated to a C₁₆-C₂₂ fatty acid via linker between the amino acid and the C₁₆-C₂₂ fatty acid. In such embodiments, X_{17} is A, I or Q, X_{20} is Aib, α Me-4-pal, Q or R,

and X₂₈ is E or A. In an embodiment, the conjugation is to the epsilon-amino group of the K side-chain.

In one embodiment, X₂₈ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one embodiment,
 5 X₂₈ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In such embodiments, X₁₇ is A, I or Q, X₂₀ is Aib, αMe-4-pal, Q or R, and X₂₄ is E, Q, D-Glu or N. In an embodiment, the conjugation is to the epsilon-amino group of the K side-chain.

In one embodiment, provided herein is a polypeptide that includes the formula III'
 10 (SEQ ID NO:1245):

X₁X₂QX₄TX₆TSDX₁₀X₁₁X₁₂X₁₃LX₁₅X₁₆X₁₇AX₁₉X₂₀X₂₁FX₂₃X₂₄X₂₅LX₂₇X₂₈X₂₉G
 X₃₁X₃₂SX₃₄X₃₅PX₃₇PX₃₉X₄₀X₄₁X₄₂X₄₃X₄₄X₄₅X₄₆,

wherein

- X₁ is Y, NMeY or H,
 15 X₂ is Aib,
 X₄ is G or D-Ala,
 X₆ is F, αMeF or αMeF(2F),
 X₁₀ is F, 3-Pal, 4-Pal, F(4CN), F(4NO₂) or Y,
 X₁₁ is S or αMeS,
 20 X₁₂ is Orn, K, R, Q, Dap, S, E or I,
 X₁₃ is αMeL, I or L,
 X₁₅ is D or E,
 X₁₆ is K, Orn, A or E,
 X₁₇ is any amino acid with a functional group available for conjugation to a fatty
 25 acid, A, I or Q or Orn,
 X₁₉ is A or Q,
 X₂₀ is any amino acid with a functional group available for conjugation to a fatty
 acid, Aib, Q, R or αMe-4-Pal,
 X₂₁ is A, Aad, Aib, S, N, Q, E, T or Orn,
 30 X₂₃ is I or V,

X_{24} is any amino acid with a functional group available for conjugation to a fatty acid E, D-Glu, Q, N or D-Gln,

X_{25} is W, Y, F, 4-Pal, α MeY or α Me-4-Pal,

X_{27} is L, I, E, V, A, Aad, T, Q or S,

5 X_{28} is any amino acid with a functional group available for conjugation to a fatty acid, E or A,

X_{29} is G, Aib, T, D-Ala or A,

X_{31} is P or E,

X_{32} is S or P,

10 X_{34} is G or Aib,

X_{35} is A, D or E,

X_{37} is P or E,

X_{39} is E, S, G, A, T or Orn,

X_{40} is absent or G, E, S, A or T,

15 wherein if X_{40} is G, E, S, A, T or D-Glu, then X_{41} is absent or is E, S, D, G, Q, T, A, γ E or D-Glu,

wherein if X_{41} is E, S, D, G, Q, T, A, γ E or D-Glu, then X_{42} is absent or G, E, D-Glu, or γ E,

wherein if X_{42} is G, E, D-Glu or γ E, then X_{43} is absent or E, γ E, or D-Glu,

20 wherein if X_{43} is E, γ E, or D-Glu, then X_{44} is absent or E,

wherein if X_{44} is E then X_{45} is absent or E, wherein if X_{45} is E then X_{46} is absent or E,

wherein if X_{40} is absent, then X_{41} through X_{46} are also absent,

wherein if X_{41} is absent, then X_{42} , through X_{46} are also absent,

25 wherein if X_{42} is absent, then X_{43} through X_{46} are also absent,

wherein if X_{43} is absent, then X_{44} through X_{46} are also absent,

wherein if X_{44} is absent, then X_{45} and X_{46} are also absent,

wherein if X_{45} is absent then X_{46} is also absent,

wherein the polypeptide comprises at least one of the following: X_6 is α MeF or α MeF(2F); X_{10} is F, 3-Pal, 4-Pal, F(4CN) or F(4NO₂); X_{11} is α MeS; X_{13} is α MeL; X_{24} is D-Glu; and/or X_{25} is α MeY,

wherein if X_{10} is F, 3-Pal, 4-Pal, F(4CN), or F(4NO₂), then X_{12} is I,

5 and wherein at least one of X_{17} , X_{20} , X_{24} or X_{28} is an amino acid with a functional group available for conjugation to a fatty acid,

wherein the C-terminal amino acid is optionally amidated; or a pharmaceutically acceptable salt thereof.

As noted before, if X_{40} absent, then X_{41} through X_{46} are also absent and the
10 polypeptide comprises a 39 amino acid sequence backbone. If X_{41} absent, then X_{42} through X_{46} are also absent and the polypeptide comprises a 40 amino acid sequence backbone. If X_{42} is absent, then the polypeptide comprises a 41 amino acid sequence backbone. If X_{43} is absent, then the polypeptide comprises a 42 amino acid sequence backbone. If X_{44} is absent, then the polypeptide comprises a 43 amino acid sequence backbone. If X_{45} is absent,
15 then the polypeptide comprises a 44 amino acid sequence backbone. If X_{46} is absent, then the polypeptide comprises a 45 amino acid sequence backbone. If none of X_{40} through X_{46} are absent (in other words all of X_{40} through X_{46} are present), the polypeptide comprises a 46 amino acid sequence backbone.

In one embodiment, X_{40} is G, E, S, A, or T, and X_{41} is absent. In such embodiment,
20 the polypeptide comprises a 40 amino acid sequence. In one embodiment, X_{40} is G, E, S, A or T, X_{41} is E, S, D or G. In such embodiment, the polypeptide comprises a 41 amino acid sequence. In one embodiment, X_{40} is G, E, S, A or T, X_{41} is E, S, D or G, and X_{42} is G, E or γ E. In such embodiment, the polypeptide comprises a 42 amino acid sequence.

In some embodiments of polypeptides of formula III', the amino acid at position
25 X_{17} , X_{20} , X_{24} or X_{28} with a functional group available for conjugation to a fatty acid is K, C, E or D. In some embodiments, the amino acid at position X_{17} , X_{20} , X_{24} or X_{28} with a functional group available for conjugation to a fatty acid is K and the conjugation is to the epsilon-amino group of the K side-chain.

In some embodiments, X_{10} is F, 3-Pal, 4-Pal, F(4CN) or F(4NO₂) and X_{12} is I. In
30 some embodiments of the polypeptide of formula III, X_{10} is Y and X_{12} is Orn, K, R, Q, Dap, S, E or I.

In some embodiments, the polypeptide comprises at least three of the following: X₁₀ is F, 3-Pal, 4-Pal, F(4CN) or F(4NO₂); X₁₁ is αMeS; X₁₃ is αMeL; X₁₆ is Orn; X₂₄ is D-Glu; and/or X₂₅ is αMeY.

In some embodiments, X₁₀ is F, 3-Pal, 4-Pal, F(4CN) or F(4NO₂).

5 In some embodiments, X₁ is Y, X₂ is Aib, X₄ is G, X₆ is αMeF(2F), X₁₀ is 4-Pal, X₁₂ is I, X₁₃ is αMeL, X₁₅ is D, X₁₆ is Orn, X₁₉ is Q, X₂₀ is αMe-4-Pal, X₂₁ is E or Orn, X₂₃ is I, X₂₄ is D-Glu, X₂₅ is αMeY, X₂₇ is I or V, X₂₈ is E, X₂₉ is G, X₃₁ is P, X₃₄ is G, X₃₅ is A or E, X₃₇ is P, X₃₉ is E or S, X₄₀ is G or T, X₄₁ is E, S, or G, X₄₂ is absent, X₄₃ is absent, and X₄₄ is absent.

10 In some embodiments, X₁₁ is S, X₂₁ is Orn, X₂₇ is I, X₃₅ is E, X₃₉ is E, X₄₀ is T and X₄₁ is E.

In some embodiments, X₁₁ is αMeS, X₂₁ is E, X₂₇ is V, X₃₅ is A, X₃₉ is S, X₄₀ is G and X₄₁ is S.

15 In some embodiments, only one of X₁₇, X₂₀, X₂₄ and X₂₈ is an amino acid with a functional group available for conjugation to a C₁₆-C₂₂ fatty acid.

In some embodiments, only one of X₁₇, X₂₀, X₂₄ and X₂₈ is conjugated to a fatty acid optionally via a linker between the amino acid and the fatty acid. Thus, in some embodiments, only one of X₁₇, X₂₀, X₂₄ and X₂₈ is conjugated to a fatty acid via a direct bond between the amino acid and the fatty acid or via a linker between the amino acid and the fatty acid. In one embodiment, only one of X₁₇, X₂₀, X₂₄ and X₂₈ is conjugated to a fatty acid via a linker between the amino acid and the fatty acid. In some embodiments, the fatty acid is a C₁₆-C₂₂ fatty acid.

20 Thus, in one embodiment, X₁₇ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one embodiment, X₁₇ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In such embodiments, X₂₀ is Aib, αMe-4-pal, Q or R, X₂₄ is E, Q, D-Glu or N, and X₂₈ is E or A. In an embodiment, the conjugation is to the epsilon-amino group of the K side-chain.


25 In one embodiment, X₂₀ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one embodiment, X₂₀ is K and is conjugated to a C₁₆-C₂₂ fatty acid via linker between the amino acid and the C₁₆-C₂₂ fatty acid. In such embodiments, X₁₇ is A, I or Q, X₂₄ is E, Q, D-Glu or N, and X₂₈


is E or A. In an embodiment, the conjugation is to the epsilon-amino group of the K side-chain.

In one embodiment, X₂₄ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one embodiment, X₂₄ is K and is conjugated to a C₁₆-C₂₂ fatty acid via linker between the amino acid and the C₁₆-C₂₂ fatty acid. In such embodiments, X₁₇ is A, I or Q, X₂₀ is Aib, αMe-4-pal, Q or R, and X₂₈ is E or A. In an embodiment, the conjugation is to the epsilon-amino group of the K side-chain.

In one embodiment, X₂₈ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In one embodiment, X₂₈ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a linker between the amino acid and the C₁₆-C₂₂ fatty acid. In such embodiments, X₁₇ is A, I or Q, X₂₀ is Aib, αMe-4-pal, Q or R, and X₂₄ is E, Q, D-Glu or N. In an embodiment, the conjugation is to the epsilon-amino group of the K side-chain.

The amino acid sequences of polypeptides described herein incorporate naturally occurring amino acids, typically depicted herein using standard one letter codes (*e.g.*, L = leucine), as well as alpha-methyl substituted residues of natural amino acids (*e.g.*, α-methyl leucine (αMeL), and certain other non-natural amino acids, such as alpha amino isobutyric acid (Aib). The structures of these amino acids are depicted below:





As used herein "Orn" means L-ornithine. As used herein "4-Pal" or "4Pal" means
 5 3-(4-Pyridyl)-L-alanine or (S)-2-amino-3-(pyridin-4-yl)propanoic acid. As used herein "3-
 Pal" or "3Pal" means 3-(3-Pyridyl)-L-alanine or (S)-2-amino-3-(pyridin-3-yl)propanoic
 acid. As used herein " α Me-4-Pal" or " α Me4Pal" means alpha-methyl-3-(4-Pyridyl)-L-
 alanine. As used herein " α MeY" means alpha-methyl-L-tyrosine. As used herein " α MeL"
 means alpha-methyl-leucine. As used herein "D-Ala" and "a" each means D-alanine. As
 10 used herein "D-Glu" and "e" each means D-glutamic acid. As used herein "Aib" means 2-
 Aminoisobutyric Acid. As used herein, "NMeY" means N-methyl-tyrosine. As used
 herein "Dap" means (S)-2,3-diaminopropanoic acid. As used herein "Dab" means (S)-2,4-
 diaminobutanoic acid. As used herein "Hyp" means Hydroxy-L-proline. As used herein
 "K(Ac)" means *N*⁶-acetyl-L-lysine. As used herein " γ Glu" means gamma L-glutamic acid.
 15 As used herein "Aad" means (S)-2-aminohexanedioic acid. As used herein "F(4CN)"

means 4-cyano-L-phenylalanine or (S)-2-amino-3-(4-cyanophenyl)propanoic acid. As used herein "F(4NO₂)" means 4-nitro-L-phenylalanine or (S)-2-amino-3-(4-nitrophenyl)propanoic acid. As used herein "αMeS" means alpha-methyl-L-serine. As used herein "αMeF" means alpha-methyl-L-phenylalanine. As used herein "αMeF(2F)" means alpha-methyl-2-fluoro-L-phenylalanine or (S)-2-amino-3-(2-fluorophenyl)-2-methylpropanoic acid. As used herein "L-Iva" and "Iva" mean L-isovaline. As used herein "D-Gln" and "q" each means D-glutamine.

As noted before, in some embodiments, the polypeptides described herein include a fatty acid moiety conjugated, for example, by way of a direct bond or a linker to a natural or non-natural amino acid with a functional group available for conjugation. Such a conjugation is sometimes referred to as acylation. In certain instances, the amino acid with a functional group available for conjugation can be K, C, E and D. In particular instances, the amino acid with a functional group available for conjugation is K, where the conjugation is to an epsilon-amino group of a K side-chain.

The acylation of the polypeptides described herein is at position X₁₇ or X₂₀ or X₂₄ or X₂₈ in SEQ ID NO:4 or 6, or at position X₁₇ in SEQ ID NO:5. The fatty acid, and in certain embodiments the linker and/or amino acid sequence backbone, may act as albumin binders, and provide a potential to generate long-acting compounds.

In some embodiments, the polypeptides described herein utilize a C₁₆-C₂₂ fatty acid chemically conjugated to the functional group of an amino acid either via a direct bond or via a linker. The length and composition of the fatty acid impacts half-life of the polypeptides, their potency in *in vivo* animal models, and their solubility and stability. Conjugation to a C₁₆-C₂₂ saturated fatty monoacid or diacid results in polypeptides that exhibit desirable half-life, desirable potency in *in vivo* animal models, and desirable solubility and stability characteristics.

Examples of saturated C₁₆-C₂₂ fatty acids for use herein include, but are not limited to, palmitic acid (hexadecanoic acid) (C₁₆ monoacid), hexadecanedioic acid (C₁₆ diacid), margaric acid (heptadecanoic acid)(C₁₇ monoacid), heptadecanedioic acid (C₁₇ diacid), stearic acid (C₁₈ monoacid), octadecanedioic acid (C₁₈ diacid), nonadecylic acid (nonadecanoic acid)(C₁₉ monoacid), nonadecanedioic acid (C₁₉ diacid), arachadic acid (eicosanoic acid)(C₂₀ monoacid), eicosanedioic acid (C₂₀ diacid), heneicosylic acid (heneicosanoic acid)(C₂₁ monoacid), heneicosanedioic acid (C₂₁ diacid), behenic acid

(docosanoic acid)(C₂₂ monoacid), docosanedioic acid (C₂₂ diacid), including branched and substituted derivatives thereof.

In certain instances, the C₁₆-C₂₂ fatty acid can be a saturated C₁₈ monoacid, a saturated C₁₈ diacid, a saturated C₁₉ monoacid, a saturated C₁₉ diacid, a saturated C₂₀ monoacid, a saturated C₂₀ diacid, and branched and substituted derivatives thereof. In more particular instances, the C₁₆-C₂₂ fatty acid can be octadecanedioic (C₁₈ diacid) or eicosanedioic acid (C₂₀ diacid).

In certain instances, the linker can have one or more (2-[2-(2-amino-ethoxy)-ethoxy]-acetyl) moieties or εK, optionally in combination with one to four amino acids.

In instances in which the linker includes at least one amino acid, the amino acid can be one to five Glu or γGlu amino acid residues. In some instances, the linker can include one or two or three or four or five Glu or γGlu amino acid residues, including the D-forms thereof. For example, the linker can include either one or two or three or four γGlu amino acid residues. Alternatively, the linker can include one to five amino acid residues (such as, for example, Glu or γGlu amino acids) used in combination with one to five (2-[2-(2-amino-ethoxy)-ethoxy]-acetyl) ("AEEA") or one to five εK moieties. Specifically, the linker can be combinations of one to five Glu or γGlu amino acids and one to five (2-[2-(2-amino-ethoxy)-ethoxy]-acetyl) moieties, or one to five Glu or γGlu amino acids and one to five εK moieties. In some instances, the linker can be combinations of one or two or three γGlu amino acids and one or two (2-[2-(2-amino-ethoxy)-ethoxy]-acetyl) or εK moieties.


For example, in some embodiments the polypeptides described herein have linker and fatty acid components having the structure of the following formula:

(γGlu)_a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)_b-(γGlu)_c-CO-(CH₂)_p-CO₂H, where a is 0, 1 or 2; b is 0, 1 or 2; c is 0, 1, 2 or 3; and p is an integer between 14 to 20.


In some preferred embodiments, a is 0 or 1; b is 0, 1 or 2; c is 1, 2 or 3; and p an integer between 14 to 20.

In some embodiments, a is 0, b is 1, c is 1 or 2 and p is 16 or 18.

For example, in some embodiments, a is 0, b is 1, c is 1 and p is 16, the structure of which is depicted below.




For example, in some embodiments, a is 0, b is 1, c is 1 and p is 18, the structure of which is depicted below.




5

In some embodiments, a is 0, b is 1, c is 2 and p is 16, the structure of which is depicted below.



10


In some embodiments, a is 0, b is 1, c is 2 and p is 18, the structure of which is depicted below.



In some embodiments, a is 0, b is 2, c is 1 and p is 16 or 18.


15

For example, in some embodiments, a is 0, b is 2, c is 1 and p is 16, the structure of which is depicted below.




In some embodiments, a is 0, b is 2, c is 1 and p is 18, the structure of which is depicted below.

20




In some embodiments, a is 0, b is 0, c is 2 and p is 16 or 18.

For example, in some embodiments, a is 0, b is 0, c is 2 and p is 16, the structure of
5 which is depicted below.




In some embodiments, a is 0, b is 0, c is 2 and p is 18, the structure of which is
depicted below.



In some embodiments, a is 0, b is 0, c is 3 and p is 16 or 18.


For example, in some embodiments, a is 0, b is 0, c is 3 and p is 16, the structure of
which is depicted below.

15




In some embodiments, a is 0, b is 0, c is 3 and p is 18, the structure of which is
depicted below.

20




In some embodiments, a is 1, b is 1, c is 1 and p is 16 or 18.

For example, in some embodiments, a is 1, b is 1, c is 1 and p is 16, the structure of which is depicted below.



5 For example, in some embodiments, a is 1, b is 1, c is 1 and p is 18, the structure of which is depicted below.




In some embodiments the polypeptides described herein have linker and fatty acid components having the structure of the following formula:


10 $(\gamma\text{Glu})_d\text{-(}\epsilon\text{K)}_e\text{-(}\gamma\text{Glu)}_f\text{-CO-(CH}_2)_q\text{-CO}_2\text{H}$, where d is 0, 1 or 2; e is 0, 1 or 2; f is 0, 1, 2 or 3; and q is an integer between 14 to 20.

For example, in one embodiment, d is 0; e is 2; f is 1; and q an integer between 14 to 20. In some embodiments, d is 0; e is 2; f is 1; and q is 16 or 18.

For example, in some embodiments, d is 0; e is 2; f is 1; and q is 16, the structure
15 of which is depicted below.



For example, in some embodiments, d is 0; e is 2; f is 1; and q is 18, the structure of which is depicted below.



As shown in the chemical structures of Examples 1-1229 below, the linker-fatty acid moieties described above can be linked to amino acid present at positions 17, 20, 24 or 28. In some embodiments, a linker-fatty acid moiety described above is linked or conjugated to amino acid present at position 17, for example to the epsilon (ϵ)-amino group of the lysine (K) side-chain present at position 17. In some embodiments, a linker-fatty

acid moiety described above is linked or conjugated to amino acid present at position 20, for example to the epsilon (ϵ)-amino group of the lysine (K) side-chain present at position 20. In some embodiments, a linker-fatty acid moiety described above is linked or conjugated to amino acid present at position 24, for example to the epsilon (ϵ)-amino group of the lysine (K) side-chain present at position 24. In some embodiments, a linker-fatty acid moiety described above is linked or conjugated to amino acid present at position 28, for example to the epsilon (ϵ)-amino group of the lysine (K) side-chain present at position 28.

In some embodiments, the polypeptides described herein comprise a sequence selected from any one of SEQ ID NO'S:7 to 1242 (described below in examples 1-1236).

10 In some embodiments, the polypeptides described herein consist of a sequence selected from any one of SEQ ID NO'S:7 to 1242 (described below in examples 1-1236).

In some embodiments, the polypeptides described herein are amidated. In some embodiments, the polypeptides described herein have a modification of the C-terminal group, wherein the modification is NH_2 or absent. In some embodiments, the polypeptides described herein have an OH group at the C-terminal.

In addition to the sequences described herein, the polypeptides described herein may include one or more conservative amino acid substitutions, provided, however, that the polypeptides remain capable of binding to and activating GIP, GLP-1 and Glucagon receptors.

20 In certain embodiments of polypeptides of any of the formulas described herein, the polypeptide is an isotopic derivative of any one of the polypeptides described herein or a pharmaceutically acceptable salt thereof. It is understood that the isotopic derivative can be prepared using any of a variety of art-recognized techniques. For example, the isotopic derivatives can generally be prepared by carrying out the procedures disclosed in the examples described herein by substituting an isotopically labeled reagent for a non-isotopically labeled reagent. In an embodiment of a polypeptide of any of the formulas described herein, or a pharmaceutically acceptable salt thereof, the polypeptide is a deuterated derivative of any one of the polypeptides described herein.

30 In the polypeptides of this invention any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when an atom is designated specifically as "H" or "hydrogen", the atom is understood to have hydrogen at its natural abundance isotopic composition. Also, unless

otherwise stated, when an atom is designated specifically as "D" or "deuterium", the atom is understood to have deuterium at an abundance substantially greater than the natural abundance of deuterium, which is 0.015%.

The affinity of the polypeptides described herein for each of the GIP, GLP-1 and glucagon receptors may be measured using techniques known in the art for measuring receptor binding levels and is commonly expressed as an inhibitory constant (K_i) value. The activity of the polypeptides described herein at each of the receptors also may be measured using techniques known in the art, including, for example, the *in vitro* activity assays described below, and is commonly expressed as an effective concentration 50 (EC_{50}) value, which is the concentration of compound causing half-maximal stimulation in a dose response curve.

The polypeptides described herein may react with any number of inorganic and organic acids/bases to form pharmaceutically acceptable acid/base addition salts. Pharmaceutically acceptable salts and common techniques for preparing them are well known in the art (*see, e.g.,* Stahl *et al.*, Handbook of Pharmaceutical Salts: Properties, Selection and Use, 2nd Revised Edition (Wiley-VCH, 2011)). Pharmaceutically acceptable salts for use herein include sodium, potassium, trifluoroacetate, hydrochloride and/or acetate salts. Thus, in some embodiments, provided herein are pharmaceutically acceptable salt forms of the GGG polypeptides. In some embodiments, the pharmaceutically acceptable forms are selected from sodium or potassium salts. In some embodiments, the pharmaceutically acceptable forms are selected from the group consisting of sodium, potassium salts. In some preferred embodiments, a pharmaceutically acceptable salt is a sodium salt.

The polypeptides described herein are suitable for administration by a parenteral route (*e.g.,* subcutaneous, intravenous, intraperitoneal, intramuscular or transdermal) or oral route (*e.g.,* tablet, capsule). In some preferred embodiments, the polypeptides described herein are suitable for oral administration. The *in vitro* permeability (P_{app}) assay and *in vivo* ileum absorption assay described herein are useful tools for assessing the potential for oral delivery of a polypeptide.

In another embodiment, provided herein is a pharmaceutical composition comprising a polypeptide described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. Some pharmaceutical

compositions and techniques for preparing the same are well known in the art. *See, e.g.*, Remington: The Science and Practice of Pharmacy (Troy, Ed., 21st Edition, Lippincott, Williams & Wilkins, 2006).

5 In some embodiments, the pharmaceutical composition is suitable for administration by a parenteral route (*e.g.*, subcutaneous, intravenous, intraperitoneal, intramuscular or transdermal). In some embodiments, the pharmaceutical composition is suitable for oral administration (*e.g.*, tablet, capsule). In some embodiments, the pharmaceutical composition is administered parenterally. In some embodiments, the pharmaceutical composition is administered orally.

10 Physiochemical properties of a polypeptide in addition to anatomical and physiological features of the gastrointestinal tract may pose challenges to efficient oral delivery of a peptide. In an embodiment a pharmaceutical composition for oral administration comprises a polypeptide described herein or a pharmaceutically acceptable salt thereof, and a permeation enhancer. In an embodiment, a pharmaceutical composition
15 for oral administration comprises polypeptide described herein or a pharmaceutically acceptable salt thereof, a permeation enhancer, and a protease inhibitor.

As used herein the term “permeation enhancer” means permeation enhancer that enhances oral absorption of a polypeptide of this invention. As used herein, permeation enhancer means permeation enhancers, such as sodium decanoate (C10), sodium
20 taurodeoxycholate (NaTDC), lauroyl carnitine (LC), dodecyl maltoside, dodecyl phosphatidylcholine, SNAC, a Rhamnolipid, and permeation enhancers reported in the literature, such as for example, Permeant inhibitor of phosphatase, PIP-250 and PIP-640. *See*, *Pharmaceutics*. 2019 Jan; 11(1): 41, (*See Biomaterials*. 2012; 33: 3464-3474), ZOT (zonula occludens toxin), ΔG (fragment of ZOT) (*See Int. J. Pharm.* 2009; 365, 121-130).
25 In an embodiment, a permeation enhancer is selected from sodium decanoate, sodium taurodeoxycholate, and lauroyl carnitine. In an embodiment, a permeation enhancer is selected from the group consisting of C10, LC, or NaTDC. In an embodiment, a permeation enhancer is selected from the group consisting of sodium decanoate, sodium taurodeoxycholate, and lauroyl carnitine. In an embodiment, a permeation enhancer is
30 selected from the group consisting of C10, LC, and NaTDC.

As used herein the term “protease inhibitor” means a protease inhibitor that may be selected from the group consisting of protein based, peptide based, and small molecule

based. Protease inhibitors are well known and may include, for example, soybean trypsin inhibitor ("SBTI"), soybean trypsin-chymotrypsin inhibitor ("SBTCI"), ecotin, sunflower trypsin inhibitor ("SFTI"), leupeptin, citric acid, ethylenediaminetetraacetic acid ("EDTA"), sodium glycocholate and 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride ("AEBSF"). In an embodiment a protease inhibitor is selected from the group consisting of SBTI, SBTCI and SFTI. In an embodiment, a protease inhibitor is SBTI.

The disclosure also provides and therefore encompasses novel intermediates and methods of synthesizing the polypeptides described herein, or pharmaceutically acceptable salts thereof. The intermediates and polypeptides described herein can be prepared by a variety of techniques known in the art. For example, a method using chemical synthesis is illustrated in the Examples below or using biological expression. The specific synthetic steps for each of the routes described may be combined in different ways to prepare the polypeptides described herein. The reagents and starting materials are readily available to one of skill in the art.

With respect to chemical synthesis, one can use standard manual or automated solid-phase synthesis procedures. For example, automated peptide synthesizers are commercially available from, for example, CEM (Charlotte, North Carolina), CSBio (Menlo Park, California) and Gyros Protein Technologies Inc. (Tucson, AZ). Reagents for solid-phase synthesis are readily available from commercial sources. Solid-phase synthesizers can be used according to the manufacturer's instructions for blocking interfering groups, protecting amino acids during reaction, coupling, deprotecting and capping of unreacted amino acids.

With respect to biological expression, one can use standard recombinant techniques to construct a polynucleotide having a nucleic acid sequence that encodes an amino acid sequence for all or part of a polypeptide, incorporate that polynucleotide into recombinant expression vectors, and introduce the vectors into host cells, such as bacteria, yeast and mammalian cells, to produce the polypeptide. See, e.g., Green & Sambrook, "Molecular Cloning: A Laboratory Manual" (Cold Spring Harbor Laboratory Press, 4th ed. 2012). The polypeptides may readily be produced in mammalian cells such as CHO, NSO, 20 HEK293, BHK, or COS cells; in bacterial cells such as E. coli, Bacillus subtilis, or Pseudomonas fluorescens; in insect cells, or in fungal or yeast cells, which are cultured

using techniques known in the art. The vectors containing the polynucleotide sequences of interest can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. Various methods of protein purification may be employed and such methods are known in the art.

5 The polypeptides described herein may be used for treating a variety of conditions, disorders, diseases or symptoms. In particular, methods are provided for treating obesity in an individual, where such methods include at least a step of administering to an individual in need of such treatment an effective amount of a polypeptide described herein, or a pharmaceutically acceptable salt thereof.

10 Additionally, methods are provided for chronic weight management in an individual, where such methods include at least a step of administering to an individual in need of such treatment an effective amount of a polypeptide described herein, or a pharmaceutically acceptable salt thereof.

 Additionally, methods are provided for treating type 2 diabetes mellitus (T2DM) in
15 an individual, where such methods include at least a step of administering to an individual in need of such treatment an effective amount of a polypeptide described herein, or a pharmaceutically acceptable salt thereof.

 Additionally, methods are provided for treating non-alcoholic fatty liver disease (NAFLD) in an individual, where such methods include at least a step of administering to
20 an individual in need of such treatment an effective amount of a polypeptide described herein, or a pharmaceutically acceptable salt thereof.

 Additionally, methods are provided for treating non-alcoholic steatohepatitis (NASH) in an individual, where such methods include at least a step of administering to an individual in need of such treatment an effective amount of a polypeptide described herein,
25 or a pharmaceutically acceptable salt thereof.

 Additionally, methods are provided for treating dyslipidemia in an individual, where such methods include at least a step of administering to an individual in need of such treatment an effective amount of a polypeptide described herein, or a pharmaceutically acceptable salt thereof.

30 Additionally, methods are provided for treating metabolic syndrome in an individual, where such methods include at least a step of administering to an individual in

need of such treatment an effective amount of a polypeptide described herein, or a pharmaceutically acceptable salt thereof.

Additionally, methods are provided for treating osteoarthritis (OA) in an individual, where such methods include at least a step of administering to an individual in need of such treatment an effective amount of a polypeptide described herein, or a pharmaceutically acceptable salt thereof.

Additionally, methods are provided for treating obesity-related sleep apnea (OSA) in an individual, where such methods include at least a step of administering to an individual in need of such treatment an effective amount of a polypeptide described herein, or a pharmaceutically acceptable salt thereof.

Additionally, methods are provided for treating polycystic ovary syndrome (PCOS) in an individual, where such methods include at least a step of administering to an individual in need of such treatment an effective amount of a polypeptide described herein, or a pharmaceutically acceptable salt thereof.

Additionally, methods are provided for inducing non-therapeutic weight loss in an individual, where such methods include at least a step of administering to an individual in need of such treatment an effective amount of a polypeptide described herein, or a pharmaceutically acceptable salt thereof.

In these methods, effectiveness of the polypeptides can be assessed by, for example, observing a significant reduction in blood glucose, observing a significant increase in insulin, observing a significant reduction in HbA1c and/or observing a significant reduction in body weight.

Alternatively, the polypeptides described herein or pharmaceutically acceptable salts thereof may be used for improving bone strength in an individual in need thereof. In some instances, the individual in need thereof has hypo-ostosis or hypo-osteoidosis, or is healing from bone fracture, orthotic procedure, prosthetics implant, dental implant, and/or spinal fusion. The polypeptides described herein also may be used for treating other disorders such as Parkinson's disease or Alzheimer's disease.

Additionally, provided is a polypeptide described herein, or a pharmaceutically acceptable salt thereof, for use in therapy. In some embodiments, provided herein is a polypeptide described herein or a pharmaceutically acceptable salt thereof, for use in treating obesity, chronic weight management, type 2 diabetes mellitus, non-alcoholic fatty

liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), dyslipidemia, metabolic syndrome, osteoarthritis (OA), obesity-related sleep apnea (OSA) and polycystic ovary syndrome (PCOS). Also provided is a use of a polypeptide described herein, or a pharmaceutically acceptable salt thereof, for inducing non-therapeutic weight loss.

5 Additionally, provided is a use of a polypeptide described herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating obesity, chronic weight management, type 2 diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), dyslipidemia, metabolic syndrome, osteoarthritis (OA), obesity-related sleep apnea (OSA) and polycystic ovary
10 syndrome (PCOS). Also provided is a use of a polypeptide described herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inducing non-therapeutic weight loss.

 The polypeptides or pharmaceutical compositions described herein may be provided as part of a kit. In some instances, the kit includes a device for administering at
15 least one polypeptide (and optionally at least one additional therapeutic agent) to an individual, such as a syringe, automatic injector or pump.

 Additional non-limiting embodiments are set forth below:

1. A polypeptide comprising:

$X_1X_2QGTX_6TSDX_{10}X_{11}X_{12}X_{13}LDX_{16}X_{17}AX_{19}X_{20}X_{21}FX_{23}X_{24}X_{25}LX_{27}X_{28}X_{29}X_{30}$
20 $X_{31}SSX_{34}X_{35}X_{36}X_{37}X_{38}X_{39}X_{40}X_{41}X_{42}$, wherein:

X_1 is Y, NMeY or H,

X_2 is Aib,

X_6 is F, α MeF or α MeF(2F),

X_{10} is F, 4-Pal, F(4CN), 3-Pal, F(4NO₂) or Y,

25 X_{11} is S or α MeS,

X_{12} is Orn, K, R, Q, Dap, Dab, S, E or I,

X_{13} is α MeL, I or L,

X_{16} is K, Orn, A or E,

X_{17} is any amino acid with a functional group available for conjugation to a
30 fatty acid, A, I or Q,

X_{19} is Q or A,

- X₂₀ is any amino acid with a functional group available for conjugation to a fatty acid, Aib, α Me-4-Pal, Q or R,
X₂₁ is A, Q, Orn, Aad, Aib, S, N, E or T,
X₂₃ is I or V,
5 X₂₄ is any amino acid with a functional group available for conjugation to a fatty acid, E, Q, D-Glu or N,
X₂₅ is W, Y, F, 4-Pal, α MeY or α Me-4-Pal,
X₂₇ is L, I, E, V, A, Q or S,
X₂₈ is any amino acid with a functional group available for conjugation to a fatty acid, E or A,
10 X₂₉ is G, D-Ala, Aib, T or A,
X₃₀ is A or G,
X₃₁ is P, H, S, 4-Pal, E, T, K(Ac) or Hyp,
X₃₄ is G or Aib,
15 X₃₅ is A, Aib, E, H or 4-Pal,
X₃₆ is P or Hyp,
X₃₇ is P, Hyp or E,
X₃₈ is P or Hyp,
X₃₉ is E, S, G, T, H, 4-Pal, γ E or A,
20 X₄₀ is absent or G, E, S, A or T,
wherein if X₄₀ is G, E, S, A or T, then X₄₁ is absent or E, S, T, 4-Pal, D, G, Q or H,
wherein if X₄₁ is E, S, T, 4-Pal, D, G, Q or H, then X₄₂ is absent or G, E or γ E,
25 wherein if X₄₀ is absent, then X₄₁ and X₄₂ are also absent,
wherein if X₄₁ is absent, then X₄₂ is also absent,
wherein at least one of X₁₇, X₂₀, X₂₄ and X₂₈ is an amino acid with a functional group available for conjugation to a fatty acid,
wherein the C-terminal amino acid is optionally amidated;
30 or a pharmaceutically acceptable salt thereof.

2. The polypeptide of embodiment 1, or a pharmaceutically acceptable salt thereof, wherein
X₄₀ is G, E, S, A or T,
X₄₁ is absent, and
5 X₄₂ is absent.
3. The polypeptide of embodiment 1, or a pharmaceutically acceptable salt thereof, wherein
X₄₀ is G, E, S, A or T,
X₄₁ is E, S, T, 4-Pal, D, G, Q or H, and
10 X₄₂ is absent.
4. The polypeptide of embodiment 1, wherein
X₄₀ is G, E, S, A or T,
X₄₁ is E, S, T, 4-Pal, D, G, Q or H, and
X₄₂ is G, E or γ E.
- 15 5. The polypeptide of any one of embodiments 1 to 4, wherein the amino acid at position X₁₇, X₂₀, X₂₄ or X₂₈ with a functional group available for conjugation to a fatty acid is K, C, E or D.
6. The polypeptide of embodiment 5, wherein the amino acid at position X₁₇, X₂₀, X₂₄ or X₂₈ with a functional group available for conjugation to a fatty acid is K.
- 20 7. The polypeptide of any one of embodiments 1 to 6, or a pharmaceutically acceptable salt thereof, wherein X₁₀ is F or 4-Pal.
8. The polypeptide of any one of embodiments 1 to 7, or a pharmaceutically acceptable salt thereof, wherein X₁₂ is Orn, K, R or Q.
9. The polypeptide of any one of embodiments 1 to 8, or a pharmaceutically acceptable salt thereof, wherein only one of X₁₇, X₂₀, X₂₄ and X₂₈ is an amino acid with a functional group available for conjugation to a fatty acid.
- 25 10. The polypeptide of any one of embodiments 1 to 9, or a pharmaceutically acceptable salt thereof, wherein only one of X₁₇, X₂₀, X₂₄ and X₂₈ is conjugated to a fatty acid via a direct bond or via a linker between the amino acid and the fatty acid.
- 30 11. The polypeptide of embodiment 10, or a pharmaceutically acceptable salt thereof, wherein only one of X₁₇, X₂₀, X₂₄ and X₂₈ is conjugated to a fatty acid via a linker between the amino acid and the fatty acid.

12. The polypeptide of any one of embodiments 1 to 11, wherein the fatty acid is a C₁₆-C₂₂ fatty acid.
13. The polypeptide of embodiment 12, or a pharmaceutically acceptable salt thereof, wherein
- 5 X₁₇ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid,
- X₂₀ is Aib, αMe-4-Pal, Q or R,
- X₂₄ is E, Q, D-Glu or N, and
- X₂₈ is E or A.
- 10 14. The polypeptide of embodiment 12, or a pharmaceutically acceptable salt thereof, wherein
- X₁₇ is A, I or Q,
- X₂₀ is K and is conjugated to the C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid,
- 15 X₂₄ is E, Q, D-Glu or N, and
- X₂₈ is E or A.
15. The polypeptide of embodiment 12, or a pharmaceutically acceptable salt thereof, wherein
- X₁₇ is A, I or Q,
- 20 X₂₀ is Aib, αMe-4-Pal, Q or R,
- X₂₄ is K and is conjugated to the C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid, and
- X₂₈ is E or A.
16. The polypeptide of embodiment 12, or a pharmaceutically acceptable salt thereof,
- 25 wherein
- X₁₇ is A, I or Q,
- X₂₀ is Aib, αMe-4-Pal, Q or R,
- X₂₄ is E, Q, D-Glu or N, and
- X₂₈ is K and is conjugated to the C₁₆-C₂₂ fatty acid via a direct bond or via
- 30 a linker between the amino acid and the C₁₆-C₂₂ fatty acid.
17. The polypeptide of embodiment 1 comprising:

YX₂QGTFTSDX₁₀SX₁₂X₁₃LDX₁₆X₁₇AQX₂₀X₂₁FIX₂₄X₂₅LX₂₇X₂₈X₂₉X₃₀X₃₁SSX₃₄
X₃₅X₃₆X₃₇X₃₈X₃₉X₄₀X₄₁X₄₂, wherein

X₂ is Aib,

X₁₀ is F, 4-Pal or F(4CN),

5 X₁₂ is Orn, K, R, Q, Dap or Dab,

X₁₃ is α MeL,

X₁₆ is K or Orn,

X₁₇ is any amino acid with a functional group available for conjugation to a
fatty acid,

10 X₂₀ is Aib, α Me-4-Pal or Q,

X₂₁ is A, Q or Orn,

X₂₄ is E or Q,

X₂₅ is W, Y, 4-Pal, α MeY or α Me-4-Pal,

X₂₇ is L or I,

15 X₂₈ is E or A,

X₂₉ is G, D-Ala or Aib,

X₃₀ is A or G,

X₃₁ is P, H, S, 4-Pal, E, T, K(Ac) or Hyp,

X₃₄ is G or Aib,

20 X₃₅ is A, Aib, E, H or 4-Pal,

X₃₆ is P or Hyp,

X₃₇ is P or Hyp,

X₃₈ is P or Hyp,

X₃₉ is E, S, G, T, H, 4-Pal or γ E,

25 X₄₀ is absent or G, E or S,

wherein if X₄₀ is G, E or S, then X₄₁ is absent or E, S, T, 4-Pal, D, G, Q or
H,

wherein if X₄₁ is E, S, T, 4-Pal, D, G, Q or H, then X₄₂ is absent or G, E or
 γ E,

30 wherein the C-terminal amino acid is optionally amidated;

or a pharmaceutically acceptable salt thereof.

18. The polypeptide of embodiment 17, or a pharmaceutically acceptable salt thereof, wherein
X₄₀ G, E or S,
X₄₁ is absent, and
5 X₄₂ is absent.
19. The polypeptide of embodiment 17, or a pharmaceutically acceptable salt thereof, wherein
X₄₀ G, E or S,
X₄₁ is E, S, T, 4-Pal, D, G, Q or H, and
10 X₄₂ is absent.
20. The polypeptide of embodiment 17, or a pharmaceutically acceptable salt thereof, wherein
X₄₀ G, E or S,
X₄₁ is E, S, T, 4-Pal, D, G, Q or H, and
15 X₄₂ is G, E or γE.
21. The polypeptide of any one of embodiments 17 to 20, wherein X₁₇ is K, C, E or D.
22. The polypeptide of embodiment 21, wherein X₁₇ is K.
23. The polypeptide of any one of embodiments 17 to 22, or a pharmaceutically acceptable salt thereof, wherein X₁₀ is F or 4-Pal.
- 20 24. The polypeptide of any one of embodiments 17 to 23, or a pharmaceutically acceptable salt thereof, wherein X₁₂ is Orn, K, R or Q.
25. The polypeptide of any one of embodiments 17 to 24, or a pharmaceutically acceptable salt thereof, wherein X₁₇ is K and is conjugated to a fatty acid via a direct bond or via a linker between the amino acid and the fatty acid.
- 25 26. The polypeptide of embodiment 25, or a pharmaceutically acceptable salt thereof, wherein X₁₇ is K and is conjugated to a fatty acid via a linker between the amino acid and the fatty acid.
27. The polypeptide of any one of embodiments 17 to 26, wherein the fatty acid is a C₁₆-C₂₂ fatty acid.
- 30 28. The polypeptide of embodiment 27, or a pharmaceutically acceptable salt thereof, wherein X₁₇ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid.

29. The polypeptide of embodiment 1 comprising:

$X_1X_2QGTX_6TSDX_{10}X_{11}X_{12}X_{13}LDX_{16}X_{17}AX_{19}X_{20}X_{21}FX_{23}X_{24}X_{25}LX_{27}X_{28}X_{29}G$
 $X_{31}SSX_{34}X_{35}X_{36}X_{37}X_{38}X_{39}X_{40}X_{41},$

wherein

- 5 X_1 is Y, NMeY or H,
 X_2 is Aib,
 X_6 is F, α MeF or α MeF(2F),
 X_{10} is F, 3-Pal, 4-Pal, F(4CN), F(4NO₂) or Y,
 X_{11} is S or α MeS,
10 X_{12} is Orn, K, R, Q, Dap, S, E or I,
 X_{13} is α MeL, I or L,
 X_{16} is K, Orn, A or E,
 X_{17} is any amino acid with a functional group available for conjugation to a
fatty acid, A, I or Q,
15 X_{19} is A or Q,
 X_{20} is any amino acid with a functional group available for conjugation to a
fatty acid Aib, Q, R or α Me-4-Pal,
 X_{21} is A, Aad, Aib, S, N, Q, E, T or Orn,
 X_{23} is I or V,
20 X_{24} is any amino acid with a functional group available for conjugation to a
fatty acid, E, D-Glu, Q or N,
 X_{25} is W, Y, F, 4-Pal, α MeY or α Me-4-Pal,
 X_{27} is L, I, E, V, A, Q or S,
 X_{28} is any amino acid with a functional group available for conjugation to a
25 fatty acid, E or A,
 X_{29} is G, Aib, T, D-Ala or A,
 X_{31} is P or E,
 X_{34} is G or Aib,
 X_{35} is A or E,
30 X_{36} is P,
 X_{37} is P or E,
 X_{38} is P,

- X₃₉ is E, S, G or A,
X₄₀ is absent or G, E, S, A or T,
wherein if X₄₀ is G, E, S, A or T, then X₄₁ is absent or is E, S, D or G,
wherein if X₄₁ is E, S, D or G, then X₄₂ is absent or G, E or γE,
5 wherein if X₁₀ is F, 3-Pal, 4-Pal, F(4CN), F(4NO₂), then X₁₂ is I,
wherein at least one of X₁₇, X₂₀, X₂₄ or X₂₈ is an amino acid with a functional
group available for conjugation to a fatty acid,
wherein the C-terminal amino acid is optionally amidated;
or a pharmaceutically acceptable salt thereof.
- 10 30. The polypeptide of embodiment 29, or a pharmaceutically acceptable salt thereof,
wherein:
X₄₀ G, E, S, A or T,
X₄₁ is absent and
X₄₂ is absent.
- 15 31. The polypeptide of embodiment 29, or a pharmaceutically acceptable salt thereof,
wherein:
X₄₀ G, E, S, A or T,
X₄₁ is E, S, D or G and
X₄₂ is absent.
- 20 32. The polypeptide of embodiment 29, or a pharmaceutically acceptable salt thereof,
wherein:
X₄₀ G, E, S, A or T,
X₄₁ is E, S, D or G and
X₄₂ is G, E or γE.
- 25 33. The polypeptide of any one of embodiments 29 to 32, wherein the amino acid at
position X₁₇, X₂₀, X₂₄ or X₂₈ with a functional group available for conjugation to a
fatty acid is K, C, E or D.
- 30 34. The polypeptide of embodiment 5, wherein the amino acid at position X₁₇, X₂₀, X₂₄
or X₂₈ with a functional group available for conjugation to a fatty acid is K.
35. The polypeptide of any one of embodiments 29 to 34, or a pharmaceutically
acceptable salt thereof, wherein X₁₀ is F, 3-Pal, 4-Pal, F(4CN) or F(4NO₂) and X₁₂ is
I.

36. The polypeptide of any one of embodiments 29 to 34, or a pharmaceutically acceptable salt thereof, wherein X_{10} is Y and X_{12} is Orn, K, R, Q, Dap, S, E or I.
37. The polypeptide of any one of embodiments 29 to 36, or a pharmaceutically acceptable salt thereof, wherein only one of X_{17} , X_{20} , X_{24} or X_{28} is an amino acid with a functional group available for conjugation to a fatty acid.
38. The polypeptide of any one of embodiments 29 to 37, or a pharmaceutically acceptable salt thereof, wherein only one of X_{17} , X_{20} , X_{24} or X_{28} is conjugated to a fatty acid via a direct bond or via a linker between the amino acid and the fatty acid.
39. The polypeptide of embodiment 38, or a pharmaceutically acceptable salt thereof, wherein only one of X_{17} , X_{20} , X_{24} or X_{28} is conjugated to a fatty acid via a linker between the amino acid and the fatty acid.
40. The polypeptide of any one of embodiments 29 to 39, wherein the fatty acid is a C_{16} - C_{22} fatty acid.
41. The polypeptide of embodiment 40, or a pharmaceutically acceptable salt thereof, wherein
- X_{17} is K and is conjugated to a C_{16} - C_{22} fatty acid via a direct bond or via a linker between the amino acid and the C_{16} - C_{22} fatty acid,
- X_{20} is Aib, α Me-4-Pal, Q or R,
- X_{24} is E, Q, D-Glu or N, and
- X_{28} is E or A.
42. The polypeptide of embodiment 40, or a pharmaceutically acceptable salt thereof, wherein:
- X_{17} is A, I or Q,
- X_{20} is K and is conjugated to a C_{16} - C_{22} fatty acid via a direct bond or via a linker between the amino acid and the C_{16} - C_{22} fatty acid,
- X_{24} is E, Q, D-Glu or N, and
- X_{28} is E or A.
43. The polypeptide of embodiment 40, or a pharmaceutically acceptable salt thereof, wherein:
- X_{17} is A, I or Q,
- X_{20} is Aib, α Me-4-Pal, Q or R,

X₂₄ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid, and

X₂₈ is E or A.

44. The polypeptide of embodiment 40, or a pharmaceutically acceptable salt thereof, wherein:

X₁₇ is A, I or Q,

X₂₀ is Aib, αMe-4-Pal, Q or R,

X₂₄ is E, Q, D-Glu or N, and

X₂₈ is K and is conjugated to a C₁₆-C₂₂ fatty acid via a direct bond or via a linker between the amino acid and the C₁₆-C₂₂ fatty acid.

45. The polypeptide of any one of embodiments 10, 11, 12, 13, 14, 15, 16, 25, 26, 27, 28, 38, 39, 40, 41, 42, 43 and 44, or a pharmaceutically acceptable salt thereof, wherein the linker comprises one to four amino acids.

46. The polypeptide of embodiment 45, or a pharmaceutically acceptable salt thereof, wherein the amino acids are Glu, γGlu or a combination thereof.

47. The polypeptide of embodiment 45 or 46, or a pharmaceutically acceptable salt thereof, wherein the linker comprises one to four (2-[2-(2-amino-ethoxy)-ethoxy]-acetyl) or εK moieties.

48. The polypeptide of embodiment 47, or a pharmaceutically acceptable salt thereof, wherein the linker comprises one to four (2-[2-(2-amino-ethoxy)-ethoxy]-acetyl) moieties.

49. The polypeptide of embodiment 45, or a pharmaceutically acceptable salt thereof, wherein the linker comprises a structure of (γGlu)_a-(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)_b-(γGlu)_c-CO-(CH₂)_p-CO₂H, wherein a is 0 or 1, b is 0, 1 or 2, c is 1, 2 or 3, and p is an integer between 14 to 20.

50. The polypeptide of embodiment 49, or a pharmaceutically acceptable salt thereof, wherein a is 0.

51. The polypeptide of embodiment 49, or a pharmaceutically acceptable salt thereof, wherein a is 1.

52. The polypeptide of any one of embodiments 49 to 51, or a pharmaceutically acceptable salt thereof, wherein b is 0.

53. The polypeptide of any one of embodiments 49 to 51, or a pharmaceutically acceptable salt thereof, wherein b is 1.
54. The polypeptide of any one of embodiments 49 to 51, or a pharmaceutically acceptable salt thereof, wherein b is 2.
- 5 55. The polypeptide of any one of embodiments 49 to 54, or a pharmaceutically acceptable salt thereof, wherein c is 1.
56. The polypeptide of any one of embodiments 49 to 54, or a pharmaceutically acceptable salt thereof, wherein c is 2.
57. The polypeptide of any one of embodiments 49 to 54, or a pharmaceutically acceptable salt thereof, wherein c is 3.
- 10 58. The polypeptide of any one of embodiments 49 to 57, or a pharmaceutically acceptable salt thereof, wherein p is 16.
59. The polypeptide of any one of embodiments 49 to 57, or a pharmaceutically acceptable salt thereof, wherein p is 18.
- 15 60. A polypeptide selected from the group consisting of SEQ ID NO's:7 to 504, or a pharmaceutically acceptable salt thereof.
61. The polypeptide of any one of embodiments 1 to 60, or a pharmaceutically acceptable salt thereof, wherein the C-terminal is amidated.
62. The polypeptide of any one of embodiments 1 to 61, or a pharmaceutically acceptable salt thereof,, wherein the pharmaceutically acceptable salt is selected from sodium, potassium, trifluoroacetate, hydrochloride or acetate.
- 20 63. The polypeptide of embodiment 62, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable salt is selected from sodium and potassium.
64. A pharmaceutical composition comprising the polypeptide or a pharmaceutically acceptable salt thereof, of any one of embodiments 1 to 63 and at least one pharmaceutically acceptable carrier, diluent, or excipient.
- 25 65. The pharmaceutical composition of embodiment 64, wherein the composition is formulated for oral administration.
66. The pharmaceutical composition of embodiment 64, wherein the composition is formulated for subcutaneous administration.
- 30 67. A method of treating a disease or condition selected from the group consisting of diabetes mellitus, obesity, chronic weight management, non-alcoholic fatty liver

disease (NAFLD), non-alcoholic steatohepatitis (NASH), dyslipidemia, metabolic syndrome, chronic kidney disease (CKD), osteoarthritis (OA), obesity-related sleep apnea (OSA) and polycystic ovary syndrome (PCOS), the method comprising a step of:

- 5 administering to an individual in need thereof an effective amount of a polypeptide, or a pharmaceutically acceptable salt thereof, of any one of embodiments 1 to 63.
68. The polypeptide, or a pharmaceutically acceptable salt thereof, as described in by any one of Embodiments 1 to 63 for use in therapy.
69. A polypeptide, or a pharmaceutically acceptable salt thereof, as described in any one
10 of Embodiments 1 to 63 for use in treating a disease or condition selected from the group consisting of diabetes mellitus, obesity, chronic weight management, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), dyslipidemia, metabolic syndrome, chronic kidney disease (CKD), osteoarthritis (OA), obesity-related sleep apnea (OSA) and polycystic ovary syndrome (PCOS).
- 15 70. Use of a polypeptide, or a pharmaceutically acceptable salt thereof, as described in any one of Embodiments 1 to 63 in the manufacture of a medicament for treating a disease or condition selected from the group consisting of diabetes mellitus, obesity, chronic weight management, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), dyslipidemia, metabolic syndrome, chronic kidney
20 disease (CKD), osteoarthritis (OA), obesity-related sleep apnea (OSA) and polycystic ovary syndrome (PCOS).
71. A polypeptide comprising a sequence having sequence identity of more than 60%, more than 70%, more than 80%, more than 90% or more than 95% to any of SEQ ID NO's. 7-1242.
- 25 72. The polypeptide of embodiment 71, comprising a sequence selected from the group consisting of SEQ ID NO's. 7-1242.
73. A polypeptide comprising a sequence having sequence identity of more than 60%, more than 70%, more than 80%, more than 90% or more than 95% to any of SEQ ID NOs. 294 to 775 or 1146 to 1240, or a pharmaceutically acceptable salt thereof.
- 30 74. A polypeptide selected from the group consisting of SEQ ID NO's: 294 to 775 or 1146 to 1240, or a pharmaceutically acceptable salt thereof.

75. The polypeptide of embodiment 74 selected from the group consisting of SEQ ID NO's: 692, 700, 702, 705, 706, 716, 718, 743, 747, 749, 767, or a pharmaceutically acceptable salt thereof.

76. The polypeptide of any of the above embodiments, wherein the polypeptide has
5 greater potency at each of the glucagon, GIP and GLP-1 receptors as compared to native glucagon (SEQ ID NO:3), GIP (SEQ ID NO:1) and GLP-1₇₋₃₆ (SEQ ID NO:2).

77. The polypeptide of any of the above embodiments, wherein one or more hydrogen atoms are replaced by deuterium; or a pharmaceutically acceptable salt thereof.

10 The invention is further illustrated by the following examples, which are not to be construed as limiting.


PEPTIDE SYNTHESIS

Example 1:

Example 1 is a compound represented by the following description:

15 Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH₂)₁₈-CO₂H)AQ-Aib-AFIEYLLAGGPSSGEPPEPPSEG-NH₂ (SEQ ID NO:7).

Below is a depiction of the structure of Example 1 using the standard single letter amino acid codes with the exception of residues Aib2, α MeL13 and Aib20, where the structures of these amino acid residues have been expanded:



The peptide backbone of Example 1 is synthesized using Fluorenylmethyloxycarbonyl (Fmoc)/tert-Butyl (t-Bu) chemistry on a Symphony 12-Channel Multiplex Peptide Synthesizer (Protein Technologies, Inc. Tucson, AZ).

25 The resin consists of 1% DVB cross-linked polystyrene (Fmoc-Rink-MBHA Low Loading Resin, 100-200 mesh, EMD Millipore) at a substitution of 0.3-0.4 meq/g.

Standard side-chain protecting groups are used. Fmoc-Lys(Mtt)-OH is used for the lysine at position 17, and Boc-Tyr(tBu)-OH is used for the tyrosine at position 1. Fmoc groups are removed prior to each coupling step (2 x 7 minutes) using 20% piperidine in DMF. All standard amino acid couplings are performed for 1 hour to a primary amine and 3 hour to a secondary amine, using an equal molar ratio of Fmoc amino acid (0.3M), diisopropylcarbodiimide (0.9M) and Oxyma (0.9M), at a 9-fold molar excess over the theoretical peptide loading. Exceptions are couplings to *Ca*-methylated amino acids, which are coupled for 3 hours. After completion of the synthesis of the peptide backbone, the resin is thoroughly washed with DCM for 6 times to remove residual DMF. The Mtt protecting group on the lysine at position 17 is selectively removed from the peptide resin using two treatments of 30% hexafluoroisopropanol (Oakwood Chemicals) in DCM (2 x 40-minute treatment).

Subsequent attachment of the fatty acid-linker moiety is accomplished by coupling of 2-[2-(2-Fmoc-amino-ethoxy)-ethoxy]-acetic acid (Fmoc-AEEA-OH, ChemPep, Inc.), Fmoc-glutamic acid *α*-t-butyl ester (Fmoc-Glu-OtBu, Ark Pharm, Inc.), mono-OtBu-eicosanedioic acid (WuXi AppTec, Shanghai, China). 3-fold excess of reagents (AA:PyAOP:DIPEA = 1:1:1 mol/mol) are used for each coupling that is 1-hour long.

After the synthesis is complete, the peptide resin is washed with DCM, and then thoroughly air-dried. The dry resin is treated with 10 mL of cleavage cocktail (trifluoroacetic acid:water:triisopropylsilane, 95:2.5:2.5 v/v) for 2 hours at room temperature. The resin is filtered off, washed twice each with 2 mL of neat TFA, and the combined filtrates are treated with 5-fold (by volume) cold diethyl ether (-20°C) to precipitate the crude peptide. The peptide/ether suspension is then centrifuged at 3500 rpm for 2 min to form a solid pellet, the supernatant is decanted, and the solid pellet is triturated with ether two additional times and dried *in vacuo*. The crude peptide is solubilized in 20% acetonitrile/20% acetic acid/60% water and purified by RP-HPLC on a Luna 5 μ m Phenyl-Hexyl Preparative Column (21 x 250 mm, Phenomenex) with linear gradients of 100% acetonitrile and 0.1% TFA/water buffer system (30-50% acetonitrile in 60 min). The purity of peptide is assessed using analytical RP-HPLC and pooling criteria is >95%. The main pool purity of Example 1 is found to be 98.8%. Subsequent lyophilization of the final main product pool yields the lyophilized peptide TFA salt. The molecular weight is determined by LC-MS (obsd: $M+4H^+/4 = 1226.8$; Calc $M+4H^+/4 = 1226.9$).

Example 2 through Example 1236

Polypeptides according to Example 2 (SEQ ID NO:8) through Example 1236 (SEQ ID NO:1242) are prepared substantially as described by the procedures of Example 1. These are listed below in Table 1. Additional depictions of certain examples are provided following Table 1.

Table 1

Ex. No.	Sequence	SEQ ID NO	MW Calculated
1	Y-Aib-QGTFTSDFSK-αMeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSEG-NH ₂	7	4916.5
2	Y-Aib-QGTFTSDFSK-αMeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSGE-NH ₂	8	4916.5
3	Y-Aib-QGTFTSDFSK-αMeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSSE-NH ₂	9	4946.6
4	Y-Aib-QGTFTSDFSK-αMeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSSEE-NH ₂	10	4988.6
5	Y-Aib-QGTFTSDFSK-αMeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H))AQ-Aib-AFIEYLLAGGPSSGEPPPSSE-NH ₂	11	5091.7
6	Y-Aib-QGTFTSDFSK-αMeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSGG-NH ₂	12	4844.5
7	Y-Aib-QGTFTSDFSK-αMeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSGG-NH ₂	13	4874.5
8	Y-Aib-QGTFTSDFSK-αMeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSGS-NH ₂	14	4874.5
9	Y-Aib-QGTFTSDFSK-αMeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPGGS-NH ₂	15	4844.5
10	Y-Aib-QGTFTSDFSK-αMeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSEG-NH ₂	16	4858.5
11	Y-Aib-QGTFTSDFSK-αMeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGE-NH ₂	17	4858.5

12	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGG-NH ₂	18	4786.4
13	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGG-NH ₂	19	4816.5
14	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGS-NH ₂	20	4816.5
15	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPGGE-NH ₂	21	4828.5
16	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPGGS-NH ₂	22	4786.4
17	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H))AQ-Aib-AFIEYLLEGGPSSGAPPPGEG-NH ₂	23	5031.7
18	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPGGS-NH ₂	24	4844.5
19	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQAFIEYLLA-Aib-GPSSGEPPPSEG-NH ₂	25	4987.6
20	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEWLLAGGPSSGEPPPSEG-NH ₂	26	4939.6
21	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEWLLAGGPSSGEPPPSGE-NH ₂	27	4939.6
22	Y--Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSEG-NH ₂	28	4888.5
23	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSGE-NH ₂	29	4888.5
24	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGAPSSGAPPPSEG-NH ₂	30	4930.6
25	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLAGGPSSGEPPPSEG-NH ₂	31	5033.6
26	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-QFIEYLLAGGPSSGEPPPSEG-NH ₂	32	4945.5

27	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIQYLLAGGPSSGEPPPSEG-NH ₂	33	4915.5
28	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSEG-NH ₂	34	4917.5
29	Y-Aib-QGTFTSDFSK-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSEG-NH ₂	35	4902.5
30	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-AFIEYLLA-Aib-GPSSGAPPPSEG-NH ₂	36	4929.6
31	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSEG-NH ₂	37	4886.5
32	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSEG-(2-[2-(2-Aminoethoxy)-ethoxy]-acetic amide)	38	5061.7
33	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSEG-(2-[2-(2-Aminoethoxy)-ethoxy]-acetic amide)	39	5061.7
34	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPSEG-NH ₂	40	4900.5
35	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGEPPPSEG-NH ₂	41	5016.6
36	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGEPPPTEG-NH ₂	42	4988.6
37	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEWLLEGGPSSGAPPPSEG-NH ₂	43	4939.6
38	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-QFIEWLLEGGPSSGAPPPSEG-NH ₂	44	4996.6
39	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIQWLLEGGPSSGAPPPSEG-NH ₂	45	4938.6
40	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEWLLEGGPSSGAPPPSEG-NH ₂	46	4939.6
41	Y-Aib-QGTFTSDFSR- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPGGS-NH ₂	47	4872.5

42	Y-Aib-QGTFTSDFSR- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPGGS-NH ₂	48	4900.5
43	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPGGS-NH ₂	49	4872.5
44	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSSG-NH ₂	50	4902.5
45	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGS-NH ₂	51	4902.5
46	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGEPPPPSEG-NH ₂	52	4974.6
47	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLEGAPSSGAPPPSEG-NH ₂	53	4930.6
48	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGPPSSGAPPPSEG-NH ₂	54	4888.5
49	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO $\gamma\gamma$ -(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPSEG-NH ₂	55	4888.5
50	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGPPSSGAPPPSEG-NH ₂	56	4874.5
51	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-QFIEYLLEGPPSSGAPPPSEG-NH ₂	57	4945.5
52	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLEGPPSSGAPPP-gE-EG-NH ₂	58	4958.6
53	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLEGPPSSGAPPP-gE-GE-NH ₂	59	4958.6
54	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLEGPPSSGEPPPGEG-(2-[2-(2-Aminoethoxy)-ethoxy]-acetic amide)	60	5089.7
55	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPGEG-NH ₂	61	5059.7
56	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGPPSSGAPPPSEG-(2-[2-(2-Aminoethoxy)-ethoxy]-acetic amide)	62	5033.6

57	Y-Aib-QGTFTSDFS- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSEG-NH ₂	63	4916.5
58	Y-Aib-QGTFTSDFS- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPSEG-NH ₂	64	4872.4
59	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGEPPPPSEG-NH ₂	65	4960.5
60	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSEG-NH ₂	66	4844.5
61	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSEG-NH ₂	67	4930.6
62	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPGGS-NH ₂	68	4802.4
63	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPGGE-NH ₂	69	4844.4
64	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPGGSG-NH ₂	70	4859.4
65	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPGGSE-NH ₂	71	4931.5
66	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPGGS-(2-[2-(2-Aminoethoxy)-ethoxy]-acetic amide)	72	4947.5
67	Y-Aib-QGTFTSDFS-Dab- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPGGS-NH ₂	73	4788.4
68	Y-Aib-QGTFTSDFS-Dap- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPGGS-NH ₂	74	4774.3
69	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GPSSGEPPPPGEG-NH ₂	75	5103.7
70	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPGEG-NH ₂	76	5045.7
71	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSEG-NH ₂	77	5075.7

72	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H))AQ-Aib-AFIEYLLEaGPSSGAPPPSEG	78	5061.7
73	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGS-NH ₂	79	4888.5
74	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGS-NH ₂	80	4860.5
75	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGS-NH ₂	81	5005.6
76	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGS-NH ₂	82	4802.4
77	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGS-NH ₂	83	4844.5
78	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEWLLEGGPSSGAPPPSGS-NH ₂	84	4883.5
79	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGS-NH ₂	85	4902.5
80	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGS-NH ₂	86	5047.7
81	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGD-NH ₂	87	4830.4
82	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGE-NH ₂	88	4844.5
83	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGS-(2-[2-(2-Aminoethoxy)-ethoxy]-acetic amide)	89	4947.6
84	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGSE-NH ₂	90	4931.5
85	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGD-NH ₂	91	4802.4
86	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGE-NH ₂	92	4816.4

87	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGT-NH ₂	93	4788.4
88	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGS- γ E-NH ₂	94	4903.5
89	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGS-(2-[2-(2-Aminoethoxy)-ethoxy]-acetic amide)	95	4919.5
90	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGSE-NH ₂	96	4903.5
91	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGE-(2-[2-(2-Aminoethoxy)-ethoxy]-acetic amide)	97	4961.6
92	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSGS-NH ₂	98	4860.5
93	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPEGS-NH ₂	99	4816.4
94	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSGS-NH ₂	100	4832.4
95	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGS-NH ₂	101	4774.4
96	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-QFIEYLLAGGPSSGAPPEGS-NH ₂	102	4873.5
97	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSGE-NH ₂	103	4874.5
98	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPEGE-NH ₂	104	4916.5
99	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPEGE-NH ₂	105	4858.5
100	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEWLLEGGPSSGAPPPSGE-NH ₂	106	4925.5
101	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEWLLEGGPSSGAPPEGE-NH ₂	107	4967.6

102	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPPEGE-NH ₂	108	4944.5
103	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEWLLAGGPSSGEPPPSGE-NH ₂	109	4925.5
104	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEWLLEGG-Hyp-SSGAPPPSGE-NH ₂	110	4941.5
105	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEWLLEGGPSSGAPP-Hyp-SGE-NH ₂	111	4941.5
106	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLAGGTSSGEPPPSGE-NH ₂	112	4906.5
107	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGPSSGAPPPSGE-NH ₂	113	5019.6
108	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPSGE-NH ₂	114	4916.5
109	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGPSSGAPPPSGE-NH ₂	115	5061.7
110	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGE-NH ₂	116	4902.5
111	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGE-NH ₂	117	5047.7
112	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGE-NH ₂	118	4817.4
113	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGE-NH ₂	119	4859.4
114	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGE-NH ₂	120	4945.5
115	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGPSSGEPPPSGE-NH ₂	121	4956.5
116	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEaGPSSGEPPPSEG-NH ₂	122	5091.7

117	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEaGPSSGEPPPSGE-NH ₂	123	5091.7
118	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGPSSGAPPPGES-NH ₂	124	5019.6
119	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEWLLEGGPSSGAPPPSGE-NH ₂	125	4897.5
120	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEWLLEGGPSSGAPPPEGE-NH ₂	126	4939.5
121	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEWLLEGGPSSGAPPPEGS-NH ₂	127	4897.5
122	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEWLLEGGHSSGAPPPSGE-NH ₂	128	4937.5
123	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEWLLEGGESSGEPPPSGE-NH ₂	129	4987.5
124	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEWLLEGGHSSGEPPPSGE-NH ₂	130	4995.6
125	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEWLLEGGESSGAPPPEGS-NH ₂	131	4929.5
126	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEWLLEGGHSSGAPPPEGS-NH ₂	132	4937.5
127	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEWLLEGGHSSGEPPPEGS-NH ₂	133	4995.6
128	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEaGPSSGAPPPSGE-NH ₂	134	5033.6
129	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEaGPSSGAPPPSGE-NH ₂	135	4888.5
130	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGPSSGAPPPEGS-NH ₂	136	4874.5
131	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGPSSGEPPPSGS-NH ₂	137	4890.5

132	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GESSGAPPPSGS-NH ₂	138	4935.5
133	Y-Aib-QGTFTSDFS-Dab- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGS-NH ₂	139	4846.4
134	Y-Aib-QGTFTSDFS-Dap- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGS-NH ₂	140	4832.4
135	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGEPPPSGE-NH ₂	141	4946.5
136	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGPSSGA-Hyp-PPSGE-NH ₂	142	4913.5
137	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGPSSGAP-Hyp-PSGE-NH ₂	143	4913.5
138	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGPSSGAPP-Hyp-SGE-NH ₂	144	4913.5
139	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGPSSGAPPPSGS-NH ₂	145	4832.4
140	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGPSSGAPPPSGS-NH ₂	146	4977.6
141	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPSGS-NH ₂	147	4846.4
142	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGPSSGAPPPSGS-NH ₂	148	4991.6
143	Y-Aib-QGTFTSDFSR- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPSGS-NH ₂	149	4874.5
144	Y-Aib-QGTFTSDFSR- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGPSSGAPPPSGS-NH ₂	150	5019.6
145	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGESSGAPPPSGS-NH ₂	151	4864.4
146	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGESSGAPPPSGS-NH ₂	152	4878.4

147	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGESSGAPPPSGS-NH ₂	153	5023.6
148	Y-Aib-QGTFTSDFSR- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGESSGAPPPSGS-NH ₂	154	4906.5
149	Y-Aib-QGTFTSDFSR- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGESSGAPPPSGS-NH ₂	155	5051.6
150	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGPSSGAPPPSGS-NH ₂	156	4846.4
151	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGS-NH ₂	157	4874.5
152	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLAGGPSSGEPPPEGS-NH ₂	158	4874.5
153	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLAGGPSSGEPPPSGS-NH ₂	159	4961.5
154	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLAGGPSSGEPPPSGS-NH ₂	160	4833.4
155	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEaGPSSGEPPPSGS-NH ₂	161	5049.6
156	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEaGPSSGEPPPSGT-NH ₂	162	5063.7
157	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEaGPSSGEPPPSGQ-NH ₂	163	5090.7
158	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGPSSGAPPPGGT-NH ₂	164	4816.4
159	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGPSSGAPPPGGQ-NH ₂	165	4843.4
160	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGPSSGAPPPEGT-NH ₂	166	4888.5
161	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGESSGAPPPGGS-NH ₂	167	4835.4

162	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGHSSGAPPPGGS-NH ₂	168	4843.4
163	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGG-4Pal-SSGAPPPGGS-NH ₂	169	4854.4
164	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGHSSGEPPPGGS-NH ₂	170	4901.4
165	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGT-NH ₂	171	5019.7
166	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GPSSGEPPPSGS-NH ₂	172	5063.7
167	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GPSSGEPPPSGT-NH ₂	173	5077.7
168	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGPSSGAPPPSGS-NH ₂	174	4855.5
169	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEWLLEGGHSSGAPPPSGE-NH ₂	175	5082.7
170	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGHSSGAPPPSGS-NH ₂	176	4895.5
171	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGHSSGAPPPSGT-NH ₂	177	4909.5
172	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGSSSGAPPPSGE-NH ₂	178	4887.5
173	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGSSSGAPPPSGS-NH ₂	179	4845.4
174	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGSSSGAPPPSGT-NH ₂	180	4859.4
175	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGTSSGAPPPSGE-NH ₂	181	4901.5
176	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGTSSGAPPPSGS-NH ₂	182	4860.4

177	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGTSSGAPPPSGT-NH ₂	183	4873.5
178	Y-Aib-QGTFTSD-F(4CN)-S-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGS-NH ₂	184	5030.6
179	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GESSGAPPPSGS-NH ₂	185	5037.6
180	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GESSGAPPPSGT-NH ₂	186	5051.7
181	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GHSSGAPPPSGS-NH ₂	187	5045.7
182	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GHSSGAPPPSGT-NH ₂	188	5059.7
183	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-G-4Pal-SSGAPPPSGS-NH ₂	189	5056.7
184	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-G-4Pal-SSGAPPPSGT-NH ₂	190	5070.7
185	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GESSGAPPPSGE-NH ₂	191	5079.7
186	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GHSSGAPPPSGE-NH ₂	192	5087.7
187	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GESSGAPPPSGS-NH ₂	193	4935.5
188	Y-Aib-QGTFTSD-4Pal-S-Dab- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GESSGAPPPSGS-NH ₂	194	4879.4
189	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-G-4Pal-SSGAPPPSGE-NH ₂	195	5098.7
190	Y-Aib-QGTFTSD-F(4CN)-S-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GHSSGAPPPSGS-NH ₂	196	4925.5
191	Y-Aib-QGTFTSD-F(4CN)-S-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGS-NH ₂	197	4885.5

192	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGS-NH ₂	198	4989.6
193	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((γ -Glu)-(2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGS-NH ₂	199	4989.6
194	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPEGS-NH ₂	200	5047.7
195	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLE-Aib-GPSSGEPPEGS-NH ₂	201	5105.7
196	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPGGS	202	4803.4
197	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPGGT	203	4817.4
198	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPGGS-NH ₂	204	4786.3
199	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPSGS-NH ₂	205	4816.4
200	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGT-NH ₂	206	4874.5
201	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGS-NH ₂	207	4844.4
202	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((γ -Glu) ₃ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGS-NH ₂	208	4973.5
203	Y-Aib-QGTFTSDFS-Dap- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGS-NH ₂	209	4816.4
204	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPSGT-NH ₂	210	4844.4
205	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((γ -Glu) ₃ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPSGT-NH ₂	211	4973.5
206	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPEGE-NH ₂	212	4930.5
207	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGHSSGAPPPSGE-NH ₂	213	4928.5

208	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaG-K(Ac)-SSGAPPPSGE-NH ₂	214	4961.6
209	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPSGS-NH ₂	215	4846.4
210	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPSGT-NH ₂	216	4860.5
211	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPSG-4Pal-NH ₂	217	4907.5
212	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPSGS	218	4847.4
213	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPSGT	219	4861.5
214	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSS-Aib-APPPSGT-NH ₂	220	4888.5
215	Y-Aib-QGTFTSDFS- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIEGGESSGAPPPSGS-NH ₂	221	4878.4
216	Y-Aib-QGTFTSDFS- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GESSGAPPPSGS-NH ₂	222	4906.5
217	Y-Aib-QGTFTSDFS- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GESSGAPPPSGE-NH ₂	223	4948.5
218	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GESSGAPPPSGS-NH ₂	224	4892.5
219	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GESSGAPPPSGE-NH ₂	225	4934.5
220	Y-Aib-QGTFTSDFS- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIEGGESSGAPPPSGS-NH ₂	226	4906.5
221	Y-Aib-QGTFTSDFS- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GESSGAPPPSGS-NH ₂	227	4934.5
222	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ- α Me4Pal-AFIEYLIE-Aib-GESSGAPPPSGE-NH ₂	228	5012.6

223	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ- α Me4Pal-AFIEYLIE-Aib-GESSGAPPPSGS-NH ₂	229	4970.5
224	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ- α Me4Pal-AFIEYLIE-Aib-GESSGAPPPSGS-NH ₂	230	5012.6
225	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ- α Me4Pal-AFIEYLIE-Aib-GESSGAPPPSGE-NH ₂	231	5054.6
226	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ- α Me4Pal-AFIEYLIE-Aib-GESSGAPPPSGS-NH ₂	232	4984.5
227	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ- α Me4Pal-AFIEYLIE-Aib-GESSGAPPPSGE-NH ₂	233	5026.6
228	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ- α Me4Pal-AFIEYLIE-Aib-GESSGAPPPSGE-NH ₂	234	5011.6
229	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ- α Me4Pal-AFIEYLIE-Aib-GESSGAPPPSGS-NH ₂	235	4969.6
230	Y-Aib-QGTFTSDFSR- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ- α Me4Pal-AFIEYLIE-Aib-GESSGAPPPSGS-NH ₂	236	5011.6
231	Y-Aib-QGTFTSDFSR- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ- α Me4Pal-AFIEYLIE-Aib-GESSGAPPPSGE-NH ₂	237	5053.6
232	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ- α Me4Pal-AFIEYLIE-Aib-GESSGAPPPSGS-NH ₂	238	4983.5
233	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ- α Me4Pal-AFIEYLIE-Aib-GESSGAPPPSGE-NH ₂	239	5025.6
234	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGG-Hyp-SSGAPPPGGS-NH ₂	240	4818.4
235	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGA-Hyp-PPGGS-NH ₂	241	4818.4
236	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAP-Hyp-PGGS-NH ₂	242	4818.4
237	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPP-Hyp-GGS-NH ₂	243	4818.4

238	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSS-Aib-APPPSGS-NH ₂	244	4888.5
239	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSG-Aib-PPPSGS-NH ₂	245	4874.5
240	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GESSGAPPPSGS-NH ₂	246	4892.5
241	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GHSSGAPPPSGS-NH ₂	247	4900.5
242	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-G-4Pal-SSGAPPPSGS-NH ₂	248	4911.5
243	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GHSSGAPPPSGS-NH ₂	249	5029.6
244	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((γ -Glu)-(2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GESSGAPPPSGS-NH ₂	250	5021.6
245	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((γ -Glu)-(2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GHSSGAPPPSGS-NH ₂	251	5029.6
246	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GESSGAPPPSGE-NH ₂	252	4934.5
247	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GHSSGAPPPSGE-NH ₂	253	4942.5
248	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-G-4Pal-SSGAPPPSGE-NH ₂	254	4953.6
249	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGPSSGAPPPHGS-NH ₂	255	4905.5
250	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGPSSGAPPTGS-NH ₂	256	4869.5
251	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGPSSGAPPP-4Pal-GS-NH ₂	257	4916.5
252	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLLEaG-4Pal-SSGAPPPSGE-NH ₂	258	4939.5

253	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEaGPSSGHPPPSGS-NH ₂	259	5057.7
254	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEaGPSSG-4Pal-PPPSGS-NH ₂	260	5068.7
255	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEaGPSSGHPPPSGH-NH ₂	261	5107.7
256	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEaGPSSGHPPPSG-4Pal-NH ₂	262	5118.7
257	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEaGPSSG-4Pal-PPPSGH-NH ₂	263	5118.7
258	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEaGPSSG-4Pal-PPPSG-4Pal-NH ₂	264	5129.8
259	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEaGPSSGAPPPSGH-NH ₂	265	4896.5
260	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGPSSGAPPPSGT-NH ₂	266	4830.4
261	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEYLLEGGPSSGAPPPGG-4Pal-NH ₂	267	4863.5
262	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEWLLEGGPSSGAPPPEG-4Pal-NH ₂	268	4958.6
263	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEWLLEaGSSSGAPPPSGT-NH ₂	269	4873.5
264	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEWLLE-Aib-GSSSGAPPPSGT-NH ₂	270	4887.5
265	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEWLLEaGHSSGAPPPSGE-NH ₂	271	4951.5
266	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEWLLE-Aib-GHSSGAPPPSGE-NH ₂	272	4965.6
267	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEWLLEGG-4Pal-SSGAPPPSGE-NH ₂	273	4948.5

268	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGG-4Pal-SSGAPPPSGT-NH ₂	274	4920.5
269	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGHSSGAPPPSGH-NH ₂	275	4945.5
270	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGSSSGAPPPSGH-NH ₂	276	4895.5
271	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Aib-AFIEWLLEGGHSSGAPPPGGE-NH ₂	277	5052.6
272	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGSSSGAPPPGGT-NH ₂	278	4829.4
273	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGHSSGAPPPGGE-NH ₂	279	4907.5
274	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPSG-4Pal-NH ₂	280	4908.5
275	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSS-Aib-APPPSGT-NH ₂	281	4889.5
276	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((γ -Glu)-(2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGT-NH ₂	282	5003.6
277	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((γ -Glu)-(2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSG-4Pal-NH ₂	283	5050.7
278	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGT-NH ₂	284	5003.6
279	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSG-4Pal-NH ₂	285	5050.7
280	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GESSGAPPPSGS-NH ₂	286	4907.5
281	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GESSGEPPPSGE-NH ₂	287	5007.6
282	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GESSGEPPPSGS-NH ₂	288	4965.5

283	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIEaGESSGAPPPSGS-NH ₂	289	4893.5
284	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIEaGESSGEPPPSGS-NH ₂	290	4951.5
285	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIA-Aib-GESSGAPPPSGS-NH ₂	291	4849.4
286	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIA-Aib-GESSGEPPPSGE-NH ₂	292	4949.5
287	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIA-Aib-GESSGEPPPSGS-NH ₂	293	4907.5
288	Y-Aib-QGTFTSDFSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLEGPPSSGEPPPSEG-NH ₂	294	4959.6
289	Y-Aib-QGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQRAFIEYLLEGPPSSGEPPPSEG-NH ₂	295	5046.6
290	H-Aib-QGT- α MeF(2F)-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AA-Aib-AFIEYLIETGPSSGEPPPSEG-NH ₂	296	4954.5
291	H-Aib-QGT- α MeF(2F)-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-AFIEYLIETGPSSGEPPPSEG-NH ₂	297	4926.5
292	Y-Aib-QGT- α MeF(2F)-TSDYSK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-QFIEYLEEGPPSSGEPPPSEG-NH ₂	298	5053.5
293	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLLEGPPSSGEPPPSEG-NH ₂	299	5021.6
294	Y-Aib-QGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AA-Aib-AFIEYLLEGPPSSGEPPPSEG-NH ₂	300	5063.7
295	Y-Aib-QGT- α MeF(2F)-TSDYSKLLDKIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLLEGPPSSGEPPPSEG-NH ₂	301	5036.6
296	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKIAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLIEGGPPSSGEPPPSEG-NH ₂	302	4964.5
297	NMeY-Aib-QGT- α MeF-TSDYSSLLDKIAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLLEGPPSSGEPPPSEG-NH ₂	303	5079.7

298	H-Aib-QGT- α MeF(2F)-TSDYSILLDDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AA-Aib-AFIEYLIEAGPSSGEPPPSEG-NH ₂	304	4924.5
299	NMeY-Aib-QGT- α MeF-TSDYSILLDKIAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLIEGGPSSGEPPPSEG-NH ₂	305	5105.7
300	NMeY-Aib-QGT- α MeF-TSDYSILLDKIAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFVQWLIAGGPSSGEPPPSEG-NH ₂	306	5055.7
301	NMeY-Aib-QGT- α MeF-TSDYSILLDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFVQWLIAGGPSSGEPPPSEG-NH ₂	307	5070.7
302	NMeY-Aib-QGT- α MeF-TSDYSILLDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFVQWLIAGGPSSGEPPPSEG-NH ₂	308	5128.7
303	Y-Aib-QGT- α MeF(2F)-TSDYSKLLDEIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLLIEGGPSSGEPPPSEG-NH ₂	309	5037.6
304	Y-Aib-QGT- α MeF(2F)-TSDYSKLLDKIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLIEGGPSSGEPPPSEG-NH ₂	310	5036.6
305	Y-Aib-QGTFTSDYSI- α MeL-LDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFVEWLLAGGPSSGEPPPSEG-NH ₂	311	5057.7
306	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKAAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)-Orn-FIEYLIEGGPSSGEPPPSEG-NH ₂	312	5022.6
307	Y-Aib-QGT- α MeF-TSDYSILLDKIAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)NFIEYLVEGGPSSGEPPPSEG-NH ₂	313	5092.7
308	Y-Aib-QGTFTSDYSI- α MeL-LDKIAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)-Orn-FVQYLIAGGPSSGEPPPSEG-NH ₂	314	5061.7
309	Y-Aib-QGT- α MeF(2F)-TSDYSKLLDKQAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFIEYLIEGGPSSGEPPPSEG-NH ₂	315	5108.6
310	Y-Aib-QGT- α MeF(2F)-TSDYSKLLDKIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)-Orn-FIEWLIEGGPSSGEPPPSEG-NH ₂	316	5102.7
311	Y-Aib-QGT- α MeF(2F)-TSDYSKILDKIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLLIEGGPSSGEPPPSEG-NH ₂	317	5036.6
312	Y-Aib-QGTFTSDYSI- α MeL-LDKIAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFVEYLIAGGPSSGEPPPSEG-NH ₂	318	5076.7

313	Y-Aib-QGTFTSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQRAFIEYLLEGGPSSGEPPPSG-NH ₂	319	4917.5
314	Y-Aib-QGTFTSDYSK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQQAFIQWLEGGPSSGEPPPSEG-NH ₂	320	5055.6
315	Y-Aib-QGTFTSDYSK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQQAFVQWLEGGPSSGEPPPSEG-NH ₂	321	5041.6
316	Y-Aib-QGTFTSDYSKLLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFVQWLEGGPSSGEPPPSEG-NH ₂	322	5012.6
317	Y-Aib-QGTFTSDYSI- α MeL-LDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFVEWLLA-Aib-GPSSGEPPPSEG-NH ₂	323	5085.7
318	Y-Aib-QGTFTSDYSI- α MeL-LDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFIEWLIEGGPSSGEPPPGEG-NH ₂	324	5156.7
319	Y-Aib-QGTFTSDYSI- α MeL-LDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFIEWLIEGGPSSGEPPPGAE-NH ₂	325	5170.8
320	Y-Aib-QGTFTSDYSI- α MeL-LDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFVEWLLAGGPSSGEPPPGEG-NH ₂	326	5084.7
321	Y-Aib-QGT- α MeF(2F)-TSD-F(4CN)-SILLDKQAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLLEGGPSSGEPPPSEG-NH ₂	327	5190.7
322	Y-Aib-QGTFTSDYSK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQQAFIEYLIAGGPSSGAPPPSSE-NH ₂	328	4947.5
323	Y-Aib-QGTFTSDYSI- α MeL-LDKIAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFVQWLE-Aib-GPSSGEPPPSEG-NH ₂	329	5184.8
324	Y-Aib-QGTFTSDYSI- α MeL-LDKIAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFVEWLLA-Aib-GPSSGEPPPSEG-NH ₂	330	5127.8
325	Y-Aib-QGTFTSDYSI- α MeL-LDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFVNWLLA-Aib-GPSSGEPPPSEG-NH ₂	331	5127.8
326	Y-Aib-QGTFTSDYSI- α MeL-LDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFVEWLIA-Aib-GPSSGEPPPSEG-NH ₂	332	5142.8
327	Y-Aib-QGTFTSDYSI- α MeL-LDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFVEWLLA-Aib-GPSSGAPPPSEG-NH ₂	333	5084.7

328	Y-Aib-QGTFTSDYSI- α MeL-LD-Orn-QAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFVEWLLA-Aib-GPSSGEPPPSEG-NH ₂	334	5128.7
329	Y-Aib-QGTFTSDYSI- α MeL-LDKQAAK((ϵ -K) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFVEWLLA-Aib-GPSSGEPPPSEG	335	5108.8
330	Y-Aib-QGT- α MeF(2F)-TSDYSKLLDKIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AFIEYLIEGGPSSGEPPPSEG-NH ₂	336	5008.6
331	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AFIEYLIEGGPSSGEPPPSEG-NH ₂	337	5009.5
332	Y-Aib-QGTFTSDYSI- α MeL-LDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFVEWLIAGGPSSGEPPPAEG-NH ₂	338	5098.7
333	Y-Aib-QGTFTSDYSI- α MeL-LDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFVEWLIA-Aib-GPSSGEPPPGEG-NH ₂	339	5112.7
334	Y-Aib-QGTFTSDYSI- α MeL-LDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFVEWLIA-Aib-GPSSGEPPPAEG-NH ₂	340	5126.8
335	Y-Aib-QGTFTSDYSI- α MeL-LDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFVEWLIA-Aib-GPSSGEPPPGSG-NH ₂	341	5070.7
336	Y-Aib-QGTFTSDYSI- α MeL-LDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFVEWLIA-Aib-GPSSGEPPPGTG-NH ₂	342	5084.7
337	Y-Aib-QGTFTSDYSK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQQAFIEYLIAGGPSSGEPPPSGD-NH ₂	343	4961.5
338	Y-Aib-QGT- α MeF(2F)-TSDYSKLLDKIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIQYLIEGGPSSGEPPPSEG-NH ₂	344	5035.6
339	Y-Aib-QGT- α MeF(2F)-TSDYSKLLDKIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLIEGGPSSGAPPPSEG-NH ₂	345	4978.6
340	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)EFIEYLIEGGPSSGAPPPSEG-NH ₂	346	4979.5
341	Y-Aib-QGT- α MeF(2F)-TSD-F(4CN)-SILLDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIQYLLEGGPSSGEPPPSEG-NH ₂	347	5044.6
342	Y-Aib-QGTFTSDYSK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQQAFVQWLIEaGPSSGEPPPSEG-NH ₂	348	5055.6
343	Y-Aib-QGTFTSDYSK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFVQWLLEGGPSSGEPPPSEG-NH ₂	349	4998.6

344	Y-Aib-QGTFTSDYSK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQQAFIEYLLAGGPSSGEPPPSGE-NH ₂	350	4975.6
345	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKQAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLLEGGPSSGEPPPSEG-NH ₂	351	5181.7
346	Y-Aib-QGT- α MeF(2F)-TSDFSILLDKQAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLLEGGPSSGEPPPSEG-NH ₂	352	5165.7
347	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKQAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLLEGGPSSGEPPPSEG-NH ₂	353	5166.7
348	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)EFIEYLIEGGPSSGEPPPSEG-NH ₂	354	5182.7
349	Y-Aib-QGTFTSDYSI- α MeL-LDKQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)QFIEYLIA-Aib-GPSSGEPPPSEG-NH ₂	355	5133.8
350	Y-Aib-QGT- α MeF(2F)-TSD-F(4CN)-SILLDKQAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLLEGGPSSGEPPPSAG-NH ₂	356	5132.7
351	Y-Aib-QGT- α MeF(2F)-TSDYSILLDAQAAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)EFIEYLIEGGPSSGEPPPSEG-NH ₂	357	4980.5
352	Y-Aib-QGT- α MeF(2F)-TSD-F(4CN)-SILLDKQAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLLEGGPSSGEPPPSEG-NH ₂	358	5174.7
353	Y-Aib-QGT- α MeF(2F)-TSD-F(4CN)-SILLDKQAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIQYLLEGGPSSGEPPPSEG-NH ₂	359	5189.8
354	Y-Aib-QGT- α MeF(2F)-TSDYSKILDKIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIQYLIEGGPSSGEPPPSEG-NH ₂	360	5035.6
355	Y-Aib-QGT- α MeF(2F)-TSDYSKILDKIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLIEGGPSSGAPPPSEG-NH ₂	361	5036.6
356	Y-Aib-QGT- α MeF(2F)-TSDYSKLLDKIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLIEGGPSSGAPPPSGE-NH ₂	362	4978.6
357	Y-Aib-QGT- α MeF(2F)-TSDYSKLLDKIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLIEGGPSSGAPPPEGE-NH ₂	363	5020.6
358	Y-Aib-QGTFTSDYSK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGESSGAPPPSGS-NH ₂	364	4894.4

359	Y-Aib-QGTFTSDYS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGESSGAPPPSGS-NH ₂	365	4880.4
360	Y-Aib-QGTFTSDYS-Dap- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGESSGAPPPSGS-NH ₂	366	4852.4
361	Y-Aib-QGTFTSDYSR- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGESSGAPPPSGS-NH ₂	367	4922.5
362	Y-Aib-QGTFTSDYSQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGESSGAPPPSGS-NH ₂	368	4894.4
363	Y-Aib-QGT- α MeF(2F)-TSD-F(4CN)-SKLLDKIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLIEGGPSSGAPPPSGS-NH ₂	369	4945.5
364	Y-Aib-QGT- α MeF(2F)-TSD-F(4CN)-SKLLDKIAQK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AFIEYLIEGGPSSGEPPPSGS-NH ₂	370	5003.6
365	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LLEGGPSSGEPPPS	371	4849.5
366	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-Aib-FIe- α MeY-LLEGGPSSGEPPPS	372	4820.4
367	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LLEGGPSSGEPPPS	373	4821.4
368	Y-Aib-QGT- α MeF(2F)-TSDY- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LLEGGPSSGEPPPS-NH ₂	374	4850.4
369	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LLEGGPSSGEPPPS-NH ₂	375	4835.4
370	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LLEGGPSSGEPPPE-NH ₂	376	4863.4
371	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LLEGGPSSGEPPPS-NH ₂	377	4805.4
372	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LLEGGPSSGEPPPE-NH ₂	378	4847.4
373	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LLEGGPSS-Aib-EPPPE-NH ₂	379	4875.5

374	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LLEGGPSSGEPPPS-NH ₂	380	4819.4
375	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LIEGGPSSGEPPPS-NH ₂	381	4819.4
376	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LLEGGPSSGEPPPS-NH ₂	382	4964.5
377	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LLEGGPSSGEPPPE-NH ₂	383	4877.5
378	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LIEGGPSSGEPPPE-NH ₂	384	4877.5
379	H-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LLEGGPSSGEPPPE-NH ₂	385	4905.5
380	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LLEGGPSS-Aib-EPPPE-NH ₂	386	4851.4
381	H-Aib-QGT- α MeF(2F)-TSDY- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGEPPPE-NH ₂	387	4809.4
382	Y-Aib-QGTFTSDY- α MeS-I- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPS-NH ₂	388	4890.5
383	Y-Aib-QGT- α MeF(2F)-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AA-Aib-AFIEYLIETGPSSGAPPSEG-NH ₂	389	5067.7
384	Y-Aib-QGT- α MeF(2F)-TSDY- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLLEGGPSSGAPPPS	390	4906.5
385	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPS-NH ₂	391	4894.5
386	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPE-NH ₂	392	4936.5
387	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPS-NH ₂	393	4737.2

388	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPE-NH ₂	394	4779.3
389	Y-Aib-QGT- α MeF-TSDY- α MeS-S- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LLEGGPSSGEPPPE-NH ₂	395	4848.4
390	Y-Aib-QGT- α MeF-TSDY- α MeS-SLLD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LLEGGPSSGEPPPE-NH ₂	396	4834.4
391	Y-Aib-QGT- α MeF-TSDY- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLLEGGPSSGEPPPE-NH ₂	397	4860.5
392	Y-Aib-QGT- α MeF-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPS-NH ₂	398	4719.3
393	Y-Aib-QGT- α MeF-TSDY- α MeS-ILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPS-NH ₂	399	4733.3
394	Y-Aib-QGT- α MeF-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPS-NH ₂	400	4733.3
395	Y-Aib-QGT- α MeF-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSEG-NH ₂	401	4919.4
396	Y-Aib-QGT- α MeF-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPE-NH ₂	402	4775.3
397	Y-Aib-QGT- α MeF-TSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPE	403	4761.3
398	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSEG-NH ₂	404	4923.4
399	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPEEG-NH ₂	405	4965.4
400	Y-Aib-QGT- α MeF(2F)-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPE	406	4793.3
401	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LIEGGPSSGEPPPSEG-NH ₂	407	5021.6
402	Y-Aib-QGT- α MeF(2F)-TSDY- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LLEGGPSSGEPPPE-NH ₂	408	5053.6

403	Y-Aib-QGT- α MeF(2F)-TSDY- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LEEGPSSGEPPPEEG-NH ₂	409	5094.6
404	Y-Aib-QGT- α MeF(2F)-TSDYSI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIeYLLEGGPSSGAPPPSEG-NH ₂	410	4907.5
405	Y-Aib-QGTFTSDFSK- α MeL-LDKK((ϵ -K) ₂ -(γ -Glu)-CO-(CH ₂) ₁₈ -CO ₂ H)AQ-Aib-AFIEYLAAGGPSSGEPPPSGE-NH ₂	411	5027.7
406	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPS-NH ₂	412	4721.2
407	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGEPPPS-NH ₂	413	4795.3
408	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPE-NH ₂	414	4866.4
409	Y-Aib-QGT- α MeF(2F)-TSDYSSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPS-NH ₂	415	4711.2
410	Y-Aib-QGT- α MeF(2F)-TSDYSILLDAK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AFIEYLEEGGPSSGAPPPSEG-NH ₂	416	4866.3
411	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE-4Pal-LEEGPSSGAPPPSEG-NH ₂	417	4908.4
412	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEFLEEGGPSSGAPPPSEG-NH ₂	418	4907.4
413	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPS-NH ₂	419	4706.2
414	Y-Aib-QGT- α MeF(2F)-TSDYSILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPS-NH ₂	420	4707.2
415	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Aad-FIEYLEEGGPSSGAPPPS-NH ₂	421	4793.3
416	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-NFIEYLEEGGPSSGAPPPS-NH ₂	422	4764.2
417	Y-Aib-QGT- α MeF(2F)-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLETGPSSGAPPPSEG-NH ₂	423	4951.5
418	Y-Aib-QGT- α MeF-TSD-4Pal-SILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPS-NH ₂	424	4833.4

419	Y-Aib-QGT- α MeF-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPS-NH ₂	425	4848.5
420	Y-Aib-QGT- α MeF-TSDY- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGEPPPE-NH ₂	426	4817.4
421	Y-Aib-QGT- α MeF(2F)-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPS-NH ₂	427	4751.3
422	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPS-NH ₂	428	4736.3
423	Y-Aib-QGT- α MeF(2F)-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPEPS-NH ₂	429	4783.3
424	Y-Aib-QGT- α MeF(2F)-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSE-NH ₂	430	4880.4
425	H-Aib-QGT- α MeF(2F)-TSDYSILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPS-NH ₂	431	4711.2
426	H-Aib-QGT- α MeF(2F)-TSDYSILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPS-NH ₂	432	4695.2
427	Y-Aib-QGT- α MeF(2F)-TSDYSILLD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPS-NH ₂	433	4852.4
428	Y-Aib-QGT- α MeF(2F)-TSDYSILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPS-NH ₂	434	4691.2
429	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LIEGGPSSGAPEPSEG-NH ₂	435	4995.6
430	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKIAQ-Aib-AFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)YLEEGGPSSGAPPPS-NH ₂	436	4721.3
431	Y-Aib-QGT- α MeF(2F)-TSDYSI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSEG-NH ₂	437	4937.4
432	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGEPPPS-NH ₂	438	4779.2
433	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSE-NH ₂	439	4850.3
434	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSEG-NH ₂	440	4907.4

435	Y-Aib-QGT- α MeF(2F)-TSDYSILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGE-NH ₂	441	4907.4
436	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-SFie- α MeY-LIEGGPSSGEPPPE-NH ₂	442	4834.4
437	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib--Orn-Fie- α MeY-LAEGGPSSGEPPPE-NH ₂	443	4819.4
438	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-Fie- α MeY-LSEGGPSSGEPPPE-NH ₂	444	4835.3
439	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-Fie- α MeY-LQEGGPSSGEPPPE-NH ₂	445	4876.4
440	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPS-NH ₂	446	4720.2
441	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPS-NH ₂	447	4706.2
442	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGEPPPS-NH ₂	448	4794.3
443	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPEPS-NH ₂	449	4768.3
444	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-IAQ-Aib-Orn-Fie- α MeY-LIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)GGPSSGEPPPE	450	4861.5
445	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPE-NH ₂	451	4778.3
446	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLSEGGPSSGAPPPS-NH ₂	452	4678.2
447	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-E- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-Fie- α MeY-LIEGGPSSGEPPPE-NH ₂	453	4877.4
448	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib--Orn-FieYLIEGGPSSGEPPPE-NH ₂	454	4847.4
449	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-NFieYLIEGGPSSGEPPPE-NH ₂	455	4847.4

450	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-NFle- α MeY-LQEGGPSSGEPPPE-NH ₂	456	4876.4
451	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-NFle- α MeY-LIEGGPSSGEPPPE-NH ₂	457	5006.5
452	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-NFle- α MeY-LIEGGPSSGEPEPE-NH ₂	458	4893.4
453	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α Me4Pal-LIEGGPSSGEPPPE-NH ₂	459	4862.5
454	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLD-Orn-IAQ-Aib-AFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)YLEEGGPSSGAPPPS-NH ₂	460	4692.3
455	Y-Aib-QGT- α MeF(2F)-TSDYSI- α MeL-LDKIAQ-Aib-AFIK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)YLEEGGPSSGAPPPS-NH ₂	461	4735.3
456	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-NFle- α MeY-LIEGGPSSGEPPPE-NH ₂	462	4877.4
457	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-TFIe- α MeY-LIEGGPSSGEPPPE-NH ₂	463	4864.4
458	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPE	464	4863.4
459	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLIEGGPSSGEPPPE-NH ₂	465	4863.4
460	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPE-NH ₂	466	4863.4
461	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LIEGGPSSGEPEPE-NH ₂	467	4909.5
462	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LIEGGPSSGEPPPEEG-NH ₂	468	5063.6
463	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-	469	5007.6

	(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSEG-NH ₂		
464	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-ILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPE-NH ₂	470	4778.3
465	Y-Aib-QGT- α MeF(2F)-TSD-3Pal- α MeS-ILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPE-NH ₂	471	4778.3
466	H-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFieYLIEGGPSSGEPPPE-NH ₂	472	4794.3
467	Y-Aib-QGT- α MeF(2F)-TSDY- α MeS-ELLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPE-NH ₂	473	4809.3
468	Y-Aib-QGT- α MeF(2F)-TSDY- α MeS-ILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPE-NH ₂	474	4938.5
469	Y-Aib-QGT- α MeF(2F)-TSDY- α MeS-ILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGEPPPE-NH ₂	475	4996.5
470	Y-Aib-QGT- α MeF(2F)-TSDYSILLDDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPEEG-NH ₂	476	4979.4
471	Y-Aib-QGT- α MeF(2F)-TSDYSILLDDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPEEG-NH ₂	477	4949.4
472	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LIEGGPSSGAPEPSEG-NH ₂	478	5140.7
473	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-NFIe- α MeY-LIEGGPSSGEPEPSEG-NH ₂	479	5037.5
474	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-NFIe- α MeY-LIEGGPSSGEPEPEEG-NH ₂	480	5079.6
475	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ- α Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPPPEEG-NH ₂	481	5126.7
476	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLIEGGPSSGEPPPEEG-NH ₂	482	5049.6
477	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLIEGGPSSGEPPPEEG-NH ₂	483	5035.6

478	H-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ- α Me4Pal-NFIEYLLEGGPSSGEPPPE-NH ₂	484	4900.4
479	H-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGEPEPE-NH ₂	485	4826.3
480	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIE- α MeY-LIEGGPSSGEPPPSEG-NH ₂	486	5005.6
481	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIE- α MeY-LIEGGPSSGEPEPSEG-NH ₂	487	5053.6
482	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-NFIEYLIEGGPSSGEPPPEEG-NH ₂	488	5049.6
483	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-NFIEYLIEGGPSSGEPPPEGE-NH ₂	489	5049.6
484	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLIEAGPSSGEPPPEEG-NH ₂	490	5063.6
485	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLIEAGPSSGEPPPEEG-NH ₂	491	5192.8
486	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGEPPPS-NH ₂	492	4780.3
487	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGEPPPE-NH ₂	493	4836.3
488	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGEPPPSEG-NH ₂	494	4980.5
489	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLIEGGPSSGEPPPSEG-NH ₂	495	4993.5
490	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIE- α MeY-LIEGGPSSGEPPPSEG-NH ₂	496	5166.8
491	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-	497	5152.7

	(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLIEGGPSSGEPPPSEG-NH ₂		
492	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLIEGGPSSGAPEPSEG-NH ₂	498	5126.7
493	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGEPPPSEG-NH ₂	499	4980.5
494	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib--Orn-FIEYLLEGGPSSGEPPPSEG-NH ₂	500	5035.6
495	Y-Aib-QGT- α MeF(2F)-TSD-F(4NO ₂)-SI- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPE-NH ₂	501	4822.3
496	Y-Aib-QGTFTSDFS-Orn-aMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE-4Pal-LLEGGPSSGAPPPGGS-NH ₂	502	4787.4
497	Y-Aib-QGTFTSD-4Pal-S-Orn-aMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ- α Me4Pal-AFIE-aMeY-LIEGGPSSGAPPPSGS-NH ₂	503	4924.5
498	Y-Aib-QGTFTSD-4Pal-SQ-aMeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ- α Me4Pal-AFIE- α Me4Pal-LIE-Aib-GPSSGAPPPSGS-NH ₂	504	4951.5
499	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPPPEGT	505	5084.7
500	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIeYLIEGGPSSGEPPPEGT-NH ₂	506	5084.7
501	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGTE-NH ₂	507	5108.7
502	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGT	508	4980.5
503	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPEGTE-NH ₂	509	5163.7
504	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPSGTE-NH ₂	510	5121.6

505	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIE- α MeY-LIEGGPSSGEPPEGT-NH ₂	511	5098.7
506	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIE- α MeY-LEEPPSSGEPPEGT-NH ₂	512	5114.6
507	Y-Aib-QGT- α MeFTSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIE- α MeY-LIEGGPSSGEPPEGT-NH ₂	513	5098.7
508	Y-Aib-QGT- α MeFTSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIE- α MeY-LIEGGPSSGAPPEGT-NH ₂	514	5040.6
509	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGTE-NH ₂	515	4993.5
510	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGTGE-NH ₂	516	5050.5
511	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGTE	517	4994.4
512	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGTGE	518	5051.5
513	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGTE-NH ₂	519	4979.4
514	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGTGE-NH ₂	520	5036.5
515	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGTE	521	4980.4
516	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGTGE	522	5037.5
517	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIE- α MeY-LSEGGPSSGEPPPSGTE-NH ₂	523	5080.6

518	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LSEGGPSSGEPPPSGTGE-NH ₂	524	5137.6
519	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LSEGGPSSGEPPPSGTE	525	5081.6
520	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LSEGGPSSGEPPPSGTGE	526	5138.6
521	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGTE-NH ₂	527	5092.6
522	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGTE	528	5093.6
523	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGTGE-NH ₂	529	5149.7
524	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGTGE	530	5150.7
525	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-NFIe- α MeY-LQEGGPSSGEPPPEGTE-NH ₂	531	5034.5
526	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-NFIe- α MeY-LQEGGPSSGEPPPEGTE-NH ₂	532	5163.6
527	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-NFIe- α MeY-LQEGGPSSGEPPPEGTE-NH ₂	533	5220.7
528	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-QFIe- α MeY-LQEGGPSSGEPPPEGTE-NH ₂	534	5177.7
529	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-QFIe- α MeY-LQEGGPSSGEPPPEGTE-NH ₂	535	5234.7
530	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLSEGGPSSGEPPPSGTE-NH ₂	536	5066.6
531	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I-LLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGTE-NH ₂	537	5078.6

532	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGTE-NH ₂	538	5092.6
533	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGTEE-NH ₂	539	5237.8
534	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGTEEE-NH ₂	540	5366.9
535	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGTEE-NH ₂	541	5221.8
536	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGTEEE-NH ₂	542	5350.9
537	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGTEE	543	5238.8
538	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGTEEE-NH ₂	544	5367.9
539	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGTEE	545	5222.7
540	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGTEEE-NH ₂	546	5351.8
541	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIeYLIEGGPSSGEPPPEGT	547	5068.6
542	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LTEGGPSSGEPPPSGTE-NH ₂	548	5094.6
543	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LTEGGPSSGEPPPSGTGE-NH ₂	549	5151.7
544	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LAEGGPSSGEPPPSGTE-NH ₂	550	5064.6

545	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LAEGGPSSGEPPPSGTGE-NH ₂	551	5121.6
546	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-ILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPEGAE-NH ₂	552	5119.6
547	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-ILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPSGAE-NH ₂	553	5077.6
548	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-ILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGTGE-NH ₂	554	5135.7
549	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDK-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLEEGGPSSGAPPPSGTE-NH ₂	555	5016.5
550	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDK-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE-4Pal-LEEGGPSSGAPPPSGTE-NH ₂	556	4978.5
551	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDK-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LEEGGPSSGAPPPSGTE-NH ₂	557	5007.5
552	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDK-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE-Me4Pal-LEEGGPSSGAPPPSGTE-NH ₂	558	4992.5
553	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDK-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLQEGGPSSGAPPPSGTE-NH ₂	559	4992.5
554	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDK-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLTEGGPSSGAPPPSGTE-NH ₂	560	4965.5
555	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-ILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSETE-NH ₂	561	5120.7
556	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-ILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPEGTEE-NH ₂	562	5249.8
557	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPEGTEE-NH ₂	563	5292.9
558	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPEGTEEE-NH ₂	564	5422.0

559	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LSEGGPSSGEPPPSGGE-NH ₂	565	5036.6
560	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LSEGGPSSGEPPPSGSE-NH ₂	566	5066.6
561	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LSEGGPSSGEPPPSGTEE-NH ₂	567	5209.8
562	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LSEGGPSSGEPPPSGTEEE-NH ₂	568	5338.9
563	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((Glu)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LSEGGPSSGEPPPSGTE-NH ₂	569	5080.7
564	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((Glu)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LSEGGPSSGEPPPSGTEE-NH ₂	570	5209.8
565	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu)-(Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LSEGGPSSGEPPPSGTE-NH ₂	571	5080.7
566	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu)-(Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LSEGGPSSGEPPPSGTEE-NH ₂	572	5209.8
567	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LSEGGPSSGEPPPSGAEE-NH ₂	573	5179.8
568	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LSEGGPSSGEPPPSGGEE-NH ₂	574	5165.7
569	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LSEGGPSSGEPPPSGSEE-NH ₂ -NH ₂	575	5195.7
570	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LSEGGPSSGEPPPSGQEE-NH ₂	576	5236.8
571	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LAEGGPSSGEPPPSGTEE-NH ₂	577	5193.8
572	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPSGTEE-NH ₂	578	5250.8

573	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPSGTEEE-NH ₂	579	5379.9
574	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-ILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPEGAE-NH ₂	580	5248.8
575	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-ILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPSGAEE-NH ₂	581	5206.8
576	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-ILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPSGTEE-NH ₂	582	5207.8
577	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-ILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPPEGTEEE-NH ₂	583	5379.0
578	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLQEGGPSSGAPPPSGTEE-NH ₂	584	5144.7
579	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLQEGGPSSGEPPPSGTEE-NH ₂	585	5202.7
580	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLQEGGPSSGAPPPSGTEE-NH ₂	586	5121.7
581	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLQEGGPSSGAPPPSGTEE-NH ₂	587	5107.6
582	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLQEGGPSSGAPPPSGTEE-NH ₂	588	5150.7
583	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLQEGGPSSGEPPPSGTEE-NH ₂	589	5165.7
584	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIeYLIEGGPSSGEPPPSGTEE-NH ₂	590	5270.9
585	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPEGSEE-NH ₂	591	5278.8
586	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPEGGEE-NH ₂	592	5248.8

587	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPEGAAEE-NH ₂	593	5262.8
588	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPEGEEEE-NH ₂	594	5320.9
589	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LAEGGPSSGEPPPSGSEE-NH ₂ -NH ₂	595	5179.7
590	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LAEGGPSSGEPPPSGGEE-NH ₂	596	5149.7
591	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LAEGGPSSGEPPPSGAEE-NH ₂	597	5163.7
592	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LAEGGPSSGEPPPSGEEEE-NH ₂	598	5221.8
593	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((Glu)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPEGTEE-NH ₂	599	5292.9
594	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((Glu)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPEGTEEE-NH ₂	600	5422.0
595	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPEGTEE-NH ₂	601	5292.9
596	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPEGTEEE-NH ₂	602	5422.0
597	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LTEGGPSSGEPPPEGTEE-NH ₂	603	5265.8
598	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LTEGGPSSGEPPPEGTEEE-NH ₂	604	5395.0
599	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPEGTEE-NH ₂	605	5320.9
600	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPPEGTEEE-NH ₂	606	5450.0

601	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPEEGTEE	607	5293.8
602	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPEEGTEE	608	5423.0
603	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-ILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPEEGSEE-NH ₂	609	5235.8
604	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-ILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPEEGAAEE-NH ₂	610	5219.8
605	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-ILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPEEGGEE-NH ₂	611	5205.8
606	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-ILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIeYLIEGGPSSGEPPEEGEEE-NH ₂	612	5277.8
607	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGEPPPSGTGE-NH ₂	613	5108.6
608	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGEPPPSGTEE-NH ₂	614	5180.7
609	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGTEE-NH ₂	615	5122.7
610	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGSEE-NH ₂	616	5108.6
611	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGEEE-NH ₂	617	5150.7
612	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGGEE-NH ₂	618	5078.6
613	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LLEGGPSSGAPPPSGE-NH ₂	619	5186.8

614	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGAPPPSGE-NH ₂	620	5041.7
615	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LLEGGPSSGAPPPSGE-NH ₂	621	5041.7
616	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGAPPPSGE-NH ₂	622	5025.6
617	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LLEGGPSSGAPPPSGE-NH ₂	623	5025.6
618	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGSGE-NH ₂	624	5036.6
619	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGGGE-NH ₂	625	5006.5
620	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGAGE-NH ₂	626	5020.6
621	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGEGE-NH ₂	627	5078.6
622	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGTGE-NH ₂	628	5064.6
623	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGEGE-NH ₂	629	5092.6
624	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGEPSPSGTGE-NH ₂	630	5122.7
625	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGEPSPSGEGE-NH ₂	631	5150.7
626	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPEGTGE-NH ₂	632	5106.7

627	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPEGTGE-NH ₂	633	5134.7
628	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGEPPPEGTGE-NH ₂	634	5164.7
629	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGEPPPEGTGE-NH ₂	635	5192.7
630	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGEPPPSGSEE-NH ₂	636	5166.7
631	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLAEGGPSSGEPPPSGSEE-NH ₂	637	5108.6
632	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLSEGGPSSGEPPPSGSEE-NH ₂	638	5124.6
633	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLTEGGPSSGEPPPSGSEE-NH ₂	639	5138.6
634	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLQEGGPSSGEPPPSGSEE-NH ₂	640	5165.7
635	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLEEGGPSSGEPPPSGSEE-NH ₂	641	5209.7
636	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLAEGGPSSGEPPPSGSEE-NH ₂	642	5151.7
637	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLSEGGPSSGEPPPSGSEE-NH ₂	643	5167.7
638	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLTEGGPSSGEPPPSGSEE-NH ₂	644	5181.7
639	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLQEGGPSSGEPPPSGSEE-NH ₂	645	5208.7
640	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -	646	4999.6

	CO ₂ H)AQ-Me4Pal-EFle- α MeY-LIEGGPSSGAPPPSGS-NH ₂		
641	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFle- α MeY-LLEGGPSSGAPPPSGS-NH ₂	647	4999.6
642	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFle- α MeY-LAEGGPSSGAPPPSGS-NH ₂	648	4957.5
643	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFle- α MeY-LQEGGPSSGAPPPSGS-NH ₂	649	5014.6
644	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFle- α MeY-LIEGGPSSGEPPPSGS-NH ₂	650	5057.7
645	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFle- α MeY-LLEGGPSSGEPPPSGS-NH ₂	651	5057.7
646	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFle- α MeY-LAEGGPSSGAPPPSGS-NH ₂	652	4941.5
647	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFle- α MeY-LQEGGPSSGAPPPSGS-NH ₂	653	4998.6
648	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFle- α MeY-LQEGGPSSGEPPPSGS-NH ₂	654	5072.6
649	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFle- α MeY-LQEGGPSSGEPPPSGS-NH ₂	655	5056.6
650	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLAEGGPSSGEPPPEGSEE-NH ₂	656	5193.7
651	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLSEGGPSSGEPPPEGSEE-NH ₂	657	5209.7

652	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLTEGGPSSGEPPEGSEE-NH ₂	658	5223.8
653	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIEYLQEGGPSSGEPPEGSEE-NH ₂	659	5250.8
654	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu)-(6-aminohexanoic acid)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPEGTEE-NH ₂	660	5305.0
655	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPEGTEE-NH ₂	661	5337.0
656	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu)-(ϵ -Lys)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPEGTEE-NH ₂	662	5320.0
657	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu)-e-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPEGTEE-NH ₂	663	5320.9
658	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu)-(Gly)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LQEGGPSSGEPPEGTEE-NH ₂	664	5248.9
659	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPEGTE-NH ₂	665	5035.6
660	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPEGTGE-NH ₂	666	5092.6
661	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLAadEGGPSSGAPPPSGTGE-NH ₂	667	5064.6
662	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLEEGGPSSGAPPPSGTGE-NH ₂	668	5066.6
663	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLAadEGGPSSGAPPPSGTGE-NH ₂	669	5080.7
664	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LEEGGPSSGAPPPSGTGE-NH ₂	670	5064.6

665	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LEEGPSSGAPPPSGTGE-NH ₂	671	5050.6
666	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LEEGPSSGAPPPSGSGE-NH ₂	672	5050.6
667	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LEEGPSSGAPPPSGEGE-NH ₂	673	5092.6
668	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LEEGPSSGAPPPSGGGE-NH ₂	674	5020.6
669	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LEEGPSSGAPPPSGTGE-NH ₂	675	5080.7
670	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIE- α MeY-LLEGGPSSGAPPPSGE	676	4985.6
671	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	677	4879.5
672	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIE- α MeY-LLEGGPSSGAPPPSGS-NH ₂	678	4879.5
673	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	679	4863.5
674	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SILLD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIE- α MeY-LEEGPSSGAPPPSGTGE-NH ₂	680	5093.7
675	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIE- α MeY-LIEGGPSSGEPPEGE-NH ₂	681	5126.8
676	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIE- α MeY-LIEGGPSSGEPPEAE-NH ₂	682	5140.8
677	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -	683	5156.8

	CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPPPESE-NH ₂		
678	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPPPETE-NH ₂	684	5170.8
679	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPPPEGTE-NH ₂	685	5227.9
680	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPPPEGTGE-NH ₂	686	5284.9
681	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPPPEEG-NH ₂	687	5110.7
682	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPPPSGE-NH ₂	688	5068.7
683	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPPPEGE-NH ₂	689	5110.7
684	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPPPEAE-NH ₂	690	5124.8
685	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPPPESE-NH ₂	691	5140.8
686	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPPPETE-NH ₂	692	5154.8
687	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPPPEGTE	693	5211.8
688	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPPPEGTGE-NH ₂	694	5268.9
689	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGTGE-NH ₂	695	5079.7

690	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGTGE-NH ₂	696	5063.7
691	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPPPEGTE-NH ₂	697	5227.9
692	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPPPEGE-Ge-NH ₂	698	5284.9
693	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LVEGGPSSGAPPPSGS-NH ₂	699	4865.5
694	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGAPPPSGS-NH ₂	700	4999.6
695	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LVEGGPSSGEPPPSGS-NH ₂	701	4907.5
696	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGAPPPSGS-NH ₂	702	4983.6
697	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LIEGGPSSGEPPPEGTGE-NH ₂	703	5221.9
698	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-Orn-FIe- α MeY-LIEGGPSSGEPPPEGE-NH ₂	704	5063.7
699	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGS-NH ₂	705	5013.7
700	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGS-NH ₂	706	4997.6
701	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGE-NH ₂	707	4921.6

702	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGSE-NH ₂	708	5008.6
703	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGEE-NH ₂	709	5022.7
704	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGSEE-NH ₂	710	5137.7
705	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGEEE-NH ₂	711	5151.8
706	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPSPSGS-NH ₂	712	5042.7
707	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGEPSPSGS-NH ₂	713	4937.6
708	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGS-NH ₂	714	4921.5
709	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGTGE-NH ₂	715	5121.7
710	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGEPSPSGS-NH ₂	716	5071.7
711	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGEPSPSGTGE-NH ₂	717	5271.9
712	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGSE-NH ₂	718	5142.8
713	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGSEE-NH ₂	719	5271.9

714	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGTGE-NH ₂	720	5213.9
715	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGEPPPSGS-NH ₂	721	5055.7
716	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGEPPPSGSE-NH ₂	722	5184.8
717	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGSE-NH ₂	723	5126.7
718	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGTGE-NH ₂	724	5197.8
719	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGEPPPSGTE-NH ₂	725	5022.7
720	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGEPPPSGSe-NH ₂	726	5022.7
721	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGe-NH ₂	727	4921.6
722	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGAPPPSG- γ E-NH ₂	728	4921.6
723	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGTGe-NH ₂	729	5079.7
724	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGTG- γ E-NH ₂	730	5079.7
725	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGTEE-NH ₂	731	5151.8

726	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGTE- γ E-NH ₂	732	5151.8
727	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGDPPPEGE-NH ₂	733	5112.7
728	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGDPPPEAE-NH ₂	734	5126.8
729	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGDPPPESE-NH ₂	735	5142.8
730	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGDPPPETE-NH ₂	736	5156.8
731	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGDPPPEGTE-NH ₂	737	5213.9
732	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGDPPPEGTGE-NH ₂	738	5270.9
733	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGEPPPSGS-NH ₂	739	5057.7
734	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGEPPPSGTGE-NH ₂	740	5257.9
735	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGEPPPSGGGE-NH ₂	741	5213.8
736	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGEPPPSGSEE-NH ₂	742	5315.9
737	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGEPPPSGS-NH ₂	743	5041.6

738	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGEPPPSGTGE-NH ₂	744	5241.8
739	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGEPPPSGGGE-NH ₂	745	5197.8
740	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGEPPPSGSEE-NH ₂	746	5299.9
741	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGGGE-NH ₂	747	5169.8
742	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGEPPPSGGGE-NH ₂	748	5227.8
743	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGGGE-NH ₂	749	5153.8
744	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGEPPPSGGGE-NH ₂	750	5211.8
745	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGGGE-NH ₂	751	5035.7
746	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGEPPPSGGGE-NH ₂	752	5093.7
747	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGGGE-NH ₂	753	5019.6
748	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-EFIe- α MeY-LIEGGPSSGEPPPSGGGE-NH ₂	754	5077.7
749	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGAPPPSGE-NH ₂	755	5041.7
750	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-	756	5099.7

	(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie-αMeY-LVEGGPSSGEPPPSGE-NH ₂		
751	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-αMeS-I-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie-αMeY-LVEGGPSSGAPPPSGSE-NH ₂	757	5128.7
752	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-αMeS-I-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie-αMeY-LVEGGPSSGEPPPSGE-NH ₂	758	5186.8
753	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-SI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-Fie-αMeY-LIEGGPSSGEPPPESEE-NH ₂	759	5285.9
754	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-SI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-Fie-αMeY-LIEGGPSSGEPPPESEEE-NH ₂	760	5343.0
755	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-SI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-Fie-αMeY-LIEGGPSSGAPPPPESE-NH ₂	761	5098.8
756	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-SI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-Fie-αMeY-LIEGGPSSGAPPPPESEE-NH ₂	762	5227.9
757	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-SI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-Fie-αMeY-LIEGGPSSGEPPPEGGE-NH ₂	763	5240.9
758	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-SI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-Fie-αMeY-LIEGGPSSGAPPPPEGGE-NH ₂	764	5182.8
759	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-αMeS-I-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie-αMeY-LIEGGPSSGAPPPPEGGE-NH ₂	765	5211.8
760	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-αMeS-I-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie-αMeY-LIEGGPSSGEPPPEGGE-NH ₂	766	5269.9
761	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-αMeS-I-αMeL-LD-Orn-K((γ-Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie-αMeY-LIEGGPSSGAPPPPEGGE-NH ₂	767	5195.8

762	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGEPPPEGGE-NH ₂	768	5253.8
763	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGEPPPEGTGE-NH ₂	769	5313.9
764	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGAPPPEGTGE-NH ₂	770	5239.8
765	Y-Aib-QaT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-Fie- α MeY-LIEGGPSSGEPPPESE-NH ₂	771	5170.8
766	Y-Aib-QaT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGEPPPSGTGE-NH ₂	772	5285.9
767	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)YQ-Me4Pal-EFie- α MeY-LVEGGPSSGAPPPSGS-NH ₂	773	5091.7
768	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LE-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LVEGGPSSGAPPPSGS-NH ₂	774	5013.7
769	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LVEGGPSSGAPPPSGGGE-NH ₂	775	5155.8
770	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSS-Aib-APPPGGS-NH ₂	776	4814.4
771	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSG-Aib-PPPGGS-NH ₂	777	4800.37
772	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPEGS-NH ₂	778	4830.4
773	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGEPPPSGS-NH ₂	779	4846.4

774	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEWLLEGGPSSGAPPEGS-NH ₂	780	4911.5
775	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPSGS-NH ₂	781	4860.4
776	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPSGT-NH ₂	782	4874.5
777	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPSG-4Pal-NH ₂	783	4921.5
778	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPSGT	784	4875.4
779	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSS-Aib-APPPSGT-NH ₂	785	4902.5
780	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSS-Aib-APPPSGT	786	4903.5
781	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGT-NH ₂	787	4888.5
782	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSG-4Pal-NH ₂	788	4935.5
783	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGT	789	4889.5
784	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GPSSGAPPPSGS-NH ₂	790	4858.4
785	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GESSGAPPPSGT-NH ₂	791	4920.5
786	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GESSGAPPPSGT	792	4921.5
787	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GESSGAPPPSGS-NH ₂	793	5051.6

788	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GESSGEPPPSGS-NH ₂	794	4964.5
789	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GESSGAPPPSGE-NH ₂	795	4948.5
790	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLE-Aib-GESSGEPPPSGE-NH ₂	796	5006.5
791	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIEGGESSGAPPPSGS-NH ₂	797	4942.5
792	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIEGGESSGAPPPSGS-NH ₂	798	4984.5
793	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIEGGESSGAPPPSGS-NH ₂	799	4956.5
794	Y-Aib-QGTFTSDFS- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIEGGESSGAPPPSGS-NH ₂	800	4983.5
795	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIEGGESSGAPPPSGS-NH ₂	801	4955.5
796	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	802	4860.5
797	Y-Aib-QGTFTSDFS- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	803	4874.5
798	Y-Aib-QGTFTSDFS- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	804	4902.5
799	Y-Aib-QGTFTSDFS-Dab- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	805	4846.4
800	Y-Aib-QGTFTSDFS-Dap- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	806	4832.4
801	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	807	4875.5

802	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	808	4903.5
803	Y-Aib-QGTFTSD-4Pal-SDab- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	809	4847.4
804	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-SPSSGAPPPSGS-NH ₂	810	4890.5
805	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-SPSSGAPPPSGS-NH ₂	811	4904.5
806	Y-Aib-QGTFTSDFSR- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-SPSSGAPPPSGS-NH ₂	812	4932.5
807	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-SPSSGAPPPSGS-NH ₂	813	4933.5
808	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	814	4938.5
809	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	815	4980.6
810	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	816	4952.5
811	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	817	4937.6
812	Y-Aib-QGTFTSDFSR- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	818	4979.6
813	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	819	4951.5
814	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	820	5083.7
815	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	821	5125.7

816	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	822	5097.7
817	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	823	5096.7
818	Y-Aib-QGTFTSDFSQ- α MeL-LD-Orn-K((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	824	4937.5
819	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	825	4935.5
820	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPSGS-NH ₂	826	4861.4
821	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPSGT-NH ₂	827	4875.4
822	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPSG-4Pal-NH ₂	828	4922.5
823	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSSGAPPPSGT	829	4876.4
824	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSS-Aib-APPPSGT	830	4903.5
825	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEaGPSS-Aib-APPPSGT	831	4904.5
826	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIEGGPSSGAPPPSGS-NH ₂	832	4924.5
827	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGS-NH ₂	833	4866.4
828	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGEPPPSGS-NH ₂	834	4924.5
829	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIEaGPSSGAPPPSGS-NH ₂	835	4938.5

830	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEWLIEGGPSSGAPPPSGS-NH ₂	836	4947.5
831	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEWLIEGGPSSGAPPPSGT-NH ₂	837	4961.5
832	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEWLIEGGPSSGAPPPSG-4Pal-NH ₂	838	5008.6
833	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	839	4938.5
834	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGT-NH ₂	840	4966.6
835	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSG-4Pal-NH ₂	841	5013.6
836	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	842	4847.4
837	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	843	4889.5
838	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	844	4861.4
839	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	845	4846.4
840	Y-Aib-QGTFTSDFSR- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	846	4888.5
841	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	847	4860.4
842	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	848	4924.5

843	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	849	4966.6
844	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	850	4938.5
845	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	851	4923.5
846	Y-Aib-QGTFTSDFS- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	852	4965.6
847	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	853	4937.5
848	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSSS-NH ₂	854	4982.6
849	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	855	4924.5
850	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	856	4847.4
851	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPEGS-NH ₂	857	4994.6
852	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGAPPPEGS-NH ₂	858	4980.5
853	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LIEGGPSSGAPPPEGS-NH ₂	859	4903.5
854	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	860	5009.6
855	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	861	4995.6

856	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	862	4995.6
857	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	863	4981.5
858	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	864	4936.5
859	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₃ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	865	5065.6
860	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	866	5081.6
861	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	867	5081.6
862	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((γ -Glu) ₃ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	868	5064.6
863	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	869	5080.7
864	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	870	5080.7
865	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	871	4922.5
866	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₃ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	872	5051.6
867	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	873	5067.7
868	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	874	5067.7

869	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGS-NH ₂	875	4995.6
870	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGS-NH ₂	876	4850.4
871	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEWLIEGGPSSGAPPPSGS-NH ₂	877	5076.6
872	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEWLIEGGPSSGAPPPSGS-NH ₂	878	4931.5
873	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGS-NH ₂	879	4923.5
874	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGS-NH ₂	880	4907.4
875	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGS-NH ₂	881	4865.4
876	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGS-NH ₂	882	4849.4
877	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEWLIEGGPSSGAPPPSGS-NH ₂	883	4946.5
878	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEWLIEGGPSSGAPPPSGS-NH ₂	884	4930.5
879	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	885	4995.6
880	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-DFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	886	4981.6
881	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGE-NH ₂	887	4994.6
882	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGE-NH ₂	888	4978.5

883	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGE-NH ₂	889	4892.4
884	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPEGE-NH ₂	890	5020.6
885	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS	891	4953.5
886	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSE-NH ₂	892	5081.6
887	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSE	893	5082.6
888	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSGE-NH ₂	894	5138.7
889	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSGE	895	5139.7
890	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSE-NH ₂	896	5065.6
891	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSGE	897	5122.6
892	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSE	898	5066.6
893	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSGE	899	5123.6
894	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((Glu)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	900	4936.5
895	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((Glu) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	901	5065.6
896	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((Glu)-(γ -Glu)-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	902	5065.6

897	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSEE-NH ₂	903	5210.8
898	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSEEE-NH ₂	904	5339.9
899	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSEE-NH ₂	905	5194.7
900	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSEEE-NH ₂	906	5323.8
901	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GPSSGAPPPSGSE-NH ₂	907	5005.6
902	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GPSSGAPPPSGSEE-NH ₂	908	5134.7
903	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GPSSGAPPPSGSEEE-NH ₂	909	5263.8
904	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GPSSGAPPPSGSE-NH ₂	910	4988.6
905	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GPSSGAPPPSGSEE-NH ₂	911	5117.7
906	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GPSSGAPPPSGSEEE-NH ₂	912	5246.8
907	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	913	4859.4
908	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLIEGGPSSGAPPPSGS-NH ₂	914	4847.4
909	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LLEGGPSSGAPPPSGS-NH ₂	915	4889.5
910	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LLEGGPSSGAPPPSGS-NH ₂	916	4861.4

911	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LLEGGPSSGAPPPSGS-NH ₂	917	4847.4
912	Y-Aib-QGTFTSDFSK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE-Me4Pal-LIE-Aib-GPSSGAPPPSGS-NH ₂	918	4873.5
913	Y-Aib-QGTFTSDFSQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE-Me4Pal-LIE-Aib-GPSSGAPPPSGS-NH ₂	919	4873.5
914	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE-Me4Pal-LIE-Aib-GPSSGAPPPSGS-NH ₂	920	4874.5
915	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	921	4952.6
916	Y-Aib-QGTFTSD-4Pal-SK- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIE-Aib-GPSSGAPPPSGS-NH ₂	922	4951.6
917	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIE-Aib-GPSSGAPPPSGS-NH ₂	923	4951.5
918	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSeG	924	4995.5
919	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSeE	925	5067.6
920	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	926	4936.5
921	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((e) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	927	5065.6
922	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu)-(e) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	928	5065.6
923	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK(e-(γ -Glu)-e-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	929	5065.6
924	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSE-NH ₂	930	5066.6

925	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((e) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSE-NH ₂	931	5195.7
926	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu)-(e) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSE-NH ₂	932	5195.7
927	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK(e-(γ -Glu)-e-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSE-NH ₂	933	5195.7
928	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSEE-NH ₂	934	5195.7
929	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((e) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSEE-NH ₂	935	5324.8
930	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu)-(e) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSEE-NH ₂	936	5324.8
931	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK(e-(γ -Glu)-e-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSEE-NH ₂	937	5324.8
932	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LLEGGPSSGAPPPSGS-NH ₂	938	4924.5
933	Y-Aib-QGTFTSD-4Pal-S-Orn-- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LLEGGPSSGAPPPSGS-NH ₂	939	4833.4
934	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	940	4979.5
935	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	941	4922.5
936	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSE-NH ₂	942	5051.6
937	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSEE-NH ₂	943	5180.7

938	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDK-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LLEGGPSSGAPPPSGS-NH ₂	944	4845.4
939	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	945	4908.5
940	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIEYLIE-Aib-GPSSGAPPPSGS-NH ₂	946	4965.5
941	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	947	4831.4
942	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LLEGGPSSGAPPPSGS-NH ₂	948	4831.4
943	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₃ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGSE-NH ₂	949	5166.7
944	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LLEGGPSSGAPPPSGSEE-NH ₂	950	5089.6
945	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LLEGGPSSGAPPPSGSEE-NH ₂	951	5103.6
946	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LLEGGPSSGAPPPSGSEE-NH ₂	952	5089.6
947	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGEPPPSGS-NH ₂	953	5053.6
948	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIEGGPSSGAPPPSGS-NH ₂	954	4923.5
949	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIEGGPSSGAPPPSGS-NH ₂	955	4909.5
950	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIEGGPSSGAPPPSGS-NH ₂	956	4951.5

951	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIEGGPSSGAPPPSGS-NH ₂	957	4907.4
952	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIEGGPSSGAPPPSGS-NH ₂	958	4893.5
953	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIEGGPSSGAPPPSGS-NH ₂	959	4935.5
954	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIEGGPSSGAPPPSGSEE-NH ₂	960	5181.7
955	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIEGGPSSGAPPPSGSEE-NH ₂	961	5167.7
956	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIEGGPSSGAPPPSGSEE-NH ₂	962	5209.8
957	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIEGGPSSGAPPPSGSEE-NH ₂	963	5165.7
958	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIEGGPSSGAPPPSGSEE-NH ₂	964	5151.7
959	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIEGGPSSGAPPPSGSEE-NH ₂	965	5193.7
960	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGSEE-NH ₂	966	5109.6
961	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGSEE-NH ₂	967	5095.6
962	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGSEE-NH ₂	968	5137.7
963	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGESSGAPPPSGSEE-NH ₂	969	5141.6

964	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGESSGAPPPSGSEE-NH ₂	970	5127.6
965	Y-Aib-QGTFTSD-4Pal-SR- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGESSGAPPPSGSEE-NH ₂	971	5169.7
966	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGAPPPSGSE-NH ₂	972	5038.6
967	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGAPPPSGSEE-NH ₂	973	5167.7
968	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGEPPPSGS-NH ₂	974	4908.4
969	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPEGS	975	4892.4
970	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGEPPPEGS	976	4951.5
971	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGEPPPSGSSE	977	5095.6
972	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIEGGPSSGAPPPSGSEE-NH ₂	978	5209.8
973	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIE- α MeY-LIEGGPSSGAPPPSGSEE-NH ₂	979	5210.8
974	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIE- α MeY-LIEGGPSSGAPPPSGSEE-NH ₂	980	5195.8
975	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LLEGPPSSGAPPPSGSEE-NH ₂	981	5209.8
976	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIE- α MeY-LLEGPPSSGAPPPSGSEE-NH ₂	982	5210.8
977	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGEPPPSGSE	983	5024.5

978	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGEPPPSGSGE	984	5081.6
979	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGEPPPSGSE-NH ₂	985	4936.5
980	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGEPPPSGTE-NH ₂	986	5037.6
981	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGEPPPSGTEE-NH ₂	987	5166.7
982	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGEPPPSGTEEE-NH ₂	988	5295.8
983	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGEPPPSGSE-NH ₂	989	4922.5
984	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGEPPPSGTE-NH ₂	990	5023.6
985	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGEPPPSGTEE-NH ₂	991	5152.7
986	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGEPPPSGTEEE-NH ₂	992	5281.8
987	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIE-Aib-GPSSGEPPPSGS-NH ₂	993	5124.7
988	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIE-Aib-GPSSGEPPPSGSE-NH ₂	994	5253.8
989	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIE-Aib-GPSSGEPPPSGS-NH ₂	995	4979.6
990	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIE-Aib-GPSSGEPPPSGSE-NH ₂	996	5108.7

991	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIE-Aib-GPSSGEPPPSGS-NH ₂	997	4965.5
992	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIAGGPSSGAPPPSGSEE-NH ₂	998	5136.8
993	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIE- α MeY-LIAGGPSSGAPPPSGSEE-NH ₂	999	5137.7
994	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIE- α MeY-LIAGGPSSGAPPPSGSEE-NH ₂	1000	5122.8
995	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LLAGGPSSGAPPPSGSEE-NH ₂	1001	5136.8
996	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIE- α MeY-LLAGGPSSGAPPPSGSEE-NH ₂	1002	5137.7
997	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIE- α MeY-LLAGGPSSGAPPPSGSEE-NH ₂	1003	5122.8
998	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LLAGGPSSGAPPPSGSEE-NH ₂	1004	5150.7
999	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIE- α MeY-LLAGGPSSGAPPPSGSEE-NH ₂	1005	5151.7
1000	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIEYLIAGGPSSGAPPPSGSEE-NH ₂	1006	5137.7
1001	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIEYLIAGGPSSGAPPPSGSEE-NH ₂	1007	5138.7
1002	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIEYLLAGGPSSGAPPPSGSEE-NH ₂	1008	5137.7
1003	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIEYLLAGGPSSGAPPPSGSEE-NH ₂	1009	5138.7
1004	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-Orn-FIEYLLAGGPSSGAPPPSGSEE-NH ₂	1010	5123.8

1005	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIEYLIAGGPSSGAPPPSGSEE-NH ₂	1011	5151.7
1006	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIEYLLAGGPSSGAPPPSGSEE-NH ₂	1012	5151.7
1007	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGEPPPSGS-NH ₂	1013	4894.4
1008	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGEPPPSGSE-NH ₂	1014	5023.5
1009	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDK-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGSE-NH ₂	1015	4965.5
1010	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDK-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSESE-NH ₂	1016	5007.6
1011	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGSE-NH ₂	1017	4951.5
1012	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSESE-NH ₂	1018	4993.5
1013	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGAPPPSGS-NH ₂	1019	4894.5
1014	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIAGGPSSGEPPPSGS-NH ₂	1020	4908.5
1015	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIAGGPSSGAPPEGS-NH ₂	1021	4892.6
1016	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIEaGPSSGAPPPSGS-NH ₂	1022	5053.7
1017	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIEaGPSSGAPPPSGS-NH ₂	1023	4908.5
1018	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIEaGPSSGEPPPSGS-NH ₂	1024	5111.7

1019	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIEaGPSSGEPPPSGS-NH ₂	1025	4966.5
1020	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIEaGPSSGAPPPEGS-NH ₂	1026	5095.7
1021	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIEaGPSSGAPPPEGS-NH ₂	1027	4950.5
1022	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIEaGPSSGAPPPSGSE-NH ₂	1028	5182.8
1023	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIEaGPSSGAPPPSGSE-NH ₂	1029	5037.6
1024	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIEaGPSSGAPPPSGSE-NH ₂	1030	5196.8
1025	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIEaGPSSGAPPPSGSE-NH ₂	1031	5051.6
1026	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIEGGPSSGEPPPSGSEE-NH ₂	1032	5281.8
1027	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGEPPPSGSEE-NH ₂	1033	5224.8
1028	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -(Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGEPPPSGSEE-NH ₂	1034	5224.8
1029	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGSEE-NH ₂	1035	5124.7
1030	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((Glu)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGSEE-NH ₂	1036	5108.7
1031	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGSEE-NH ₂	1037	5094.7
1032	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-KK((Glu)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGSEE-NH ₂	1038	5110.7

1033	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((Glu) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGSEE-NH ₂	1039	5094.7
1034	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGSEE-NH ₂	1040	5223.8
1035	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGSEE-NH ₂	1041	5094.7
1036	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLLAGGPSSGAPPPSGSEE-NH ₂	1042	5108.7
1037	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLLAGGPSSGAPPPSGSEE-NH ₂	1043	5124.7
1038	Y-Aib-QGTFTSDFSQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLaGPSSGAPPPSGSEEE-NH ₂	1044	5233.8
1039	Y-Aib-QGTFTSDFSQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLaGPSSGAPPPSGSEEE-NH ₂	1045	5217.8
1040	Y-Aib-QGTFTSDFSQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE-Me4Pal-LLEaGPSSGAPPPSGSEEE-NH ₂	1046	5216.8
1041	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGAPPPSGSEE-NH ₂	1047	5182.8
1042	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGAPPPSGSEE-NH ₂	1048	5182.8
1043	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGAPPPSGSEE-NH ₂	1049	5166.7
1044	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGAPPPSGSEE-NH ₂	1050	5166.7
1045	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIEGGPSSGAPPPSGSEE-NH ₂	1051	5239.8

1046	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIEGGPSSGAPPPSGSEE-NH ₂	1052	5223.8
1047	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPGGSEE-NH ₂	1053	5074.7
1048	Y-Aib-QGTFTSDFS-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLEGGPSSGAPPPGGSEE-NH ₂	1054	5060.7
1049	Y-Aib-QGTFTSDFS-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LLEGGPSSGAPPPGGSEE-NH ₂	1055	5074.7
1050	Y-Aib-QGTFTSDFS-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE-Me4Pal-LLEGGPSSGAPPPGGSEE-NH ₂	1056	5059.7
1051	Y-Aib-QGTFTSDFS-Orn- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPEGSEE-NH ₂	1057	5016.6
1052	Y-Aib-QGTFTSDFS-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPEGSEE-NH ₂	1058	5002.6
1053	Y-Aib-QGTFTSDFS-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE-Me4Pal-LLAGGPSSGAPPPEGSEE-NH ₂	1059	5001.6
1054	Y-Aib-QGTFTSD-4Pal-S-Dab- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE-Me4Pal-LLAGGPSSGAPPPEGSEE-NH ₂	1060	5061.6
1055	Y-Aib-QGTFTSD-4Pal-S-Dab- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LLAGGPSSGAPPPEGSEE-NH ₂	1061	5138.7
1056	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLLAGGPSSGAPPPSGSEE-NH ₂	1062	5094.7
1057	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((Glu)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLLAGGPSSGAPPPSGSEE-NH ₂	1063	5094.7
1058	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LLEGGPSSGAPPPSGSEE-NH ₂	1064	5166.7
1059	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGSEE-NH ₂	1065	5080.7

1060	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LDKK((Glu)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGSEE-NH ₂	1066	5094.7
1061	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((Glu)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGSEE-NH ₂	1067	5080.7
1062	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((Glu) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGSEE-NH ₂	1068	5209.8
1063	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGSEE-NH ₂	1069	5080.7
1064	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LLEGGPSSGAPPPSGSEE-NH ₂	1070	5075.7
1065	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LLEGGPSSGAPPPSGSEE-NH ₂	1071	5075.7
1066	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((Glu)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LLEGGPSSGAPPPSGSEE-NH ₂	1072	5075.7
1067	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((Glu) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIE- α MeY-LLEGGPSSGAPPPSGSEE-NH ₂	1073	5204.8
1068	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLLAGGPSSGAPPPSGSEE-NH ₂	1074	5080.7
1069	Y-Aib-QGTFTSD-4Pal-S-Orn- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-AFIEYLLAGGPSSGAPPPSGSEE-NH ₂	1075	5003.6
1070	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGAPPPSGSEE-NH ₂	1076	5166.7
1071	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIEGGPSSGAPPPSGSEEE-NH ₂	1077	5295.9
1072	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIQ- α MeY-LIEGGPSSGAPPPSGSEE-NH ₂	1078	5165.8
1073	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIQ- α MeY-LIEGGPSSGAPPPSGSEEE-NH ₂	1079	5294.9

1074	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIAGGPSSGAPPPSGSEE-NH ₂	1080	5108.7
1075	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIAGGPSSGAPPPSGSEEE-NH ₂	1081	5237.8
1076	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIQ- α MeY-LIEGGPSSGAPPPSGSEEE-NH ₂	1082	5294.9
1077	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((Glu)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIQ- α MeY-LIEGGPSSGAPPPSGSEEE-NH ₂	1083	5294.9
1078	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-KK((Glu) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIQ- α MeY-LIEGGPSSGAPPPSGSEEE-NH ₂	1084	5424.0
1079	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((Glu)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIAGGPSSGAPPPSGSEEE-NH ₂	1085	5237.8
1080	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((Glu) ₂ -(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIAGGPSSGAPPPSGSEEE-NH ₂	1086	5366.9
1081	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIAGGPSSGAPPPSGSEEE-NH ₂	1087	5294.9
1082	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LLAGGPSSGAPPPSGSEEE-NH ₂	1088	5237.8
1083	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIQ- α MeY-LLEGGPSSGAPPPSGSEEE-NH ₂	1089	5294.9
1084	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LLAGGPSSGAPPPSGSEEE-NH ₂	1090	5294.9
1085	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGE-NH ₂	1091	4892.5
1086	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((Glu)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGE-NH ₂	1092	4892.5
1087	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((Glu) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGE-NH ₂	1093	5021.6

1088	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGEEEE-NH ₂	1094	5150.7
1089	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((Glu)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGEEEE-NH ₂	1095	5150.7
1090	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((Glu) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIAGGPSSGAPPPSGEEEE-NH ₂	1096	5279.9
1091	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIA-Aib-GPSSGAPPPSGSEE-NH ₂	1097	5122.7
1092	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIA-Aib-GPSSGEPPPSGSEE-NH ₂	1098	5180.8
1093	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIE-Aib-GPSSGEPPPSGSEE-NH ₂	1099	5252.8
1094	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIA-Aib-GPSSGEPPPSGSEE-NH ₂	1100	5194.8
1095	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIA-Aib-GPSSGEPPPSGSEE-NH ₂	1101	5196.8
1096	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIQ-Aib-GPSSGEPPPSGSEE-NH ₂	1102	5253.9
1097	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIE-Aib-GPSSGEPPPSGSEE-NH ₂	1103	5268.9
1098	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIE-Aib-GPSSGEPPPSGSEE-NH ₂	1104	5325.9
1099	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIA-Aib-GPSSGEPPPSGSEE-NH ₂	1105	5210.8
1100	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -	1106	5267.9

	CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIA-Aib-GPSSGEPPPSGSEE-NH ₂		
1101	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIA-Aib-GPSSGEPPPSGSEE-NH ₂	1107	5180.8
1102	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIQ-Aib-GPSSGEPPPSGSEE-NH ₂	1108	5237.8
1103	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIE-Aib-GPSSGEPPPSGSEE-NH ₂	1109	5252.8
1104	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIE-Aib-GPSSGEPPPSGSEE-NH ₂	1110	5309.9
1105	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIA-Aib-GPSSGEPPPSGSEE-NH ₂	1111	5194.8
1106	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIA-Aib-GPSSGEPPPSGSEE-NH ₂	1112	5251.8
1107	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIA-Aib-GPSSGAPPPSGSEE-NH ₂	1113	5136.8
1108	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIE-Aib-GPSSGAPPPSGSEE-NH ₂	1114	5210.8
1109	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIE-Aib-GPSSGAPPPSGSEE-NH ₂	1115	5267.9
1110	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIA-Aib-GPSSGAPPPSGSEE-NH ₂	1116	5152.8
1111	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIA-Aib-GPSSGAPPPSGSEE-NH ₂	1117	5209.8
1112	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIE-Aib-GPSSGAPPPSGSEE-NH ₂	1118	5194.8

1113	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIE-Aib-GPSSGAPPPSGSEE-NH ₂	1119	5251.8
1114	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE- α MeY-LIA-Aib-GPSSGAPPPSGSEE-NH ₂	1120	5136.8
1115	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIA-Aib-GPSSGAPPPSGSEE-NH ₂	1121	5193.8
1116	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIE-Aib-GPSSGAPPPSGTE-NH ₂	1122	5094.8
1117	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((2-[2-(2-Aminoethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIE-Aib-GPSSGAPPPSGTGE-NH ₂	1123	5151.8
1118	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIE-Aib-GPSSGAPPPSGTE-NH ₂	1124	5078.7
1119	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIE-Aib-GPSSGAPPPSGTGE-NH ₂	1125	5078.7
1120	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIE-Aib-GPSSGAPPPSGE-NH ₂	1126	5135.8
1121	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIE-Aib-GPSSGAPPPSGEE-NH ₂	1127	4977.6
1122	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIE-Aib-GPSSGAPPPSGSEE-NH ₂	1128	5106.7
1123	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIE-Aib-GPSSGEPPPSGE-NH ₂	1129	5193.8
1124	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIE-Aib-GPSSGEPPPSGEEE-NH ₂	1130	5035.6
1125	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIE-Me4Pal-LIE-Aib-GPSSGEPPPSGSEE-NH ₂	1131	5293.9
1126	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGTE-NH ₂	1132	5251.8

1127	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LDKK((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIEYLIE-Aib-GPSSGAPPPSGTGE-NH ₂	1133	5079.7
1128	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIQ- α MeY-LIA-Aib-GPSSGEPPPSGGGE-NH ₂	1134	5136.8
1129	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIQ- α MeY-LIE-Aib-GPSSGEPPPSGGGE-NH ₂	1135	5206.8
1130	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIQ- α MeY-LIA-Aib-GPSSGEPPPSGGGE-NH ₂	1136	5091.7
1131	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-AFIQ- α MeY-LIE-Aib-GPSSGEPPPSGGGE-NH ₂	1137	5149.8
1132	Y-Aib-QGTFTSD-4Pal- α MeS-Q- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIQ- α MeY-LIA-Aib-GPSSGAPPPSGGGE-NH ₂	1138	5104.8
1133	Y-Aib-QGTFTSD-4Pal- α MeS-Q- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIQ- α MeY-LIAGGPSSGEPPPSGGGE-NH ₂	1139	5134.7
1134	NMeY-Aib-QGTFTSD-4Pal- α MeS-Q- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIQ- α MeY-LIE-Aib-GPSSGAPPPSGGGE-NH ₂	1140	5176.8
1135	NMeY-Aib-QGTFTSD-4Pal- α MeS-I- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIQ- α MeY-LIE-Aib-GPSSGAPPPSGGGE-NH ₂	1141	5161.9
1136	Y-Aib-QGTFTSD-4Pal- α MeS-I- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIQ- α MeY-LIE-Aib-GPSSGAPPPSGGGE-NH ₂	1142	5147.8
1137	Y-Aib-QGTFTSD-4Pal- α MeS-Q- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQIvaQFIQ- α MeY-LIE-Aib-GPSSGAPPPSGGGE-NH ₂	1143	5099.7
1138	Y-Aib-QGTFTSD-4Pal- α MeS-Q- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIQ- α MeY-LLE-Aib-GPSSGAPPPSGGGE-NH ₂	1144	5162.8
1139	Y-Aib-QGTFTSD-4Pal- α MeS-Q- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQIvaQFIQ- α MeY-LLE-Aib-GPSSGAPPPSGGGE-NH ₂	1145	5099.7
1140	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-	1146	5055.7

	(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe-αMeY-LIEGGPSSGAPPPSGE-NH ₂		
1141	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-αMeS-I-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe-αMeY-LIEGGPSSGEPPPSGE-NH ₂	1147	5113.7
1142	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-αMeS-I-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe-αMeY-LIEGGPSSGAPPPPTGE-NH ₂	1148	5069.7
1143	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-αMeS-I-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe-αMeY-LIEGGPSSGEPPPTGE-NH ₂	1149	5127.8
1144	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-αMeS-I-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe-αMeY-LIEGGPSSGAPPPGGE-NH ₂	1150	5025.7
1145	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-αMeS-I-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe-αMeY-LIEGGPSSGEPPPGGE-NH ₂	1151	5083.7
1146	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-αMeS-I-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe-αMeY-LIEGGPSSGAPPPPESE-NH ₂	1152	5127.8
1147	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-αMeS-I-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe-αMeY-LIEGGPSSGEPPPESE-NH ₂	1153	5185.8
1148	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-αMeS-I-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe-αMeY-LIEGGPSSGAPPPEGE-NH ₂	1154	5097.7
1149	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-αMeS-I-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe-αMeY-LIEGGPSSGEPPPEGE-NH ₂	1155	5155.8
1150	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-αMeS-I-αMeL-LD-Orn-K((γ-Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe-αMeY-LIEGGPSSGAPPPSGE-NH ₂	1156	5039.7
1151	Y-Aib-QGT-αMeF(2F)-TSD-4Pal-αMeS-I-αMeL-LD-Orn-K((γ-Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe-αMeY-LIEGGPSSGEPPPSGE-NH ₂	1157	5097.7

1152	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGAPPPTGE-NH ₂	1158	5055.7
1153	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGEPPPTGE-NH ₂	1159	5113.7
1154	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGAPPPGGE-NH ₂	1160	5011.6
1155	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGEPPPGGE-NH ₂	1161	5069.7
1156	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGAPPESE-NH ₂	1162	5113.7
1157	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGEPPPESE-NH ₂	1163	5171.8
1158	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGAPPPEGE-NH ₂	1164	5083.7
1159	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGEPPPEGE-NH ₂	1165	5141.7
1160	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGAPPPSGE-NH ₂	1166	5025.6
1161	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGEPPPSGE-NH ₂	1167	5083.7
1162	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGAPPPSGSE-NH ₂	1168	5112.7
1163	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGEPPPSGSE-NH ₂	1169	5170.7

1164	Y-Aib-QGT- α MeF-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGAPPPSGE-NH ₂	1170	5037.7
1165	Y-Aib-QGT- α MeF-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGEPPPSGE-NH ₂	1171	5095.7
1166	Y-Aib-QGT- α MeF-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGAPPPSGSE-NH ₂	1172	5124.8
1167	Y-Aib-QGT- α MeF-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGEPPPSGSE-NH ₂	1173	5182.8
1168	Y-Aib-QGT- α MeF-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGAPPPSGGGE-NH ₂	1174	5151.8
1169	Y-Aib-QGT- α MeF-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGEPPPSGGGE-NH ₂	1175	5209.4
1170	Y-Aib-QGT- α MeF-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGAPPPSGE-NH ₂	1176	5021.7
1171	Y-Aib-QGT- α MeF-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGEPPPSGE-NH ₂	1177	5079.7
1172	Y-Aib-QGT- α MeF-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGAPPPSGSE-NH ₂	1178	5108.7
1173	Y-Aib-QGT- α MeF-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGEPPPSGSE-NH ₂	1179	5166.8
1174	Y-Aib-QGT- α MeF-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGAPPPSGGGE-NH ₂	1180	5135.8
1175	Y-Aib-QGT- α MeF-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGEPPPSGGGE-NH ₂	1181	5193.8

1176	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGAPPPSGE-NH ₂	1182	5184.8
1177	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGEPPPSGE-NH ₂	1183	5242.8
1178	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGAPPPSGE-NH ₂	1184	5271.9
1179	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGEPPPSGE-NH ₂	1185	5329.9
1180	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGAPPPSGGGE-NH ₂	1186	5298.9
1181	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFie- α MeY-LIEGGPSSGEPPPSGGGE-NH ₂	1187	5356.9
1182	Y-Aib-QGTFTSD-4Pal- α MeS-Q- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIA-Aib-GPSSGEPPPSGGGE-NH ₂	1188	5163.8
1183	Y-Aib-QGTFTSD-4Pal- α MeS-Q- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIQ- α MeY-LIE-Aib-GPSSGEPPPSGGGE-NH ₂	1189	5220.8
1184	Y-Aib-QGTFTSD-4Pal- α MeS-Q- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIE-Aib-GPSSGEPPPSGGGE-NH ₂	1190	5221.8
1185	Y-Aib-QGTFTSD-4Pal- α MeS-Q- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIA-Aib-GPSSGAPPPSGGGE-NH ₂	1191	5105.7
1186	Y-Aib-QGTFTSD-4Pal- α MeS-Q- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIQ- α MeY-LIE-Aib-GPSSGAPPPSGGGE-NH ₂	1192	5162.8
1187	Y-Aib-QGTFTSD-4Pal- α MeS-Q- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIE- α MeY-LIE-Aib-GPSSGAPPPSGGGE-NH ₂	1193	5163.8

1188	Y-Aib-QGTFTSD-4Pal- α MeS-Q- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-QFIQ- α MeY-LIEGGPSSGEPPPSGGGE-NH ₂	1194	5192.8
1189	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPPS-Aib-Orn-PPP-Orn-GS-NH ₂	1195	5121.9
1190	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPPS-Aib-EPPPEGE-NH ₂	1196	5193.9
1191	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGEPPPEGE-NH ₂	1197	5165.8
1192	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSS-Aib-APPPEGE-NH ₂	1198	5183.8
1193	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPPS-Aib-EPPP-Orn-GE-NH ₂	1199	5178.9
1194	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPPS-Aib-Orn-PPPEGE-NH ₂	1200	5178.9
1195	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPPS-Aib-Orn-PPP-Orn-GE-NH ₂	1201	5163.9
1196	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPPS-Aib-Orn-PPP-Orn-SE-NH ₂	1202	5194.0
1197	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPPS-Aib-Orn-PPP-Orn-GGGE-NH ₂	1203	5278.0
1198	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPPS-Aib-Orn-PPPSGSE-NH ₂	1204	5223.9
1199	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPPS-Aib-Orn-PPPSGGGE-NH ₂	1205	5251.0

1200	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPPS-Aib-EPPPSGSE-NH ₂	1206	5238.9
1201	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPPS-Aib-EPPPSGGGE-NH ₂	1207	5265.9
1202	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIq- α MeY-LIEGGPSSGAPPPSGS-NH ₂	1208	5012.7
1203	Y-Aib-QaT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGS-NH ₂	1209	4950.6
1204	Y-Aib-QaT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIe- α MeY-LVEGGPSSGAPPPSGS-NH ₂	1210	4936.6
1205	Y-Aib-QaT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGAPPPSGS-NH ₂	1211	4999.6
1206	Y-Aib-QaT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGS-NH ₂	1212	5013.7
1207	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGS-NH ₂	1213	5158.8
1208	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) ₂ -(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGEPPPSGS-NH ₂	1214	5216.9
1209	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-Orn((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H))AQ-Me4Pal-Orn-FIe- α MeY-LIEGGPSSGEPPPETE-NH ₂	1215	5140.8
1210	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-Orn((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LVEGGPSSGAPPPSGS-NH ₂	1216	4985.6
1211	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-Orn((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGS-NH ₂	1217	4999.6

1212	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-Orn((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGSE-NH ₂	1218	5128.7
1213	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-Orn((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGGGE-NH ₂	1219	5155.8
1214	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGGGEE-NH ₂	1220	5298.9
1215	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGGGEEE-NH ₂	1221	5428.0
1216	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPEGGGEE-NH ₂	1222	5341.0
1217	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPEGGGEEE-NH ₂	1223	5470.1
1218	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGGGEE-NH ₂	1224	5282.9
1219	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGGGEEE-NH ₂	1225	5412.0
1220	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPEGGGEE-NH ₂	1226	5324.9
1221	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPEGGGEEE-NH ₂	1227	5454.0
1222	Y-Aib-QaT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGSE-NH ₂	1228	5079.7
1223	Y-Aib-QaT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGGGE-NH ₂	1229	5106.7


1224	Y-Aib-QaT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGSE-NH ₂	1230	5063.7
1225	Y-Aib-QaT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Aib-EFIe- α MeY-LIEGGPSSGAPPPSGGGE-NH ₂	1231	5090.7
1226	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPPS-Aib--Orn-PPP-Orn-GS-NH ₂	1232	5105.8
1227	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPPS-Aib--Orn-PPP-Orn-GE-NH ₂	1233	5147.9
1228	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPPS-Aib--Orn-PPP-Orn-SE-NH ₂	1234	5177.9
1229	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-K((γ -Glu) ₂ -CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIEGGPPS-Aib--Orn-PPP-Orn-GG-NH ₂	1235	5262.0
1230	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-QAQ-Me4Pal--Orn-FIe- α MeY-LIEGGPSSGEPPPETE-NH ₂	1236	4600.1
1231	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-QAQ-Me4Pal-EFIe- α MeY-LVEGGPSSGAPPPSGS-NH ₂	1237	4428.9
1232	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-QAQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGS-NH ₂	1238	4442.9
1233	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-QAQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGSE-NH ₂	1239	4572.0
1234	Y-Aib-QGT- α MeF(2F)-TSD-4Pal- α MeS-I- α MeL-LD-Orn-QAQ-Me4Pal-EFIe- α MeY-LIEGGPSSGAPPPSGGGE-NH ₂	1240	4599.0
1235	Y-Aib-QGTFTSD-4Pal-SQ- α MeL-LD-Orn-K(e-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AQ-Me4Pal-EFIe- α MeY-LIAGGPSSGAPPPSGSEEE-NH ₂	1241	5295.9
1236	Y-Aib-QGT- α MeF(2F)-TSD-4Pal-SI- α MeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ -Glu)-CO-(CH ₂) ₁₆ -CO ₂ H)AA-Aib-AFIe- α MeY-LLEGGPSSGEPPPS-NH ₂	1242	4749.3

Depictions of the structures of certain examples are provided below:


[illegible]

The chemical structure represents a 12-residue peptide. The sequence of residues, starting from the N-terminus, is: Glycine (G), Threonine (T) with a 2-fluorophenyl side chain, Serine (S) with a 4-pyridyl side chain, Aspartic acid (D) with a hydroxymethyl side chain, Leucine (L) with an isopropyl side chain, Lysine (K) with a 4-pyridyl side chain, Alanine (A), Glutamic acid (E) with a 3-pyridyl side chain, Valine (V) with an isopropyl side chain, Proline (P), Glycine (G), and a C-terminal amide group (NH₂). The side chains are highlighted with different colors: yellow for the long alkyl chain of the lysine residue, green for the fluorinated phenyl group of the threonine residue, and blue for the hydroxymethyl group of the aspartic acid residue.


Example 686 (SEQ ID NO:692)




Example 712 (SEQ ID NO:718)




Example 741 (SEQ ID NO:747)




Example 510 (SEQ ID NO:516)



Example 883 (SEQ ID NO:889)



5 Example 548 (SEQ ID NO:554)



Example 558 (SEQ ID NO:564)

IN VITRO FUNCTION

Functional Activity:

Functional activity is determined in GIP-R, GLP-1R, and GcgR-expressing HEK-293 clonal cell lines. Each receptor cell line is treated with peptide (20 point concentration response curves with 2.75-fold serial dilutions prepared with a Labcyte Echo Acoustic Liquid Handler) in DMEM (Gibco Cat# 31053) supplemented with 1X GlutaMAX™ (L-alanyl-L-glutamine dipeptide, Gibco Cat# 35050), 0.1% Casein (Sigma Cat# C4765), 1% HSA (Human Serum Albumin, Sigma Cat# A3782) 500 μM IBMX (3-isobutyl-1-methylxanthine) and 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) in a 20 μl assay volume.

After a 30-minute incubation at 37°C, the resulting increase in intracellular cAMP is quantitatively determined using the CisBio cAMP Dynamic 2 HTRF Assay Kit (62AM4PEJ). Briefly, cAMP levels within the cell are detected by adding the cAMP-d2 conjugate in cell lysis buffer followed by the antibody anti-cAMP-Eu³⁺-Cryptate, also in cell lysis buffer. The resulting competitive assay is incubated for at least 60 minutes at room temperature and then detected using a Pherastar Instrument (BMG Labtech) with excitation at 320 nm and emission at 665 nm and 620 nm. Raw data values (emission at 665nm/620nm*10,000) are inversely proportional to the amount of cAMP present and were converted to cAMP (nM) per well using a cAMP standard curve.

The amount of cAMP generated (nM) in each well is converted to a percent of the maximal response observed with either human GLP-1(7-36)NH₂, human Glucagon (Gcg), or human GIP(1-42)NH₂. A relative EC₅₀ value is derived by non-linear regression analysis using the percent maximal response vs. the concentration of peptide added, fitted to a four-parameter logistic equation.

The Geometric mean of relative EC₅₀ data for exemplary analogs and hGIP(1-42)NH₂, hGLP-1(7-36)NH₂ and hGcg are shown in Table 2 below.

Table 2. Functional cAMP Potency (Rel EC₅₀) for Exemplary Analogs and Comparators in the Presence of 1% HSA.

Example	cAMP Rel EC ₅₀ , nM		
	<i>hGcgR</i>	<i>hGIPR</i>	<i>hGLP-1R</i>
<i>hGcg</i>	2.2	>300	160
<i>hGIP</i> 1-42 amide	>9950	0.536	>9950
<i>hGLP-1</i> 7-36 amide	>99.5	>99.5	0.346
1	1690	73.9	524
2	1630	75.5	631
3	1590	48.1	546
4	1580	62.3	869
5	2670	32.5	675
6	1380	46.6	446
7	1210	50.6	494
8	1560	39.4	603
9	1430	41.8	402
10	1640	43	375
11	1700	40.8	337
12	1490	30.2	216
13	1670	29.2	282
14	1420	34.7	232
15	1980	36.3	276
16	1660	35.9	281
17	2040	91.7	543
18	1210	59.6	561
19	1010	66.2	1310
20	587	42.3	326
21	1510	29.1	324
22	532	81	592
23	573	25.5	308
24	1390	102	447

25	939	19.8	520
26	980	35.4	623
27	1180	72.3	464
28	1550	63.8	686
29	1350	70.1	493
30	969	72.9	806
31	1750	63.6	737
32	1440	66.1	422
33	1310	70.7	436
34	855	44.2	242
35	1390	194	1130
36	1330	170	1360
37	1870	56.4	514
38	2770	102	884
39	1090	30.5	260
40	2750	76.7	138
41	2310	97.9	711
42	1520	32.3	700
43	850	29.6	539
44	1050	35.9	591
45	879	33.4	493
46	393	19.6	601
47	2140	154	1270
48	728	46.9	570
49	1310	44.9	151
50	1040	69.6	1110
51	856	98.4	1210
52	1740	111	1250
53	1780	113	1030
54	1940	168	1300
55	960	27.8	479

56	265	30.3	167
57	113	3.78	42.7
58	115	3.75	20.7
59	2160	166	1370
60	1210	33	409
61	1310	55.2	704
62	396	31.2	299
63	709	40.4	348
64	626	24.9	397
65	808	30.2	462
66	415	29.9	329
67	781	73.3	683
68	1160	85.1	612
69	387	25.6	279
70	717	27.4	620
71	2800	48.1	1010
72	1910	56.7	683
73	1530	57.9	810
74	709	15.9	627
75	1040	16.8	878
76	2240	45.5	436
77	2610	37.9	339
78	2640	78.4	560
79	903	14.3	437
80	1190	10.1	627
81	1580	50.2	430
82	1070	87.8	394
83	1270	91.8	653
84	2280	57.4	701
85	1270	22.1	387
86	1130	19.6	421

87	1110	12.8	290
88	915	24.7	363
89	916	19.3	458
90	990	24.9	371
91	1200	23.9	356
92	2540	62	735
93	1390	27.9	397
94	1220	21.4	480
95	1130	18.2	380
96	2150	49.3	836
97	1270	23.9	605
98	867	33.8	660
99	1130	29.5	588
100	2390	77.2	1190
101	2810	133	1090
102	2710	159	1060
103	2590	35.1	482
104	1260	97.5	698
105	2790	72.5	768
106	2000	91	977
107	1690	61.3	1110
108	1290	56.5	777
109	2760	22.3	671
110	627	19.8	821
111	1260	10.4	878
112	1810	29	892
113	2090	32.3	467
114	1120	19.6	1370
115	2210	73.9	1460
116	882	40.4	401
117	867	29.9	524

118	2460	63.4	1450
119	839	19.7	387
120	1540	33.4	664
121	442	24.6	348
122	548	32.6	468
123	1740	94.6	1500
124	567	54.7	801
125	901	67.8	1050
126	1120	40.3	838
127	1010	62.9	1000
128	1090	24.3	679
129	510	24.3	284
130	1080	60.5	865
131	976	91.8	984
132	632	25.9	823
133	642	23.1	1180
134	1200	38.3	549
135	557	23.4	472
136	960	32.9	625
137	905	23.7	447
138	1480	40.1	657
139	1250	64.8	710
140	2360	2.94	165
141	877	62.1	562
142	1230	14.1	391
143	1690	63.9	594
144	2600	46.2	990
145	693	108	1480
146	463	74.6	678
147	877	108	964
148	1330	74.2	870

149	1420	44.9	801
150	1920	50.6	463
151	1420	14.9	384
152	1090	23.2	491
153	1210	16.8	488
154	1040	29.7	569
155	1310	18.9	503
156	1520	25.8	695
157	838	22.2	496
158	325	24.7	184
159	475	49.7	588
160	479	44.4	482
161	902	87.3	963
162	558	37.5	786
163	790	52	762
164	411	59	962
165	1250	18.6	808
166	724	21	1500
167	938	24.7	1300
168	1270	31.9	281
169	439	21.5	216
170	1800	43.5	361
171	502	27.1	287
172	605	29.3	457
173	745	49.9	293
174	307	20.8	208
175	579	29.6	386
176	461	40.7	389
177	758	34.8	483
178	816	47.3	397
179	1440	21.3	904

180	1320	24	891
181	772	12.7	365
182	1480	9.95	398
183	504	13.7	295
184	1050	16.2	465
185	504	21.1	502
186	1280	18	690
187	2970	15.6	178
188	2920	43.8	436
189	853	22.2	423
190	331	59.4	172
191	344	47.4	230
192	560	9.86	719
193	1120	12.7	473
194	813	19.7	697
195	605	28.8	829
196	620	51.4	458
197	613	44.1	440
198	1300	38.8	761
199	1000	41.6	1060
200	360	13.7	395
201	969	14.3	679
202	697	11.7	376
203	1160	19	532
204	572	16.7	306
205	397	24.4	234
206	545	38.8	372
207	770	15.2	225
208	578	22	336
209	433	23.3	276
210	501	23.5	264

211	370	20.6	234
212	324	32.3	360
213	429	22.9	327
214	302	15.1	186
215	1510	87.3	162
216	895	12	90.6
217	1570	15	130
218	1480	15	152
219	1870	23.3	221
220	1990	87.1	189
221	1620	17.1	127
222	440	52.5	753
223	373	37.2	627
224	452	21.5	333
225	561	40.2	438
226	763	32.2	354
227	937	39.7	418
228	322	37.8	311
229	332	27.8	249
230	388	21.6	199
231	443	27.4	223
232	482	24.6	226
233	453	28.1	223
234	702	31.1	604
235	700	40.8	457
236	309	24.8	261
237	441	30.9	291
238	334	8.78	262
239	693	12	419
240	521	10.4	396
241	543	9.36	264

242	484	5.94	242
243	711	12.1	610
244	1230	18.8	645
245	1120	10.5	540
246	639	22	845
247	443	12.9	291
248	241	10.6	438
249	604	22.5	256
250	201	11.7	194
251	1500	22	301
252	528	24.8	504
253	963	26.6	355
254	767	21.4	265
255	883	21.9	272
256	625	17.4	235
257	1210	21	388
258	1280	23.3	492
259	317	18.4	220
260	162	12.4	160
261	520	38.4	383
262	720	40.4	400
263	893	25.7	257
264	1000	12.4	688
265	1890	29	381
266	923	17.3	583
267	1380	55.5	1020
268	1300	33.7	437
269	1100	21.9	428
270	1060	36.5	658
271	2680	15.7	887
272	1540	36.3	486

273	1770	21.8	516
274	1120	27.6	560
275	882	27.7	692
276	113	6.28	103
277	1690	13.3	639
278	274	7.69	241
279	427	11.6	367
280	1600	15.6	171
281	1370	25.8	295
282	1830	22.1	217
283	1470	47.2	233
284	1530	59.8	271
285	409	8.22	365
286	228	11.5	925
287	291	9.94	562
288	3580	59.1	616
289	1750	105	139
290	878	53.4	90
291	311	38	24.5
292	583	92.7	129
293	1740	9.63	295
294	518	54.1	554
295	605	61.1	232
296	517	21.8	171
297	2320	325	1130
298	1570	41.3	70.9
299	1700	40.2	380
300	976	12.9	98
301	1500	81.8	82.4
302	1370	91.8	73.6
303	9950	44.7	257

304	1720	48	172
305	1500	92.4	415
306	2820	95.3	126
307	1880	65.3	209
308	4950	237	477
309	3910	424	251
310	4000	15	177
311	2500	26.1	1080
312	4070	97.7	589
313	3290	86.4	135
314	1030	65.9	100
315	1560	85.1	140
316	2090	102	78.7
317	1500	62.8	234
318	1970	52.8	111
319	1650	60.1	119
320	1170	55.3	328
321	836	13	110
322	2620	89.3	135
323	1440	37.7	293
324	1410	20.7	1060
325	774	82.7	371
326	1500	83.7	172
327	1400	63.3	473
328	2040	91.1	462
329	842	42.6	204
330	398	7.33	91.8
331	339	47.5	207
332	3340	78.2	298
333	1410	36.3	182
334	2070	72.1	171

335	1410	46.7	150
336	1740	64.4	227
337	2950	99.1	272
338	659	10.9	172
339	1510	28.8	192
340	647	60.4	246
341	2930	49.6	395
342	2130	71.3	62
343	475	16.7	178
344	1440	70.7	523
345	3300	15.3	256
346	4310	28.3	514
347	3650	17.3	254
348	1250	36.4	136
349	2280	52.6	218
350	3760	33.6	360
351	2470	57.5	272
352	4020	34.1	407
353	3080	53.7	222
354	1440	23.8	175
355	3430	33.2	351
356	2680	19.2	206
357	1810	42.9	248
358	876	38.8	492
359	957	103	826
360	1470	78.3	989
361	987	46.3	376
362	1450	38.7	450
363	4080	91.8	217
364	3190	101	260
365	1490	14	75.2

366	1830	4.27	85.9
367	668	4.89	30.1
368	111	2.62	37.4
369	111	4.58	26.8
370	803	4.23	37.5
371	463	1.47	47.4
372	468	2.63	53.1
373	666	1.97	54.5
374	65.4	2.28	24.5
375	137	1.78	18
376	115	5.42	26
377	163	11.1	29.4
378	176	2.15	18.8
379	344	24	14.2
380	150	7.77	30.6
381	176	7.01	24.5
382	1050	17.7	61.5
383	530	32.3	79.1
384	1730	3.63	19.3
385	700	4.03	86.1
386	734	5.62	98.6
387	184	5.64	26.5
388	603	14.1	52.5
389	889	18.3	18.9
390	549	37.8	19.6
391	808	11.5	34.4
392	611	28.7	41.5
393	151	12.4	29.6
394	1090	7.22	33.2
395	1190	6.69	34.7
396	468	9.5	38.2

397	1110	10.1	34.9
398	375	12.4	42.2
399	560	19.6	42.8
400	265	3.86	29.1
401	111	1.71	12
402	1030	44.9	86.6
403	527	36.9	70
404	735	2.03	32.2
405	2530	32.1	285
406	254	10.5	27.8
407	485	11.7	37.2
408	472	15.3	37.9
409	1190	66.6	41.7
410	1950	49.3	84.4
411	1170	23.8	82.1
412	467	12.5	46
413	629	23.5	41.4
414	487	14.9	32.8
415	1090	28.9	52.6
416	348	27.6	40.8
417	386	4.46	67
418	627	6.02	36.6
419	1650	9.47	65.5
420	433	2.61	31.3
421	468	2.98	31.9
422	493	4.4	27.1
423	319	3.07	28.7
424	443	3.21	29.5
425	1150	46.9	20.3
426	740	29.8	16.6
427	1440	4.25	42.9

428	536	4.55	38.2
429	138	1.89	12.1
430	559	4.65	78.9
431	352	3.73	35.2
432	384	11.4	41.7
433	532	15.3	43.4
434	525	10.6	35
435	334	10.3	33.6
436	182	1.18	11.7
437	188	16.9	26.9
438	431	53.8	41.1
439	165	14.6	15.1
440	830	1.81	27.4
441	855	1.96	24.7
442	342	1.81	23.9
443	265	1.57	34.3
444	1280	1.74	54.6
445	448	2.41	23.2
446	516	3.01	24.5
447	1090	1.81	11.3
448	302	1.35	19.5
449	424	1.66	18.9
450	553	3.75	18.4
451	384	0.96	10.9
452	240	0.846	12.4
453	261	1.95	20.6
454	1280	4.31	135
455	1200	5.2	105
456	230	0.993	12.5
457	333	0.881	11.7
458	319	8.07	22.7

459	73.6	2.06	12.6
460	142	8.93	31.1
461	131	2.51	12
462	183	1.62	12.9
463	496	6.36	24.7
464	194	19.9	45.5
465	233	44.6	56.3
466	348	5.65	13.3
467	850	10.7	36.4
468	195	4.76	30.7
469	155	4.24	61.7
470	519	5.52	37.4
471	181	5.45	37.9
472	229	0.927	7.88
473	311	1.11	11.4
474	166	0.743	10.6
475	254	1.85	18.6
476	90.2	1.29	14.6
477	716	1.44	18.7
478	665	26	28.6
479	432	7.11	23.5
480	65.5	0.722	8.39
481	100	1.19	14.2
482	325	1.58	14.9
483	231	1.17	18.2
484	204	1.59	16
485	298	0.869	11.8
486	647	2.57	35
487	477	2.26	27.7
488	651	2.31	43.3
489	523	1.25	11.8

490	262	0.861	9.8
491	159	0.688	9.55
492	128	0.84	9.85
493	333	3.34	47
494	333	1.08	19.9
495	205	5.74	53.8
496	1500	60.8	1480
497	418	32.6	161
498	257	4.70	196
499	192	3.12	26.4
500	494	3.9	50.3
501	455	2.32	38
502	395	2.42	30.6
503	233	2.02	26.1
504	162	1.8	16.5
505	92	2.1	39
506	2330	28.7	224
507	209	1.12	21.3
508	255	0.856	17.5
509	617	5.01	69.2
510	564	6.4	74.2
511	594	6.55	108
512	891	9.2	112
513	1440	10.3	78.2
514	1150	10	82
515	1070	14.9	108
516	1410	13.6	111
517	337	9.12	50
518	265	7.1	51
519	356	10.8	66.5
520	407	9.09	60.6

521	275	0.967	24.8
522	441	1.95	35.5
523	234	0.869	27.1
524	464	1.46	32.7
525	460	2.07	20.2
526	530	2.12	22.9
527	580	2.6	26.8
528	474	1.55	24.3
529	398	1.39	24.5
530	1280	63.7	437
531	465	5.2	37.8
532	157	1.49	47.3
533	453	3.23	30
534	499	3.73	34.9
535	238	1.16	29.9
536	351	1.5	32.5
537	454	4.48	46.9
538	677	5.07	44.9
539	461	1.63	33.8
540	405	1.93	38.2
541	520	1.28	38.7
542	256	1.69	29.6
543	300	1.88	32
544	171	2.4	43
545	180	2.74	40.2
546	225	11.9	34.4
547	237	7.26	27.7
548	295	3.48	38
549	655	3.67	76.2
550	996	5.94	262
551	210	1.88	38.2

552	289	1.67	86.2
553	523	2.97	51
554	946	4.08	60.8
555	274	5.31	42
556	366	5.51	47.4
557	223	2.99	20.8
558	291	3.62	28
559	323	9.15	49.7
560	355	7.94	52
561	544	10.1	76.1
562	427	10.2	89.5
563	1010	11.8	98.7
564	667	10.8	101
565	1770	21.9	204
566	1780	30.1	252
567	521	13.4	102
568	477	13.2	116
569	697	12.4	84.4
570	648	13.6	95.1
571	243	4.23	42.7
572	330	3.13	30.4
573	388	3.15	31.6
574	435	20.5	37.2
575	484	16.2	37.1
576	646	8.12	56.8
577	937	10	81.8
578	781	3.73	54.7
579	679	3.79	67.3
580	922	6.29	55.3
581	1500	7.29	65.9
582	1060	10.8	35.5

583	1250	12.3	71
584	497	5.5	137
585	436	3.93	38.6
586	302	2.46	29.1
587	252	3.47	31.9
588	259	2.86	34.1
589	289	3.83	44.4
590	309	4.25	58.7
591	234	3	44.5
592	195	4.05	55.6
593	591	2.71	35.3
594	570	3.32	49.1
595	353	1.73	30.4
596	385	1.98	36.6
597	329	2.38	36.4
598	457	3.49	47.3
599	629	9.67	89.3
600	587	9.56	85.7
601	201	2.11	27.7
602	190	3.53	31.9
603	419	4.99	49.5
604	427	4.84	51
605	353	6.69	56.2
606	474	5.69	53.1
607	565	6.63	139
608	669	8.51	201
609	647	6.19	121
610	536	7.02	130
611	627	7.35	146
612	640	7.58	126
613	1410	0.791	81.6

614	724	0.597	33.2
615	697	0.95	82.9
616	734	0.467	28.9
617	547	0.643	67.4
618	691	4.63	88.9
619	819	6.78	94
620	665	5.96	90.7
621	901	7.31	111
622	641	1.19	52.3
623	832	1.48	62.2
624	808	1.17	63.4
625	657	1.81	72.1
626	546	1.75	60.8
627	813	1.47	75.1
628	651	1.87	79.8
629	898	2.37	110
630	872	2.96	74.5
631	1250	3.92	55
632	1600	5.48	88.2
633	1500	1.63	41.2
634	979	1.48	34.9
635	753	2.7	53.9
636	935	4.3	36.6
637	968	7.23	76.2
638	1090	2.39	36
639	750	2.04	27.9
640	730	0.591	27.8
641	451	0.832	68.3
642	519	0.791	67.1
643	1170	1.61	60.1
644	626	0.601	34.3

645	398	0.863	76.3
646	1260	1.09	90.5
647	1210	0.691	36.1
648	1170	1.4	86.5
649	669	0.76	62.9
650	574	3.1	31.4
651	639	6.3	53.9
652	764	1.92	26.8
653	542	1.38	25
654	886	10.9	116
655	883	8.86	76.9
656	662	7.13	119
657	226	6.43	74.5
658	376	12	106
659	735	5.75	81.5
660	455	4.64	76.9
661	160	4.62	50.9
662	561	4.69	84.5
663	226	10.2	79
664	179	1.18	27.7
665	285	2.1	32.8
666	224	1.39	32.3
667	215	1.46	33
668	203	1.69	27.1
669	173	1.41	27.3
670	489	1.9	104
671	152	0.657	17.6
672	162	1.53	49.4
673	114	0.419	10.8
674	168	2.54	17.3
675	207	1.16	25

676	208	1.07	24.4
677	190	1.03	20.8
678	245	0.929	22.1
679	188	1.02	21.6
680	256	1.04	28.6
681	104	0.395	14.2
682	127	0.415	14
683	137	0.492	14.3
684	143	0.436	14.2
685	160	0.497	18.7
686	169	0.542	19.1
687	157	0.595	21.3
688	182	0.61	19.5
689	182	0.951	25.1
690	142	0.522	17.4
691	308	1.17	28.9
692	380	1.25	25.2
693	304	1.1	18
694	206	0.787	25
695	164	0.772	19.5
696	173	0.53	19.1
697	130	0.607	18.2
698	124	0.824	20.6
699	144	0.566	25.3
700	132	0.397	20
701	226	0.979	24.9
702	196	1.25	28.4
703	201	0.961	27.1
704	239	1.2	33.9
705	234	1.15	33.7
706	240	0.913	23.7

707	199	1.05	30.6
708	124	0.562	22.1
709	107	0.63	23.4
710	126	0.589	28.7
711	197	0.786	35.2
712	171	0.584	30.8
713	180	0.879	37.7
714	197	0.754	33.2
715	126	0.51	19.7
716	100	0.557	24.1
717	130	0.561	21.4
718	144	0.531	23.2
719	181	0.882	23.2
720	239	1.02	28.3
721	183	1.19	27.1
722	170	0.953	27.2
723	179	1.02	26.5
724	209	1.06	26.4
725	244	1.39	29.1
726	226	1.22	33.3
727	287	1.09	24.1
728	298	1.45	26.7
729	276	1.43	27
730	216	1.29	33
731	291	1.27	27.4
732	327	1.26	27.2
733	207	1.15	34.3
734	230	1.3	38.1
735	236	1.32	40.7
736	245	1.23	46.3
737	122	0.498	22.3

738	162	0.64	28.2
739	155	0.507	27.1
740	181	0.629	29.7
741	200	0.817	32.4
742	203	0.857	33.3
743	133	0.432	21.2
744	111	0.488	22.1
745	266	1.36	29
746	255	1.44	38.6
747	169	0.651	20.3
748	156	0.865	22.9
749	281	1.47	33.9
750	205	1.34	39.1
751	267	1.27	32.3
752	228	1.74	44
753	351	1.86	38.2
754	381	1.94	33.3
755	274	1.39	23.9
756	372	1.61	28.2
757	310	1.81	30.8
758	388	1.59	31.3
759	223	1.05	34.8
760	239	1.29	43.6
761	162	0.635	26.1
762	119	0.692	27.6
763	222	1.16	42.5
764	146	0.649	38.8
765	111	44.6	26.1
766	65.7	14.1	32.5
767	207	1.51	56.8
768	2270	2.65	33.2

769	269	1.02	34
770	390	18.2	240
771	955	44.2	665
772	1880	21.6	206
773	2260	26.3	241
774	2330	32.8	404
775	724	25.8	202
776	908	25.7	191
777	1320	22.2	231
778	1370	30.5	245
779	1020	19.3	175
780	1250	22.1	211
781	808	13.1	244
782	1380	15.5	354
783	1300	16.9	497
784	711	11.8	284
785	1210	21.3	391
786	1490	25.9	536
787	2060	18.6	382
788	1420	20.7	528
789	1200	20.4	379
790	1200	34.1	858
791	456	143	980
792	376	108	619
793	1660	135	559
794	297	68.4	233
795	566	67.3	221
796	1000	17.5	125
797	963	16.7	102
798	NA	NA	NA
799	574	18.4	179

800	2500	40.2	164
801	1200	18.1	133
802	2520	16.9	153
803	NA	NA	NA
804	2310	17.6	161
805	1210	13	146
806	2760	15.1	128
807	NA	NA	NA
808	286	27.3	406
809	377	20.4	249
810	540	23.6	256
811	175	25.8	246
812	207	13.2	161
813	314	19.5	184
814	554	27.8	649
815	798	17.9	342
816	1100	15.9	310
817	690	12.3	151
818	516	13.8	91.7
819	393	9.79	134
820	1270	17.5	299
821	989	26.1	362
822	2100	18.1	322
823	1410	25.6	421
824	1110	28.9	343
825	1810	39.3	303
826	441	81.6	202
827	424	19.5	53.8
828	481	14.9	114
829	325	22.4	130
830	809	44.8	180

831	1450	38.2	237
832	1360	18.6	209
833	305	17.5	148
834	533	15.7	208
835	558	16.8	274
836	2100	26.7	103
837	2060	20.7	69.6
838	3070	23.2	72.2
839	1110	21.9	60.6
840	1810	12.5	61
841	2410	17.3	64.2
842	415	31.2	164
843	367	32.8	135
844	583	43.3	151
845	203	23.3	89.1
846	599	19.5	93.1
847	532	22.2	105
848	615	20.2	313
849	1160	36.6	111
850	3660	27	57.8
851	558	24.4	428
852	1230	45.6	182
853	4500	32.4	102
854	1280	18.7	570
855	1030	46.1	207
856	772	20.4	200
857	1050	36.1	87.3
858	678	13.1	258
859	2250	32.3	543
860	565	19.2	414
861	1350	18.3	322

862	1110	12.4	201
863	334	12.2	183
864	1480	13.2	110
865	248	10.8	351
866	669	23.8	483
867	242	16.2	474
868	622	17.7	822
869	571	14.1	114
870	736	7.29	71.2
871	2060	35.4	230
872	1890	30.1	287
873	506	44.2	138
874	603	36.2	201
875	689	13.8	78.6
876	940	7.94	70
877	1090	22.7	112
878	1130	16.7	137
879	329	20.1	591
880	562	76.2	943
881	507	30.1	321
882	559	26.6	361
883	578	9.41	120
884	613	23.5	298
885	574	19.7	326
886	540	26.5	271
887	525	37.1	403
888	567	30.8	238
889	688	21.6	371
890	559	14.2	290
891	581	16	330
892	529	21.5	405

893	508	21.4	305
894	2330	30.9	711
895	1250	34	599
896	1110	16.8	535
897	658	25.9	557
898	770	25.5	584
899	814	15.6	592
900	885	17	666
901	1150	34	193
902	1360	28.5	232
903	1630	31.2	387
904	1330	15	198
905	1390	10.4	215
906	1170	15.4	236
907	1210	8.86	123
908	980	26.7	174
909	1740	20.2	243
910	2640	25.7	239
911	2390	26.6	255
912	955	6.15	59.6
913	1140	5.62	258
914	983	5.94	91.7
915	174	15.3	226
916	158	4.78	166
917	424	6.2	195
918	590	18	484
919	467	25.8	454
920	1090	9.05	322
921	2130	12.4	261
922	1170	6.39	357
923	1840	18.5	870

924	910	15.7	402
925	2500	23	708
926	1380	13.5	600
927	1210	22.2	584
928	1090	15.1	604
929	2690	22.6	593
930	1700	19.9	824
931	2300	20.8	878
932	513	25	249
933	1530	35.1	557
934	1380	28.1	175
935	659	16.9	172
936	899	18.2	244
937	1160	19.7	261
938	2830	21.5	263
939	423	14.1	287
940	429	13.7	498
941	1430	22.1	113
942	1560	28.3	490
943	960	23.1	382
944	1840	37.2	985
945	2420	42.5	555
946	1950	57.4	576
947	727	16.6	150
948	537	22.9	304
949	317	26	721
950	327	18.1	328
951	657	18.2	382
952	266	16.6	439
953	275	10.9	347
954	450	35.3	357

955	366	42.3	1380
956	406	32.1	643
957	947	25	747
958	340	27.1	850
959	316	24.5	503
960	813	14.1	161
961	342	13.6	216
962	485	9.71	132
963	900	25.1	215
964	324	21.4	267
965	430	23.2	194
966	581	35.9	257
967	508	39.5	345
968	625	11.7	103
969	660	12.6	113
970	809	20.1	186
971	1340	30.2	294
972	660	30.4	327
973	2270	60.1	1140
974	870	80.9	283
975	374	30.1	1810
976	848	82.7	2860
977	839	23	159
978	824	33.9	174
979	359	19.2	257
980	239	15.4	290
981	477	21.1	330
982	307	19.4	310
983	576	19.4	207
984	409	23.5	160
985	374	24	217

986	702	31.3	380
987	267	11.7	515
988	320	11.8	743
989	247	8	402
990	276	9.87	557
991	405	14.8	315
992	863	12.5	643
993	1860	14.5	1210
994	1050	30.8	395
995	295	6.12	1660
996	1160	11.2	4810
997	527	27.8	1880
998	794	6.78	1470
999	2130	10.4	3020
1000	501	15.5	279
1001	1170	20	295
1002	197	11.6	1290
1003	371	15.9	1950
1004	237	35.4	973
1005	1670	14.5	171
1006	315	11.8	574
1007	636	12	95.1
1008	1010	15.2	126
1009	268	9.72	174
1010	214	15.1	218
1011	459	13.5	148
1012	533	15.9	223
1013	285	22.6	137
1014	277	5.62	86.4
1015	357	9.08	92.4
1016	626	30.6	156

1017	649	28.3	118
1018	568	14.1	163
1019	579	21.3	161
1020	478	27.3	146
1021	588	29	174
1022	586	27.9	203
1023	856	26	230
1024	760	32.5	330
1025	625	31.5	352
1026	2080	61.3	299
1027	1470	58.1	252
1028	3910	157	986
1029	511	22.3	170
1030	1830	21	385
1031	1200	17.3	152
1032	900	21.9	148
1033	2170	23.4	221
1034	1890	23	317
1035	1380	16	167
1036	353	13	1080
1037	291	13.7	625
1038	1300	29.8	349
1039	2020	26.8	413
1040	2020	20.8	322
1041	1720	75.7	316
1042	1890	84.8	642
1043	2240	44.9	268
1044	2410	88.7	1110
1045	1540	107	276
1046	1680	85	528
1047	1510	60.8	1960

1048	1930	108	1900
1049	1280	56.2	780
1050	2040	68.5	1240
1051	1800	32.6	NA
1052	1980	38	NA
1053	3470	19.3	NA
1054	1630	79.4	NA
1055	450	78.9	NA
1056	1650	29.6	NA
1057	2780	25.9	NA
1058	1450	45.6	NA
1059	748	48.9	NA
1060	4900	44.7	NA
1061	2910	55.6	NA
1062	2380	67.5	NA
1063	2290	26.6	626
1064	1940	62.5	912
1065	3080	39.1	2290
1066	4260	69.9	1850
1067	1860	86.4	2610
1068	295	20.2	1330
1069	2160	39.5	1290
1070	1940	27.3	321
1071	2990	40.2	425
1072	914	9.94	95.1
1073	1490	15.7	114
1074	1990	8.49	101
1075	3020	9.88	109
1076	1650	20.2	187
1077	3160	27.8	408
1078	1680	38.6	264

1079	4090	18.9	175
1080	2820	18.2	281
1081	2130	8.44	151
1082	1530	12.3	677
1083	1030	20.5	547
1084	1390	17.2	761
1085	1370	9.84	188
1086	3140	21.2	496
1087	2460	23.3	439
1088	1710	15.6	367
1089	2580	34.6	449
1090	2010	27.3	619
1091	550	5.79	145
1092	506	7.83	230
1093	958	26.8	141
1094	831	5.86	64.4
1095	337	8.73	159
1096	397	11.6	194
1097	752	27.3	141
1098	994	31.2	184
1099	472	8.64	75.8
1100	577	9.04	77.2
1101	827	6.31	246
1102	516	5.12	295
1103	1350	19.5	183
1104	1470	13.9	272
1105	1260	5.59	92.5
1106	1030	4.23	119
1107	864	5.29	59
1108	468	5.22	76.2
1109	510	20.2	102

1110	449	5.4	52
1111	299	3.66	51.3
1112	588	8.02	68.3
1113	343	3.47	88.2
1114	514	2.34	39
1115	420	1.28	60.4
1116	364	10.8	198
1117	355	8.31	237
1118	802	5.45	183
1119	237	3.95	152
1120	291	9.21	171
1121	566	4.55	165
1122	474	4.54	177
1123	441	3.89	191
1124	400	12	304
1125	264	3.95	243
1126	452	13.5	208
1127	425	7.72	234
1128	869	3.18	52.8
1129	796	4.16	56.6
1130	1240	3.73	44.5
1131	1140	5.47	63.7
1132	184	1.89	38.8
1133	216	4.24	47.8
1134	180	2.41	78.9
1135	142	0.864	63.2
1136	121	0.949	39.2
1137	663	2.05	36.2
1138	72.8	3.4	164
1139	269	2.87	155
1140	228	0.869	39.2

1141	169	0.816	47.5
1142	203	0.748	38
1143	182	0.751	49.6
1144	196	0.72	36.5
1145	148	0.848	39.1
1146	198	0.825	40.1
1147	167	0.831	45.4
1148	175	0.873	44.3
1149	184	0.96	52.2
1150	161	0.583	30
1151	206	0.287	40
1152	287	1.21	43.8
1153	215	1.39	52.7
1154	320	0.954	44.5
1155	288	0.888	44.4
1156	337	1.33	47.1
1157	384	1.28	57.5
1158	301	1.42	46.8
1159	238	1.29	64.1
1160	183	0.598	31.2
1161	217	0.733	35.5
1162	199	0.656	34.5
1163	163	0.721	35.4
1164	359	1.17	63.5
1165	358	1.36	87.7
1166	427	1.1	65.6
1167	274	1.22	89.2
1168	364	0.999	65.4
1169	304	1.18	80
1170	249	0.663	50.2
1171	233	0.718	52.9

1172	303	0.7	45.5
1173	254	0.764	59.1
1174	347	0.707	60.2
1175	282	0.768	60.7
1176	229	0.462	43.8
1177	156	0.544	43.6
1178	270	0.544	39
1179	197	0.58	37.9
1180	205	0.341	35.6
1181	203	0.666	48.2
1182	172	2.73	80.4
1183	127	3.16	53.6
1184	295	8.39	179
1185	206	2.31	66.1
1186	164	3.17	52.1
1187	370	7.11	154
1188	130	7.02	77.1
1189	248	0.584	45.4
1190	192	0.954	77.4
1191	243	0.931	82.3
1192	218	1.06	59.5
1193	202	0.803	66.2
1194	215	0.759	57.4
1195	242	0.637	44.2
1196	257	0.605	45.4
1197	288	0.639	46.1
1198	314	0.67	61
1199	352	0.733	63.9
1200	278	0.896	91.4
1201	234	1.02	93.9
1202	70.3	0.471	23.1

1203	436	8.5	38.9
1204	507	15.8	37.4
1205	325	16.3	50
1206	251	7.04	44.1
1207	470	0.633	39.8
1208	451	0.786	44.8
1209	124	0.565	37.7
1210	288	0.635	38.1
1211	211	0.489	33.2
1212	230	0.614	38.2
1213	268	0.616	44
1214	210	0.771	50
1215	272	0.937	58.5
1216	225	0.914	66.9
1217	253	1.06	62.7
1218	185	0.626	48.7
1219	168	0.629	46.8
1220	168	0.609	48.5
1221	185	0.814	57.8
1222	470	12.4	44.8
1223	472	9.25	40.7
1224	208	3.78	28.4
1225	275	3.67	31.4
1226	184	0.443	34.4
1227	199	0.527	39.5
1228	185	0.522	39.1
1229	175	0.504	37.7
1230	68.4	0.0152	1.14
1231	17.1	0.00994	1.22
1232	8.53	0.00687	0.694
1233	9.9	0.00988	1.06

1234	11.7	0.011	1.15
1235	>9950	20.3	1800
1236	502	11.9	95.8

5 NOTE: EC₅₀ determination of human GLP-1(7-36)NH₂ at human GLP-1R, human Gcg at human GcgR, and human GIP(1-42)NH₂ at human GIP-R: the peptide concentration ranges were 346 pM to 9950 nM. EC₅₀ determination of Examples at human GLP-1R, human GcgR, and human GIP-R: the peptide concentration ranges were 6.87 pM to 9.95 μM.

10 As seen in Table 2, in the presence of HSA, exemplary analogs have agonist activities as determined by human GIP-R, GLP-1R, and GcgR cAMP assays, which are lower than the native ligands.

 To determine the intrinsic potency of exemplary analogs and comparator molecules, the cAMP assays described above were performed in the presence of 0.1% casein only
15 (without human serum albumin). Casein is used as a nonspecific blocker in both cAMP assays and does not interact with the fatty acid moieties of the analyzed molecules.

 Intracellular cAMP levels are determined by extrapolation using a standard curve. Dose response curves of compounds are plotted as the percentage of stimulation normalized to minimum (buffer only) and maximum (maximum concentration of each control ligand)
20 values and analyzed using a four parameter non-linear regression fit with a variable slope (Genedata Screener 13). EC₅₀ is the concentration of compound causing half-maximal simulation in a dose response curve. Each relative EC₅₀ value for the Geometric mean calculation is determined from a curve fitting.

 Data are provided below in Table 3.

25 **Table 3. Functional Activation of hGLP-1R, hGIPR, hGcgR in the Presence of 0.1% Casein.**

Example	Relative cAMP EC ₅₀ , nM		
	<i>hGcgR</i>	<i>hGIPR</i>	<i>hGLP-1R</i>
<i>hGcg</i>	2.07	>300	116
<i>hGIP 1-42 amide</i>	>99.5	0.498	>9950
<i>hGLP-1 7-36 amide</i>	>99.5	>99.5	0.314

1	3.72	0.207	1.42
2	4.29	0.207	1.65
3	3.8	0.217	1.67
4	3.2	0.192	1.66
5	7.4	0.177	2.37
6	6.89	0.232	1.95
7	5.05	0.203	2.11
8	6.65	0.231	2.11
9	7.19	0.205	1.61
10	7.62	0.226	1.85
11	12.5	0.233	2.07
12	12.2	0.17	1.46
13	7.19	0.196	1.78
14	7.23	0.17	1.67
15	11.1	0.201	1.77
16	8.84	0.217	1.54
17	8.33	0.317	2.96
18	2.7	0.337	2.31
19	2.35	0.228	3.96
20	15.4	0.381	2.45
21	12.4	0.218	2.7
22	5.42	0.246	2.94
23	5.13	0.178	2.98
24	9.66	0.308	3.09
25	6.8	0.128	3.34
26	4.82	0.2	3.44
27	8.91	0.41	2.33
28	12.6	0.255	3.68
29	11.1	0.35	3.56
30	5.22	0.247	3.18
31	8.42	0.249	2.16

32	11.6	0.28	2.55
33	7.04	0.285	1.71
34	3.47	0.122	1.16
35	4.32	0.55	3.05
36	4.32	0.482	3.57
37	6.83	0.207	1.66
38	9.5	0.304	2.4
39	10.1	0.299	2.13
40	12.3	0.139	0.693
41	8.59	0.258	2.2
42	5.83	0.115	2.17
43	2.71	0.101	1.55
44	2.46	0.116	1.66
45	2.08	0.112	1.52
46	1.53	0.0947	4.04
47	5.61	0.388	3.4
48	3.8	0.27	2.99
49	5.54	0.324	0.706
50	4.25	0.29	4.65
51	5.15	0.421	5.8
52	5.84	0.449	5.18
53	4.19	0.518	3.31
54	3.77	0.502	3.95
55	5.2	0.0856	1.96
56	2.8	0.315	4.07
57	4.37	0.098	3.06
58	4.86	0.175	2.93
59	6.57	0.54	4.8
60	8.96	0.135	1.93
61	3.57	0.122	2.05
62	3.96	0.146	2.72

63	4.1	0.255	4.78
64	4.94	0.309	4.08
65	6.49	0.739	4.21
66	3.71	0.219	3.86
67	3.7	0.34	4.07
68	8.55	0.46	3.07
69	4.75	0.136	3.25
70	6.04	0.102	2.71
71	8.74	0.105	3.12
72	5.48	0.202	1.86
73	4.58	0.114	2.44
74	2.53	0.0708	3.32
75	4.51	0.0578	4.4
76	11.1	0.196	2.25
77	15.3	0.168	1.85
78	7.06	0.228	1.93
79	3.08	0.0773	1.8
80	7.44	0.0593	2.55
81	7.78	0.246	2.19
82	6.98	0.302	3.52
83	10.2	0.185	2.85
84	8.48	0.21	1.61
85	7.63	0.157	2.73
86	7.23	0.145	2.43
87	8.51	0.128	2.75
88	7.48	0.177	3.45
89	11.6	0.167	3.31
90	9.58	0.173	2.68
91	9.13	0.243	3.39
92	12	0.212	2.08
93	7.16	0.162	2.63

94	8.16	0.154	2.63
95	8.41	0.116	1.95
96	14.1	0.456	3.92
97	6.73	0.176	3.23
98	6.91	0.179	4.35
99	6.09	0.174	3.54
100	13.1	0.293	3.21
101	10	0.436	4.3
102	9.75	0.587	3.35
103	10.5	0.2	3.27
104	7.58	0.251	3.39
105	12.5	0.269	2.86
106	6.26	0.345	3.94
107	10.8	0.426	8.5
108	3.95	0.222	3.1
109	11.2	0.279	5.95
110	2.45	0.102	2.99
111	4.25	0.0888	5.06
112	11	0.233	5.77
113	12	0.24	3.93
114	5.63	0.14	6.38
115	10.6	0.457	7.6
116	3.96	0.382	7.83
117	4.75	0.267	6.4
118	7.02	0.43	6.03
119	5.6	0.179	3.67
120	5.85	0.44	4.77
121	4.89	0.172	2.38
122	3.95	0.189	3.93
123	4.55	0.531	4.82
124	2.92	0.344	6.14

125	3.97	0.503	4.12
126	6.81	0.264	3.97
127	4.35	0.312	4.8
128	6.76	0.307	3.5
129	2.01	0.134	1.87
130	3.74	0.411	4.29
131	2.64	0.416	5.51
132	2.63	0.21	5.72
133	1.64	0.15	3.6
134	7.28	0.152	3.36
135	2.53	0.246	3.3
136	8.73	0.221	3.8
137	4.43	0.269	3.18
138	4.79	0.262	3.54
139	2.94	0.244	3.11
140	4.83	0.205	7.79
141	1.77	0.21	1.96
142	3.49	0.216	4.37
143	4.51	0.211	2.44
144	14.8	0.23	4.02
145	3.14	0.539	4.26
146	2.04	0.362	2.73
147	4.39	0.343	4.26
148	3.92	0.352	2.82
149	12.6	0.46	3.85
150	5.37	0.346	2.63
151	3.5	0.0784	1.6
152	6.91	0.259	4.03
153	14.7	0.218	7.09
154	8.72	0.227	4.94
155	5.68	0.177	2.98

156	3.62	0.208	3.37
157	4.16	0.183	3.04
158	3.72	0.245	2.49
159	6.89	0.343	4.15
160	4.32	0.354	5.39
161	4.83	0.555	5.22
162	4.72	0.222	4.72
163	5.6	0.376	6.5
164	2.92	0.302	5.02
165	4.47	0.0956	6.52
166	3.82	0.118	6.96
167	5.05	0.101	6.19
168	5.54	0.233	2.44
169	11.7	0.209	6.17
170	5.29	0.401	4.11
171	3.86	0.2	2.89
172	3.38	0.174	3.5
173	3.6	0.168	2.32
174	4.24	0.198	2.33
175	4.92	0.218	4
176	4.1	0.212	2.92
177	4.22	0.213	2.97
178	7.29	0.34	4.01
179	4.82	0.104	5.81
180	2.44	0.14	5.08
181	6.25	0.133	4.39
182	5.33	0.0781	4.8
183	3.83	0.0759	5.03
184	5.23	0.162	5.02
185	3.5	0.123	5.46
186	4.67	0.107	5.26

187	14.8	0.111	1.11
188	10.8	0.193	3.43
189	6.28	0.0695	4.46
190	2.95	0.306	1.41
191	2.11	0.422	2.48
192	4.18	0.142	9.77
193	4.51	0.0609	5.19
194	4.32	0.212	4.69
195	3.1	0.145	6.13
196	8.83	0.42	5.67
197	3.23	0.31	4.81
198	6.85	0.182	4.36
199	5.8	0.232	4.91
200	2.83	0.0739	3.19
201	3.84	0.0553	3.16
202	11.4	0.0965	4.79
203	6.92	0.125	4.72
204	6.92	0.181	2.34
205	8.98	0.16	2.71
206	2.2	0.224	2.77
207	4.24	0.321	4.36
208	2.69	0.159	3.72
209	3.08	0.129	1.78
210	2.81	0.153	1.44
211	2.05	0.116	1.23
212	3.74	0.13	1.35
213	3.61	0.124	1.9
214	2.49	0.103	1.22
215	9.77	0.418	0.803
216	2.7	0.0887	0.52
217	5.11	0.0897	0.667

218	7.89	0.0853	0.76
219	7.77	0.119	0.835
220	11.2	0.411	1.01
221	11.3	0.105	0.629
222	2.33	0.228	3.64
223	1.57	0.215	2.83
224	1.91	0.114	1.89
225	2.36	0.213	2.44
226	3.08	0.127	1.97
227	4.22	0.17	2.34
228	1.38	0.147	1.52
229	2.3	0.179	1.58
230	1.61	0.0909	0.937
231	2.12	0.119	1.3
232	2.42	0.102	0.819
233	2.25	0.0884	0.874
234	7.87	0.322	4.72
235	4.35	0.388	3.55
236	2.23	0.309	3.33
237	3.77	0.228	3.4
238	2.78	0.0909	2.71
239	2.14	0.0503	2.9
240	2.02	0.214	3.62
241	2.71	0.0748	2.3
242	3.5	0.0916	3.42
243	6.86	0.178	6.46
244	4.81	0.0972	7.68
245	7.07	0.0684	5.99
246	2.38	0.106	3.91
247	1.76	0.0794	2.8
248	3.36	0.0861	3.17

249	5.55	0.173	2.4
250	3.81	0.154	2.08
251	6.98	0.153	2.64
252	2.61	0.147	3.54
253	6.62	0.115	2.2
254	4.9	0.121	3.08
255	5.48	0.107	1.9
256	5.71	0.176	2.87
257	7.36	0.135	2.66
258	7.15	0.154	2.71
259	2.55	0.114	1.47
260	5.04	0.251	3.85
261	5.49	0.29	3.12
262	9.77	0.232	4.39
263	7.53	0.169	1.32
264	6.29	0.0884	4.67
265	5.63	0.239	2.73
266	4.57	0.166	4.77
267	5.74	0.279	5.86
268	7.69	0.274	3.14
269	7.69	0.288	3.23
270	5	0.26	3.2
271	8.51	0.152	5
272	7.91	0.254	2.62
273	6.96	0.243	4.02
274	9.37	0.296	4.9
275	7.8	0.318	4.93
276	2.82	0.0708	2.61
277	10.6	0.0672	5.56
278	4.45	0.0963	4.11
279	5.06	0.105	5.77

280	8.63	0.105	0.95
281	13.7	0.154	1.6
282	6.98	0.163	1.09
283	9.73	0.225	1.16
284	9.21	0.347	1.54
285	2.32	0.0652	2.87
286	2.2	0.0845	3.45
287	2.53	0.0633	4.25
288	5.17	0.234	1.89
289	5.02	0.382	0.449
290	2.68	0.43	0.34
291	1.88	0.26	0.22
292	1.84	1.02	1.03
293	4.01	0.0587	0.994
294	1.07	0.318	2.16
295	2.15	0.126	0.831
296	1.72	0.0806	0.536
297	3.26	0.626	2.96
298	1.04	0.138	0.277
299	2.54	0.137	0.963
300	6.54	0.0975	1.05
301	6.73	0.722	0.641
302	4.47	0.7	0.621
303	6.1	0.116	1.13
304	2.31	0.127	0.551
305	6.73	1	1.48
306	5.8	0.142	0.335
307	1.68	0.446	0.836
308	14.2	NA	3.15
309	9.28	0.32	0.808
310	3.52	0.0939	0.586

311	2.08	0.113	3.36
312	7.5	0.504	2.66
313	4.11	0.49	0.304
314	3.7	0.345	0.274
315	4.05	0.398	0.508
316	5.22	0.259	0.362
317	2.42	0.474	1.32
318	5.03	0.378	0.698
319	4.81	0.485	0.947
320	6.87	0.274	2.58
321	4.49	0.0912	0.798
322	5.41	0.264	0.394
323	6.04	0.232	1.56
324	5.74	0.164	4.4
325	2.43	0.351	1.56
326	5.34	0.3	0.555
327	3.04	0.312	1.61
328	10.3	0.544	1.3
329	3.47	0.207	0.926
330	3.91	0.0783	0.63
331	1.66	0.148	0.663
332	11.8	0.413	1.24
333	7.09	0.265	0.705
334	6.77	0.223	0.707
335	6.11	0.292	0.461
336	7.05	0.306	0.921
337	5.95	0.332	0.686
338	4.02	0.0733	1.22
339	6.81	0.101	1.06
340	2.02	0.189	0.648
341	10.7	0.213	1.62

342	10.2	0.347	0.419
343	6.83	0.184	1.31
344	9.05	0.406	2.56
345	11.3	0.0377	0.658
346	15.6	0.0738	1.17
347	8.88	0.0634	0.798
348	3.9	0.127	0.346
349	5.12	0.152	0.555
350	10.4	0.106	0.776
351	12.1	0.243	0.679
352	16.4	0.245	0.967
353	11	0.127	0.634
354	7.91	0.134	1.21
355	5.87	0.0811	1.01
356	4.76	0.0613	0.599
357	6.21	0.077	0.625
358	2.78	0.182	2.31
359	2.1	0.281	4.61
360	5.28	0.45	5.86
361	2.73	0.214	2.08
362	6.04	0.262	1.77
363	13.6	0.375	1.47
364	10.2	0.457	1.1
365	4.24	0.0336	0.265
366	4.51	0.024	0.744
367	7.95	0.0215	0.421
368	0.481	0.0121	0.242
369	0.873	0.0263	0.301
370	7.06	0.027	0.406
371	4.46	0.0128	0.327
372	7.54	0.0161	0.333

373	4.48	0.0183	0.392
374	0.908	0.0186	0.336
375	1.32	0.0165	0.299
376	1.71	0.0354	0.445
377	1.36	0.0377	0.367
378	1.45	0.0213	0.251
379	2.27	0.0946	0.158
380	1.17	0.0346	0.354
381	1.39	0.0156	0.157
382	3.72	0.0368	0.291
383	1.27	0.0406	0.258
384	5.77	0.0152	0.133
385	1	0.0141	0.235
386	1.7	0.0156	0.278
387	2.14	0.0276	0.255
388	2.15	0.0462	0.373
389	4.03	0.0354	0.134
390	3.08	0.122	0.134
391	3.04	0.0298	0.199
392	3.02	0.0571	0.253
393	0.947	0.0458	0.211
394	5.63	0.018	0.226
395	5.55	0.0248	0.349
396	4.99	0.024	0.293
397	5.22	0.0247	0.2
398	2.16	0.0318	0.186
399	1.51	0.0413	0.302
400	2.53	0.0158	0.253
401	1.99	0.0183	0.213
402	5.66	0.123	0.725
403	1.59	0.0827	0.396

404	4.1	0.0102	0.217
405	15.5	0.28	1.48
406	1.23	0.0233	0.208
407	1.49	0.0362	0.259
408	1.93	0.0329	0.253
409	7.92	0.363	0.484
410	9.94	0.0708	0.354
411	3.94	0.058	0.709
412	2.36	0.0351	0.282
413	6.3	0.0881	0.564
414	4.56	0.0303	0.176
415	8.64	0.0496	0.38
416	2.08	0.0393	0.331
417	2.83	0.0144	0.328
418	4.7	0.0153	0.264
419	8.52	0.0235	0.615
420	2.49	0.0131	0.205
421	3.25	0.0132	0.21
422	14.5	0.0216	0.252
423	1.92	0.0114	0.194
424	3.12	0.0154	0.318
425	5.49	0.0997	0.15
426	4.33	0.079	0.139
427	3.81	0.0121	0.282
428	2.35	0.01	0.207
429	1.19	0.0142	0.178
430	2.11	0.0144	0.438
431	3.32	0.0157	0.392
432	1.6	0.0297	0.431
433	5.78	0.0206	0.273
434	2.84	0.0226	0.236

435	3.01	0.0239	0.311
436	2.27	0.0294	0.173
437	1.76	0.0872	0.421
438	3.62	0.225	0.815
439	4.38	0.0634	0.293
440	7.14	0.0226	0.467
441	8	0.0239	0.365
442	5.66	0.0237	0.267
443	6.09	0.0291	0.572
444	6.49	0.0106	0.352
445	10.1	0.0206	0.731
446	8.34	0.0351	0.696
447	9.71	0.0177	0.214
448	4.54	0.0171	0.336
449	11.5	0.0205	0.568
450	4.84	0.0448	0.43
451	4.12	0.0101	0.256
452	2.44	0.0118	0.235
453	7.37	0.0184	0.374
454	9.11	0.0154	0.821
455	4.36	0.0182	0.49
456	3.48	0.00913	0.19
457	2.86	0.00918	0.226
458	5.29	0.0448	0.347
459	1.21	0.0122	0.179
460	1.89	0.0624	0.636
461	1.53	0.0171	0.194
462	1.69	0.0148	0.204
463	4.27	0.0558	0.362
464	1.25	0.072	0.466
465	1.5	0.148	0.575

466	5.84	0.0466	0.207
467	9.34	0.0855	0.358
468	1.95	0.0222	0.466
469	1.34	0.031	0.562
470	2.35	0.0263	0.323
471	2.19	0.0296	0.317
472	2.73	0.015	0.171
473	2.72	0.0101	0.173
474	3.88	0.0125	0.236
475	2.24	0.0173	0.254
476	1.34	0.0131	0.164
477	5.26	0.0127	0.173
478	8.07	0.106	0.243
479	5.98	0.0905	0.314
480	1.47	0.0107	0.215
481	1.22	0.0164	0.204
482	1.41	0.0139	0.177
483	1.77	0.0133	0.188
484	3.99	0.0152	0.201
485	4.29	0.0194	0.277
486	4.43	0.0262	0.375
487	5.36	0.0286	0.639
488	5.13	0.0263	0.682
489	2.31	0.0121	0.172
490	3.05	0.0159	0.183
491	1.58	0.0126	0.17
492	1.35	0.0119	0.146
493	6.25	0.0406	0.644
494	1.26	0.014	0.211
495	1.75	0.0361	0.274
496	8.25	0.387	9.69

497	2.70	0.297	1.08
498	4.11	0.0711	1.53
499	1.39	0.0274	0.219
500	4.04	0.0375	0.623
501	4.54	0.0373	0.401
502	3.8	0.0337	0.326
503	3.98	0.0518	0.525
504	2.83	0.0364	0.253
505	0.445	0.00707	0.205
506	17.1	0.308	2.14
507	1.86	0.0127	0.187
508	1.82	0.00883	0.173
509	4.66	0.0557	0.65
510	5.44	0.0627	0.71
511	8.75	0.0914	1.05
512	7.34	0.0697	1.32
513	9.58	0.0956	0.634
514	6.68	0.0744	0.623
515	6.47	0.0893	0.825
516	8.45	0.112	0.907
517	4.69	0.158	0.646
518	3.93	0.129	0.867
519	4.71	0.212	1.04
520	6.09	0.224	1.04
521	4.04	0.0164	0.341
522	6.32	0.033	0.51
523	3.79	0.021	0.482
524	5.11	0.0266	0.487
525	10	0.0351	0.426
526	8.62	0.0364	0.421
527	6.99	0.0386	0.446

528	7	0.0333	0.434
529	6.59	0.0273	0.467
530	17.1	0.874	4.91
531	3.79	0.0694	0.356
532	1.37	0.0159	0.577
533	5.02	0.0388	0.334
534	4.58	0.0523	0.395
535	3.16	0.0183	0.418
536	5.83	0.0211	0.521
537	5.9	0.0641	0.538
538	6.93	0.0672	0.533
539	4.97	0.0247	0.521
540	5.62	0.0296	0.686
541	4.26	0.0213	0.74
542	5.03	0.0336	0.388
543	4.56	0.0319	0.41
544	2.71	0.041	0.623
545	2.71	0.0432	0.602
546	3.67	0.25	0.517
547	3.8	0.152	0.337
548	3.94	0.0547	0.478
549	3.41	0.0255	0.395
550	11.7	0.0876	2.12
551	1.74	0.0173	0.303
552	2.53	0.0177	0.804
553	4.53	0.0371	0.398
554	6.83	0.0323	0.423
555	3.56	0.0601	0.445
556	4.14	0.0866	0.561
557	3.42	0.0486	0.45
558	4.42	0.0564	0.526

559	4.07	0.119	0.542
560	3.8	0.113	0.883
561	5.43	0.212	1.13
562	6	0.284	1.67
563	8.3	0.132	1.01
564	10.2	0.176	1.33
565	10.3	0.107	1.24
566	7.18	0.137	1.3
567	5.89	0.165	1.07
568	6.13	0.125	0.986
569	4.34	0.199	1.12
570	5.88	0.186	1.03
571	3.27	0.0746	0.603
572	3.48	0.0465	0.366
573	4.02	0.0342	0.416
574	5.04	0.235	0.499
575	3.69	0.321	0.438
576	6.37	0.0723	0.528
577	6.47	0.103	0.931
578	6.26	0.0208	0.233
579	2.36	0.0171	0.252
580	7.27	0.0426	0.615
581	8.18	0.0812	0.406
582	10.5	0.103	0.298
583	6.32	0.0692	0.542
584	5.29	0.0461	1
585	6.25	0.0801	0.601
586	4.58	0.0461	0.593
587	5.38	0.0635	0.611
588	4.72	0.0777	0.613
589	4.11	0.0672	0.713

590	4.34	0.105	0.89
591	4.67	0.0579	0.773
592	4.25	0.0971	1.12
593	6.57	0.0484	0.495
594	8.35	0.0541	0.561
595	5.06	0.0338	0.53
596	5.71	0.0455	0.592
597	5.2	0.0643	0.6
598	8.79	0.0927	0.886
599	2.9	0.0558	0.409
600	2.97	0.0478	0.377
601	3.88	0.0688	0.443
602	4.21	0.0726	0.775
603	5.43	0.102	0.688
604	5.5	0.161	0.705
605	5.49	0.132	0.795
606	5.01	0.17	0.786
607	8.91	0.0879	1.15
608	7.82	0.124	1.87
609	6.46	0.0784	1.07
610	5.75	0.133	1.66
611	6.8	0.126	1.63
612	7.13	0.087	1.21
613	20.4	0.00925	0.698
614	6.36	0.0065	0.251
615	3.93	0.00825	0.575
616	6.58	0.00727	0.29
617	4.56	0.00849	0.534
618	5.57	0.0418	1.53
619	6.34	0.0685	0.992
620	8.26	0.0706	0.981

621	6.81	0.0661	1.28
622	7.7	0.0148	0.776
623	7.94	0.0224	0.907
624	8.42	0.0222	0.95
625	8.53	0.0291	1.16
626	8.72	0.0192	0.889
627	8.82	0.0261	1.22
628	7.47	0.0278	1.11
629	9.75	0.029	1.58
630	8.07	0.0233	0.762
631	16.8	0.0375	0.658
632	13.5	0.068	0.951
633	10.2	0.0186	0.421
634	6.49	0.0195	0.403
635	7.09	0.0405	0.625
636	9.28	0.054	0.504
637	11.7	0.108	1.08
638	14	0.0354	0.4
639	8	0.0231	0.374
640	9.5	0.00696	0.288
641	3.72	0.00819	0.489
642	3.49	0.00796	0.474
643	16	0.0223	0.741
644	5.91	0.00649	0.309
645	3.25	0.00724	0.596
646	23.1	0.0336	2.58
647	18.8	0.0177	0.872
648	20.3	0.0392	1.76
649	21.2	0.0221	1.35
650	16.2	0.0814	0.649
651	10.7	0.112	1.02

652	15.3	0.0342	0.426
653	7.29	0.0303	0.426
654	2.66	0.0471	0.349
655	3.79	0.0533	0.351
656	2.04	0.0269	0.318
657	0.891	0.0393	0.429
658	1.05	0.0379	0.34
659	5.89	0.0673	1.31
660	7.38	0.0646	1.27
661	1.78	0.0665	1.13
662	4.81	0.0704	0.946
663	1.95	0.0893	1.29
664	2.12	0.0159	0.356
665	2.94	0.0223	0.284
666	2	0.0203	0.337
667	2.34	0.0217	0.42
668	2.03	0.0198	0.325
669	1.76	0.0145	0.27
670	3.28	0.0135	0.683
671	1.81	0.00807	0.166
672	1.19	0.014	0.389
673	2.31	0.00656	0.174
674	2.09	0.0264	0.21
675	2.15	0.0111	0.254
676	2.34	0.0106	0.267
677	2.21	0.0111	0.252
678	2.28	0.0132	0.251
679	3.22	0.0123	0.255
680	2	0.01	0.246
681	1.35	0.00663	0.257
682	1.91	0.00661	0.212

683	1.57	0.00798	0.214
684	2.16	0.00843	0.28
685	2.18	0.00809	0.308
686	2.43	0.00776	0.298
687	2.41	0.00903	0.277
688	2.06	0.00881	0.304
689	1.81	0.0104	0.214
690	1.65	0.00892	0.231
691	2.46	0.0117	0.26
692	2.14	0.0106	0.252
693	2.39	0.0104	0.161
694	2.04	0.00781	0.253
695	1.93	0.0136	0.254
696	1.75	0.00688	0.233
697	1.71	0.0109	0.235
698	1.53	0.0112	0.252
699	1.35	0.00663	0.196
700	1.31	0.00758	0.245
701	1.48	0.01	0.22
702	1.5	0.0116	0.243
703	1.56	0.0101	0.233
704	1.85	0.013	0.287
705	1.7	0.0128	0.305
706	2.18	0.00911	0.19
707	1.06	0.0107	0.248
708	1.44	0.00907	0.262
709	1.23	0.0129	0.323
710	1.52	0.00578	0.274
711	1.29	0.00861	0.355
712	1.36	0.00689	0.258
713	1.71	0.00928	0.331

714	1.76	0.00764	0.289
715	1	0.00644	0.267
716	1.12	0.00853	0.321
717	1.14	0.00721	0.283
718	1.2	0.00706	0.214
719	1.44	0.00998	0.22
720	1.78	0.0103	0.245
721	1.78	0.00774	0.233
722	1.71	0.01	0.252
723	1.82	0.0118	0.255
724	1.74	0.0102	0.256
725	1.49	0.0126	0.258
726	1.71	0.013	0.247
727	2.38	0.0109	0.271
728	2.45	0.0116	0.277
729	2.11	0.0113	0.288
730	2.46	0.0122	0.248
731	2.35	0.0117	0.267
732	2.18	0.0118	0.268
733	1.6	0.00894	0.293
734	2.08	0.0132	0.417
735	1.97	0.012	0.386
736	2.85	0.014	0.489
737	1.34	0.00804	0.285
738	1.87	0.00991	0.368
739	1.59	0.015	0.348
740	5.34	0.012	0.453
741	2.01	0.00612	0.239
742	1.25	0.00688	0.266
743	1.49	0.00694	0.259
744	1.04	0.00844	0.274

745	1.86	0.012	0.212
746	1.62	0.0119	0.261
747	1.71	0.00955	0.229
748	1.42	0.0105	0.258
749	2.21	0.00718	0.293
750	2	0.00784	0.302
751	1.9	0.00759	0.302
752	1.9	0.00689	0.274
753	2.7	0.0127	0.271
754	2.3	0.0102	0.222
755	2.31	0.00805	0.175
756	2.26	0.0096	0.212
757	2.32	0.00959	0.236
758	3.99	0.0212	0.195
759	1.29	0.00676	0.262
760	1.59	0.00722	0.395
761	1.5	0.00686	0.226
762	3.09	0.00882	0.273
763	1.57	0.00719	0.302
764	1.63	0.00626	0.289
765	0.952	0.0642	0.25
766	0.689	0.0323	0.273
767	1.13	0.00792	0.299
768	10.3	0.0294	0.259
769	1.33	0.00852	0.247
770	5.37	0.244	3.91
771	5.05	0.232	4.38
772	15.9	0.115	1.38
773	15.3	0.0974	1.97
774	13.7	0.128	1.89
775	4.36	0.105	0.993

776	3.73	0.112	0.889
777	3.89	0.113	0.913
778	4.39	0.136	1.16
779	4.58	0.112	0.949
780	4.84	0.111	1.26
781	4.46	0.065	1.41
782	4.96	0.0711	1.94
783	3.81	0.0806	2.13
784	5.21	0.0587	2.09
785	4.51	0.0859	2.3
786	4.46	0.0986	2.8
787	7.81	0.0675	2.55
788	3.36	0.0923	2.5
789	3.3	0.101	2.74
790	3.87	0.131	3.19
791	2.36	0.979	4.68
792	1.91	0.55	2.99
793	3.79	0.834	3.19
794	1.21	0.468	1.26
795	1.77	0.345	0.972
796	5.3	0.098	0.602
797	3.78	0.0781	0.449
798	12.1	0.0653	0.628
799	1.64	0.0668	0.462
800	21	0.283	0.486
801	5.51	0.147	0.938
802	16.6	0.124	1.41
803	9.75	0.232	2.02
804	11.5	0.0751	0.915
805	3.97	0.0875	0.715
806	8.25	0.124	0.706

807	12.4	0.108	1.72
808	1.65	0.187	3.58
809	1.74	0.194	1.87
810	3.3	0.156	2.09
811	0.724	0.14	1.48
812	1.05	0.0934	1.19
813	2.5	0.124	0.93
814	3.92	0.337	3.76
815	4.13	0.181	2.79
816	6.57	0.297	2.69
817	4.32	0.173	1.18
818	2.31	0.121	0.51
819	1.53	0.0428	0.847
820	6.83	0.121	2.78
821	6.74	0.152	2.79
822	11.6	0.186	2.51
823	7.75	0.171	2.96
824	7.92	0.123	2.43
825	5.53	0.12	3.4
826	5.59	0.581	2.75
827	4.23	0.12	0.593
828	3.58	0.149	1.17
829	2.41	0.124	1.15
830	3.21	0.132	0.791
831	4.63	0.604	0.672
832	9.1	0.187	1.07
833	3.2	0.114	1.28
834	3.36	0.094	2.64
835	3.83	0.382	2.84
836	17.1	0.294	0.794
837	7.24	0.209	0.551

838	20.7	0.225	0.379
839	5.05	0.221	0.469
840	8.38	0.147	0.481
841	9.71	0.194	0.336
842	2.35	0.284	1.08
843	3.41	0.334	0.874
844	2.83	0.27	0.61
845	0.626	0.178	0.161
846	1.19	0.204	0.82
847	1.44	0.182	0.598
848	3.22	0.148	2.29
849	6.66	0.306	0.661
850	28.4	0.346	0.451
851	3.38	0.215	3.06
852	2.26	0.34	0.871
853	26.5	0.224	0.507
854	4.31	0.158	3.32
855	2.67	0.271	0.908
856	4.41	0.237	3.37
857	6.21	0.441	0.433
858	3.44	0.0995	1.83
859	8.45	0.12	2.38
860	11	0.202	3.95
861	8.59	0.195	2.62
862	5.87	0.0896	1.7
863	2.22	0.136	1.98
864	3.56	0.048	1.05
865	1.48	0.0797	3.02
866	4.48	0.148	4.01
867	2.47	0.216	7.38
868	7.4	0.208	5.82

869	9.94	0.142	2
870	4.4	0.0698	0.962
871	12.6	0.2	2.92
872	4.18	0.205	1.01
873	2.07	0.306	0.907
874	2.19	0.142	0.991
875	3.65	0.101	0.771
876	3.28	0.053	0.456
877	3.6	0.0816	0.601
878	2.85	0.0743	0.748
879	2.16	0.169	4
880	3.53	0.116	7.69
881	4.09	0.211	2.87
882	2.73	0.129	2.33
883	4.02	0.0779	1.05
884	3.82	0.155	4.17
885	2.42	0.149	3.29
886	4.13	0.149	2.7
887	5.28	0.145	3
888	30.1	0.168	5.02
889	4.09	0.106	5.06
890	4.73	0.113	3.19
891	3.14	0.155	3.25
892	3.85	0.149	4.41
893	5.8	0.166	2.9
894	6.09	0.0752	2.01
895	4.68	0.111	3.72
896	10.6	0.12	4.64
897	3.62	0.157	3.29
898	3.39	0.287	4.62
899	4.4	0.133	4.11

900	4.74	0.173	3.99
901	9.09	0.17	1.26
902	15.9	0.19	2.58
903	12.9	0.277	2.7
904	9.88	0.194	1.94
905	12.3	0.217	2.52
906	14.7	0.212	2.48
907	5.79	0.103	1.15
908	8.11	0.246	1.2
909	6.82	0.121	1.72
910	9.76	0.111	1.49
911	9.53	0.197	1.09
912	3.76	0.0387	0.414
913	3.8	0.0349	1.05
914	10.6	0.0582	0.888
915	0.882	0.0988	1.5
916	1.09	0.0715	1.38
917	3.61	0.0724	1.52
918	3.35	0.173	2.85
919	3.51	0.182	3.91
920	4.61	0.0905	2.28
921	10.4	0.228	3.73
922	8.49	0.112	6.77
923	9.1	0.123	6.23
924	6.05	0.0798	3.12
925	8.19	0.147	4.19
926	13.2	0.166	7.71
927	15.8	0.213	8.34
928	6.85	0.0883	3.58
929	12.6	0.0953	7.51
930	13	0.244	11

931	12.2	0.256	11.3
932	2.67	0.188	1.61
933	5.51	0.259	2.32
934	2.73	0.0738	0.649
935	4.04	0.123	1.71
936	5.08	0.192	2.16
937	5.52	0.222	2.52
938	13.3	0.13	1.84
939	2.41	0.143	2.75
940	2.84	0.137	4.08
941	11.7	0.183	0.764
942	6.32	0.188	3.52
943	6.58	0.233	3.58
944	6.16	0.216	4.86
945	18	0.246	3.9
946	16.5	0.353	2.05
947	6.99	0.289	1.7
948	2.89	0.17	2.67
949	1.62	0.203	3.37
950	1.92	0.18	2.5
951	5.73	0.156	2.61
952	2.4	0.166	4.85
953	2.75	0.111	2.63
954	3.66	0.268	4.79
955	2.65	0.386	7.74
956	2.17	0.26	4.83
957	4.18	0.213	5.01
958	3.17	0.343	9.51
959	2.61	0.217	5.06
960	5.5	0.124	1.51
961	2.96	0.167	2.52

962	3.13	0.0972	1.36
963	5.81	0.244	1.77
964	2.75	0.288	2.67
965	3.35	0.13	1.39
966	1.87	0.15	1.23
967	1.94	0.205	1.75
968	4.72	0.0928	1.04
969	5.48	0.142	1.21
970	5.24	0.178	2
971	8.26	0.298	3.46
972	4.19	0.34	2.05
973	17.6	0.503	6.1
974	3.7	0.607	1.57
975	2.61	0.344	10.2
976	8.75	0.441	21.8
977	7.18	0.189	1.1
978	8.91	0.284	1.6
979	3.34	0.181	2.72
980	2.41	0.18	2.26
981	3.7	0.243	4.45
982	3.91	0.328	4.94
983	4.75	0.289	2.35
984	4.5	0.232	2.07
985	5.41	0.34	2.93
986	4.94	0.299	3.06
987	3.62	0.194	6.33
988	2.52	0.198	9.5
989	2.27	0.103	3.92
990	2.47	0.115	5.78
991	3.03	0.119	3.91
992	10.8	0.165	7.86

993	20.8	0.138	17.6
994	9.51	0.359	4.42
995	3.18	0.118	27.7
996	14.9	0.2	98.1
997	5.01	0.373	20.7
998	8.96	0.0906	14.3
999	19.4	0.128	34.8
1000	4.62	0.176	3.55
1001	22.5	0.4	4.59
1002	1.89	0.119	9.09
1003	5.07	0.272	42.4
1004	2.67	0.519	9.34
1005	9.46	0.152	1.48
1006	4.28	0.109	5.12
1007	5.34	0.116	0.668
1008	7.47	0.14	1.09
1009	4.21	0.13	2.1
1010	4.5	0.159	2.89
1011	5.27	0.21	2.13
1012	4.36	0.206	1.81
1013	2	0.208	0.449
1014	3.62	0.0412	0.718
1015	3.53	0.0822	1.01
1016	5.57	0.218	1.55
1017	6.47	0.228	1.16
1018	5.29	0.51	1.69
1019	4.36	0.169	1.33
1020	5.87	0.309	2.29
1021	4.39	0.22	1.3
1022	6.93	0.35	3.28
1023	3.82	0.235	1.47

1024	10.6	0.441	4.79
1025	3.22	0.18	2.45
1026	6.32	0.308	1.77
1027	4.99	0.208	1.23
1028	5.77	0.189	1.34
1029	5.35	0.163	1.79
1030	9.42	0.122	1.72
1031	6.98	0.146	1.15
1032	5.94	0.204	1.19
1033	15.4	0.144	1.21
1034	12.3	0.214	2.49
1035	14.5	0.131	1.29
1036	2.05	0.114	6.87
1037	3.31	0.221	5.95
1038	5.93	0.134	1.45
1039	7.46	0.118	1.65
1040	11.1	0.0717	1.69
1041	7.71	0.365	1.24
1042	27.5	1.3	10.3
1043	17.1	0.282	1.52
1044	18.8	0.896	10.7
1045	7.35	0.781	1.51
1046	10	0.352	1.94
1047	8.18	0.28	16.2
1048	6.9	0.356	6.23
1049	6.33	0.24	2.23
1050	6.8	0.152	7.65
1051	10.3	0.172	8.3
1052	7.41	0.167	3.16
1053	10.4	0.123	6.2
1054	8.06	0.797	9.53

1055	1.88	0.366	14.6
1056	3.98	0.0929	4.25
1057	5.29	0.128	5.16
1058	5.8	0.139	4.48
1059	7.52	0.468	4.61
1060	9.08	0.223	2.85
1061	17.3	0.656	4.56
1062	8.77	0.726	7.75
1063	10.6	0.318	6.96
1064	13.7	0.556	7.89
1065	19.7	0.293	11.6
1066	25.4	0.446	9.8
1067	12.6	0.471	17.6
1068	4.8	0.211	11.6
1069	21.2	0.417	8.87
1070	20.2	0.167	1.54
1071	23.5	0.261	2.06
1072	10.5	0.157	0.889
1073	12.3	0.201	1.09
1074	22.8	0.0745	0.794
1075	25	0.0778	0.878
1076	59	0.174	1.47
1077	18.8	0.23	1.48
1078	7.58	0.356	1.62
1079	30	0.0923	1.22
1080	20.9	0.176	1.59
1081	19.7	0.105	1.29
1082	12.3	0.099	4.13
1083	15	0.328	7.76
1084	11.5	0.0975	10.3
1085	11.6	0.0827	1.28

1086	12	0.117	1.23
1087	15.4	0.207	2.63
1088	14.8	0.182	2.99
1089	14	0.213	2.96
1090	15.6	0.272	5.44
1091	4.67	0.0592	1.23
1092	3.45	0.0648	1.33
1093	7.72	0.152	0.954
1094	5.84	0.0515	0.623
1095	2.75	0.065	1.17
1096	3.94	0.0799	1.47
1097	6.16	0.136	1.59
1098	6.2	0.201	1.22
1099	3.47	0.076	0.73
1100	5.28	0.0694	0.514
1101	4.72	0.0592	1.75
1102	4.37	0.0418	2.18
1103	11.1	0.0723	1.06
1104	11.1	0.09	1.7
1105	10.7	0.0427	0.875
1106	7.71	0.0312	0.87
1107	5.66	0.0447	0.51
1108	4.96	0.0507	0.752
1109	10.8	0.0626	2.3
1110	5.91	0.059	0.508
1111	5.28	0.0356	1.14
1112	10.7	0.254	0.957
1113	14.4	0.0414	1.12
1114	11.5	0.0478	0.84
1115	12.7	0.0246	2
1116	8.2	0.134	4.63

1117	4.93	0.124	3.51
1118	6.52	0.128	5.42
1119	7.61	0.0939	3.57
1120	5.17	0.096	4.5
1121	8.83	0.115	5.23
1122	10.3	0.109	5.66
1123	5.53	0.101	4.47
1124	6.97	0.187	10.1
1125	5.83	0.173	8.26
1126	3.92	0.174	4.56
1127	5.95	0.167	6.16
1128	9.88	0.0378	0.486
1129	6.11	0.048	0.501
1130	13.3	0.0441	0.641
1131	8.42	0.0472	0.483
1132	2.11	0.0335	0.681
1133	2.95	0.0719	0.768
1134	2.57	0.0391	0.957
1135	1.76	0.0126	0.746
1136	1.26	0.0131	0.453
1137	14.2	0.0334	0.582
1138	1.01	0.0491	1.93
1139	5.29	0.0431	1.85
1140	1.56	0.00821	0.323
1141	1.15	0.00921	0.412
1142	1.34	0.00706	0.329
1143	1.42	0.0087	0.381
1144	1.32	0.00649	0.282
1145	1.07	0.00689	0.313
1146	1.22	0.00628	0.281
1147	1.17	0.00753	0.347

1148	1.6	0.00801	0.299
1149	1.37	0.00804	0.352
1150	1.17	0.0069	0.278
1151	1.31	0.00339	0.262
1152	2.32	0.0101	0.371
1153	2.69	0.0109	0.33
1154	6.42	0.00879	0.344
1155	1.83	0.00917	0.434
1156	2.94	0.0127	0.444
1157	2.04	0.0124	0.408
1158	2.19	0.0126	0.419
1159	1.86	0.0118	0.45
1160	2.41	0.00773	0.365
1161	2.19	0.00973	0.39
1162	2.55	0.00818	0.372
1163	1.75	0.00951	0.449
1164	2.83	0.0104	0.495
1165	2.68	0.0121	0.632
1166	2.94	0.00999	0.478
1167	2.16	0.011	0.636
1168	2.63	0.00839	0.422
1169	2.43	0.011	0.613
1170	2.43	0.00783	0.395
1171	2.19	0.00953	0.529
1172	2.52	0.00886	0.44
1173	2.31	0.00943	0.604
1174	2.58	0.00896	0.454
1175	2.08	0.00962	0.572
1176	1.8	0.00717	0.344
1177	4.23	0.0114	0.681
1178	3.08	0.00913	0.437

1179	2.87	0.0102	0.652
1180	3.16	0.00602	0.445
1181	3.34	0.0115	0.664
1182	1.24	0.0316	0.797
1183	1.38	0.0484	0.769
1184	1.5	0.071	1.18
1185	1.64	0.0266	0.762
1186	1.46	0.0404	0.594
1187	1.81	0.0648	1.06
1188	1.16	0.0914	1.01
1189	1.59	0.00597	0.292
1190	1.68	0.0109	0.765
1191	3.06	0.00992	0.945
1192	1.54	0.00924	0.499
1193	1.56	0.00897	0.544
1194	2.02	0.00725	0.51
1195	1.74	0.00708	0.367
1196	1.9	0.00756	0.418
1197	1.88	0.00666	0.407
1198	1.8	0.00663	0.475
1199	2.05	0.0076	0.5
1200	1.5	0.00883	0.727
1201	1.76	0.00959	0.888
1202	0.5	0.00635	0.237
1203	2.58	0.0774	0.292
1204	3.5	0.21	0.338
1205	3.33	0.152	0.523
1206	1.78	0.0671	0.352
1207	7.71	0.00647	0.299
1208	3.52	0.00907	0.526
1209	0.97	0.00819	0.41

1210	2.25	0.00704	0.375
1211	1.45	0.00592	0.276
1212	1.71	0.00702	0.357
1213	1.69	0.00721	0.423
1214	1.85	0.00851	0.55
1215	2.09	0.0106	0.668
1216	1.83	0.00921	0.65
1217	1.98	0.0101	0.751
1218	1.88	0.00839	0.58
1219	1.64	0.0101	0.624
1220	1.57	0.0099	0.674
1221	2.27	0.0111	0.839
1222	2.55	0.0858	0.346
1223	2.61	0.0916	0.337
1224	2.32	0.048	0.379
1225	2.45	0.0531	0.399
1226	1.65	0.00539	0.264
1227	1.99	0.00621	0.387
1228	1.98	0.0067	0.379
1229	2.47	0.0065	0.408
1230	64.7	0.022	1.19
1231	15.7	0.0146	1.23
1232	6.69	0.00893	0.723
1233	9.48	0.012	1.09
1234	11.6	0.0135	1.17
1235	455	0.241	25.3
1236	0.947	0.052	0.304

As seen in Table 3, exemplary analogs stimulate cAMP from human GIP, GLP-1
5 and glucagon receptors in the presence of 0.1% casein.

IN VIVO STUDIES

Pharmacokinetics in Male Sprague Dawley Rats:

The pharmacokinetics of the exemplary analogs are evaluated following a single subcutaneous (SC) administration of 10 nmol/kg (dissolved in 40mM Tris pH8) or single
5 4 mg/kg (mixed with 250 mM sodium decanoate/C10 in 40 mM Tris pH8) intrajejunal (IJ)
administration to male Sprague Dawley rats. Blood samples are collected over 96 hours
following SC administration and 72 hours following IJ dosing, and resulting individual
plasma concentrations are used to calculate pharmacokinetic parameters. Peptide plasma
(K₃ EDTA) concentrations are determined using a qualified LC/MS method that measured
10 the intact mass of the analog. Each peptide and an analog as an internal standard are
extracted from rat plasma using methanol. A High Resolution Instrument was used for
LC/MS detection. Mean pharmacokinetic parameters are shown in Tables 4 and 5.

Table 4. Mean Pharmacokinetic Parameters of Peptides Following a Single Subcutaneous Administration of 10 nmol/kg to Male Sprague Dawley Rats.

	T _{1/2} (hr)	Cl/F (mL/hr/Kg)
Example 1	16.1	12.6
Example 2	12.1	8.6
Example 289	22.4	3.87
Example 321	26.2	8.2
Example 329	12.6	19.3

15 Abbreviations: T_{1/2} = half-life, CL/F = apparent clearance
NOTE: Data are the mean, where n=3/group.

Table 5. Mean Pharmacokinetic Parameters of Peptides Following a single IJ Administration of 4 mg/kg to Male Sprague Dawley Rats.

	C _{max} /D (nM/mg/kg)	T _{1/2} (hr)	Cl/F (L/hr/Kg)
Example 368	80	9.6	0.44
Example 369	70	8.2	0.68
Example 378	151	8.2	0.23
Example 381	60	8.3	0.59
Example 387	43	9.2	0.84
Example 401	36	6.6	0.98
Example 429	52	7.8	0.64
Example 462	78	11	0.6
Example 463	35	8.3	0.97
Example 472	90	9.4	0.44

Example 475	105	13.7	0.21
-------------	-----	------	------

Abbreviations: C_{max}/D = dose normalized maximum plasma concentrations; T_{1/2} = half-life, CL/F = apparent clearance.
NOTE: Data are the mean, where n=4/group.

Results from this study for Examples tested are consistent with an extended pharmacokinetic profile.

Pharmacokinetics in Cynomolgus Monkeys

A study is designed to evaluate the oral bioavailability of Example polypeptides in cynomolgus monkeys. High resolution liquid chromatography/ mass spectrometry (HR-LC/MS) is used to measure the concentrations of Examples 510, 548, 558, 694, 699, 686 712, 741, 883, and 1027 in cynomolgus monkey plasma. Standards and controls are prepared in cynomolgus monkey plasma, and any dilutions required to bring samples into the quantitative range are also performed in control cynomolgus monkey plasma. To control assay variability, an internal standard (IS) is added to all the standards and samples. The Examples and IS are extracted from 100% monkey plasma (50 µL) by protein precipitation using isopropyl alcohol and methanol (50:50 v/v). The samples are then centrifuged (3000 rpm for 10 minutes) and the supernatant is transferred to a Siricco Protein Precipitation Plate. The samples are loaded on a Sep-Pak tC18 SPE microelution plate that is conditioned with 2% formic acid in acetonitrile and water. The compounds are then washed with 2% formic acid in water and eluted using 2% formic acid in acetonitrile into a plate containing 5x Invitrosol and 1% formic acid in water prior to injecting an aliquot (10 µL) on to Xselect CSH C18, 3.5 µm, 2.1 x 20 mm for LC/MS analysis.

The plasma pharmacokinetics (PK) of Examples 510, 548, 558, 694, 699, 686 712, 741, 883, and 1027 are evaluated in male and female cynomolgus monkeys following a single intravenous (IV) dose (10 nmol/kg). Blood samples are collected over 504 hours. Plasma is harvested from blood samples by centrifugation and stored frozen (-70°C) until analysis. Plasma concentrations of the molecules are detected using the bioanalytical method described above.

Table 6: Pharmacokinetic Parameters (Mean ± SD) Following a Single IV Dose of Example polypeptides (10 nmol/kg) to male and female Cynomolgus Monkeys (n=3).

Compound	Dose	T _{1/2}	AUC _{0-inf}	CL
	(nmol/kg)	(hr)	(hr*nmol/L)	(mL/kg/hr)
Example 883	10	62.8 ± 53.9	8690 ± 623	1.15 ± 0.083
Example 510	10	55.9 ± 13.2	14500 ± 3420	0.716 ± 0.181
Example 548	10	53.2 ± 0.603	10500 ± 1580	0.971 ± 0.159
Example 558	10	107 ± 22.0	6230 ± 273	1.60 ± 0.071
Example 1027	10	76.4 ± 31.4	8570 ± 1550	1.20 ± 0.239
Example 741	10	32.1 ± 4.22	9550 ± 2280	1.09 ± 0.24
Example 712	10	54.0 ± 6.09	12400 ± 862	0.81 ± 0.06
Example 694	10	50.7 ± 16.8	10700 ± 2750	0.98 ± 0.26
Example 699	10	50.8 ± 13.7	9230 ± 1640	1.11 ± 0.19
Example 686	10	41.5 ± 2.35	7040 ± 1290	1.46 ± 0.29

Abbreviations: AUC_{0-inf} = area under the curve from time 0 hours to infinity; CL = clearance; T_{1/2} = half-life.

PK parameters of TG-2474, TG-2728, TG-2565, TG-2698, TG-2708, TG-3329, TG-3270, TG-3169, TG-3211, and TG-3120 are determined after a single 10 mg oral dose to male and female cynomolgus monkeys. Blood samples are collected up to 504 hours post-dose. Plasma is harvested from blood samples by centrifugation and stored frozen (-70°C) until analysis. Plasma concentrations of the molecules are detected using the bioanalytical method described above.

Table 7: Pharmacokinetic Parameters (Mean ± SD) Following a Single Oral Dose of Example polypeptides (10 mg per animal) with Sodium Salcaprozate ((N-[8-(2-hydroxybenzoyl) amino] caprylate) (SNAC), 300 mg) to male and female Cynomolgus Monkeys (n=4).

Compound	Dose	T _{1/2}	T _{max}	C _{max}	AUC _{0-inf}	CL/F	F
	(nmol/kg)	(hr)	(hr)	(nmol/L)	(hr*nmol/L)	(mL/kg/hr)	(%)
Example 883	519 ± 57	29.0 ± 13.4	2.0 ± 1.15	43.6 ± 22.3	1280 ± 705	666 ± 666	0.3 ± 0.2
Example 510	535 ± 69	47.0 ± 25.0	2.0 ± 1.15	126 ± 87.1	5090 ± 4290	310 ± 419	0.7 ± 0.6
Example 548	558 ± 77	45.0 ± 11.9	1.5 ± 1.0	75.7 ± 6.19	3580 ± 817	162 ± 37	0.6 ± 0.1
Example 558	448 ± 20	46.2 ± 8.01	2.75 ± 2.36	147 ± 86.9	4990 ± 2890	124 ± 85	1.8 ± 1.0
Example 1027	504 ± 53	55.7 ± 25.4	2.5 ± 1.0	135 ± 93.1	5070 ± 4080	166 ± 132	1.2 ± 0.9
Example 741	564 ± 93	58.1 ± 22.8	3.75 ± 1.5	95.8 ± 8.61	4200 ± 679	137 ± 21.2	0.8 ± 0.1
Example 712	563 ± 54	51.8 ± 16.4	3.75 ± 1.5	124 ± 49.3	6180 ± 2670	111 ± 62.9	0.9 ± 0.4
Example 694	572 ± 59	50.7 ± 13.3	3.50 ± 2.89	353 ± 192	14800 ± 10600	52.4 ± 28.1	2.4 ± 1.7
Example 699	575 ± 82	34.3 ± 7.8	2.75 ± 2.36	187 ± 102	7150 ± 2890	90.7 ± 35.6	1.3 ± 0.5
Example 686	554 ± 54	44.6 ± 6.49	1.0 ± 0.0	249 ± 319	14200 ± 22300	176 ± 158	3.6 ± 5.7

Abbreviations: AUC_{0-inf} = area under the curve from time 0 hours to infinity; CL/F = apparent clearance; C_{max} = maximum concentration; T_{max} = time to maximal concentration; T_{1/2} = half-life; F = bioavailability.

Percent F results in Table 7 demonstrate relative bioavailability of example polypeptides when administered orally as compared to IV administration.

Studies in Diet-Induced Obese C57BL/6 Mice:

To investigate the effect of the polypeptides as described herein on weight loss, exemplary polypeptides are dosed to C57BL/6 diet-induced obese (DIO) mice.

Specifically, DIO male C57BL/6 mice (Taconic, Germantown, NY) maintained on a calorie-rich diet are used in the following studies. Mice are individually housed in a temperature-controlled (24°C) facility with 12-hour light/dark cycle (lights on 22:00) and free access to food (TD95217) and water. After a minimum of 2 weeks acclimation to the facility, the mice are randomized according to their body weight, so each experimental group of animals would have similar starting body weight. The body weights range from 41 to 50 g.

All groups contain 5 mice. Mice are treated with vehicle (40 mM Tris-HCl at pH 8.0), or example polypeptides at 10 nmol/kg. Treatments are administered by subcutaneous (SC) injection (10 mL/kg) to *ad libitum* fed DIO mice 30 to 90 minutes prior to the onset of the dark cycle either once daily (QD) or once every 3 days (Q3D) for 9-16 days. Body weight and food intake are measured daily throughout the study. Body weight is presented as percent of the starting weight. The vehicle-treated mice (control group) maintain their body weight ranging from 98.00±0.84% to 101.45±2.39% throughout the study.

Data are presented as mean ± SEM of 5 animals per group in Table 7 below. Statistical analysis is performed using repeated measures ANOVA, followed by Dunnett's method comparison test.

Table 8. % Body Weight After Treatment with Exemplary polypeptides

Example	Dosing frequency	Duration (days)	Body weight (%)
2	Q3D	14	77.90+/-1.90****
4	Q3D	14	83.00+/-0.88****
21	Q3D	14	83.70+/-0.86****
23	Q3D	14	80.86+/-1.25****
24	Q3D	14	86.10+/-1.98****
29	Q3D	14	75.96+/-3.77****
30	Q3D	14	90.12+/-0.30**
62	Q3D	14	88.05+/-1.08***
75	Q3D	14	96.28+/-1.51
93	Q3D	14	86.64+/-1.94****
94	Q3D	14	84.92+/-1.79****
98	Q3D	14	90.78+/-1.26*
121	Q3D	14	85.58+/-3.20****
125	Q3D	14	97.90+/-0.32
126	Q3D	14	95.68+/-0.90
132	Q3D	14	98.66+/-0.47
134	Q3D	14	93.28+/-1.38
288	Q3D	14	86.18±0.67****
289	QD	16	60.94±1.87****
289	Q3D	14	82.32±1.25****
290	QD	16	65.40±3.45****
295	QD	16	51.58±3.24****
296	QD	16	49.64±1.97****
297	QD	16	48.42±2.86****
315	Q3D	14	79.76+/-1.72****
321	Q3D	14	87.14+/-0.59***
334	Q3D	14	84.78+/-2.74****

339	Q3D	14	82.36+/-3.01****
368	QD	14	52.52+/-2.49****
369	QD	14	52.91+/-2.17****
378	QD	15	68.84+/-1.37****
401	QD	15	71.54±3.32****
429	QD	15	70.20±1.63****
429	QD	9	74.66±3.87****
452	QD	15	74.13±4.11****
462	QD	9	73.68±2.82****
463	QD	9	83.31±2.10****
472	QD	9	76.13±2.28****
475	QD	9	69.34±2.99****
490	QD	9	80.75±3.23****
686	QD	14	72.73±3.65****
694	QD	7	71.92±1.28****
694	QD	14	69.77±2.96****
699	QD	7	68.34±0.85****
699	QD	14	56.85±2.42****
700	QD	7	75.9±3.77****
712	QD	7	69.4±0.60****
712	QD	14	63.61±3.73****
741	QD	14	59.42±2.94****

*p<0.05; **p<0.01; ***p<0.001; **** p<0.0001 compared to Control group, One way ANOVA, Dunnett's multiple comparison test

GLP1-R Internalization Assay

5 The potency of peptides to stimulate ligand-induced internalization of the GLP-1R is determined using HEK293 cells expressing the human GLP1-R.

HEK293 cells were seeded in white, 384-well plates the day before transfection at a density of 20,000 cells/well. The cells were transfected with Lipofectamine 2000 (Invitrogen) for SNAP–GLP-1R. The following day, the media was removed and the
 10 tagged receptors were labeled with 100 nM Tag-Lite SNAP-Lumi4-Tb (donor, Cisbio), in OptiMEM for 75 minutes at 37°C. Afterward, the cells were washed with internalization buffer (HBBS supplemented with 1 mM CaCl₂, 2.5 mM MgCl₂, 20 mM HEPES, and 0.1% Pluronic F-68, pH 7.4) followed by addition of 100 μM preheated fluorescein-O'-acetic acid (acceptor, Sigma-Aldrich). The plate was placed in a 37°C incubator for 5 minutes
 15 prior to ligand addition to adjust the temperature. Then, the cells were stimulated with 37°C preheated ligand, and internalization of GLP1-R was measured every 3 minutes for 60

minutes at 37°C by an EnVision plate reader. Data were normalized to maximum concentration of GLP-1 (100%) and no ligand (0%) and plotted using GraphPad Prism 7 software.

5 The potency of an exemplary polypeptide to stimulate ligand-induced internalization of the GLP-1R is reported in Table 9. Assay results identify whether a polypeptide is a partial agonist on the GLP-1R with respect to GLP-1R internalization.

Table 9.

Compound or Example Tested	GLP1R Internalization EC ₅₀ , nM	Internalization %TOP
GLP1 7-36 amide	7.17	99.4
Semaglutide	12.4	103
Tirzepatide	60.8	60.3
1	44.7	69.1
2	49.5	66.8
3	49.2	69.7
4	49.1	67.8
5	53.4	75
7	52.6	76.3
8	63.2	74
10	79.2	71.9
11	75.1	73.8
12	48.5	75.3
13	53.3	74.7
15	79	74.9
16	37.8	74.6
17	66.2	72.2
18	91.8	74.1
19	52.4	72.6
21	87.6	72.5
22	41.9	64.7
23	51.5	67.2

24	79.9	71.9
26	96.1	75.6
28	81.8	76.2
29	129	57
30	70.4	72.8
31	91.9	67.4
32	86.1	64.4
33	106	64.6
37	51.6	68.3
41	83.7	62.3
42	61.4	58.3
43	58.2	68.3
44	51.5	65
45	52.6	62.1
46	41	58.1
48	44	55.2
49	37.2	53.2
50	30.1	31.1
51	89.2	55.7
55	79.5	70.7
57	76.6	73.1
58	56.2	78.1
62	40.3	44.9
66	42.1	46.3
67	50.9	31.1
68	95.2	33.8
69	71.9	58.2
70	60	61.3
71	58.8	68.6
74	72.7	53.3
75	61.8	51.9
78	78.2	55
79	56.6	45.3

80	35.8	48.2
85	326	48.3
86	57.8	52.5
87	61.8	45.4
90	70.8	49.8
93	30.4	50.8
94	37.1	47.2
95	37.8	49.3
97	51.9	50.7
98	56	49.3
99	56.9	46.1
107	150	45.1
108	67.7	41.1
109	28.8	39
110	28.3	42.5
111	49.1	46.4
112	30.1	59.1
113	39.5	64.6
114	47.2	62.9
115	255	56.5
116	80.7	46.2
117	45.5	51
118	82.3	46.4
119	73.5	43.4
121	38.1	46.3
122	57.4	43.7
125	86.4	42.6
126	63.2	38.8
129	22.5	40.6
132	72.7	67.2
134	67.9	22.3
136	36.1	37.8
137	60.2	47.7

139	62.8	39.9
141	95.3	64.1
143	337	43
148	95.5	37.4
151	77.8	55
154	47.7	65.9
155	85.1	54.5
157	60.3	53.3
158	104	52.4
162	48.8	44.8
163	143	37.8
164	45.9	46.5
165	57.5	44.5
166	74.6	44.2
167	75.9	44.7
168	74.8	38.7
169	178	49.4
171	61.4	36.1
172	121	41.4
173	97.1	38.6
174	123	52.8
175	116	49.2
176	103	48
177	79.4	44
179	63.4	48.4
181	116	47.5
183	100	45.4
185	144	43.7
186	124	41.1
187	17.2	57
188	44.7	40.2
189	103	45.8
192	115	48.7

193	132	50.7
200	86.1	39.2
204	66.4	45.5
205	49.4	67.7
208	55.7	49.6
209	83.1	41.2
210	80.2	49.2
211	57.4	26.9
212	79.7	43
213	85.9	45.2
214	50.1	41.7
217	27.6	58.2
218	80.5	35
219	48	37.2
222	34.6	52.4
223	45.8	59.3
224	32.2	61.9
225	26	56.7
226	29.1	59.3
227	114	59.4
228	39	35
229	42.4	31.4
230	34.4	31.2
231	36.1	27.7
232	44.7	45.5
233	24.8	41.8
238	32.1	38.2
239	72.6	42.9
241	64.4	37.6
242	56	38.2
248	67.4	39.5
249	86.2	34.8
250	97	45

253	81.6	55.2
254	31.9	47.8
255	47.1	51.8
256	87.8	43.5
276	237	68.4
278	251	68.6
279	115	37.5
280	39.4	74.9
282	28.7	71.9
285	59.9	73.6
288	30.3	72.4
289	10.9	86.5
295	31.4	88.4
296	19.2	87.2
321	27.1	92.8
323	28.2	84.8
329	34	91.1
334	28.3	96.8
358	21.5	83.1
359	49.6	74.4
360	214	66.1
361	50.4	73
362	22.8	77.5
510	11.8	113
548	17.8	109
558	8.14	116
686	33.2	101
694	21.8	97.3
699	14.9	102
712	35.3	109
741	50.1	103
883	23.9	77.1
1026	47.4	80

GLP-1R CHO Cell β -Arrestin Recruitment Assay

Activated G-protein coupled receptors can interact with the β -arrestin family of signaling proteins. The potency of peptides for GLP-1R induced arrestin recruitment is determined using the PathHunter Enzyme Fragment Complementation approach substantially as described (von Degenfeld et al., FASEB J., 2007 (14):3819-26 and Hamdouchi et al., J. Med Chem., 2016 59(24):10891-10916).

CHO-K1 cells expressing Pro-Link-tagged Human GLP-1R and enzyme-acceptor-tagged β -arrestin-2 may be obtained from DiscoverX and prepared as assay-ready frozen cells. Test peptides are solubilized in DMSO and serial dilutions are performed using the Echo acoustic dispenser (LabCyte). Assay media is the PathHunter Cell Assay Buffer (DiscoverX) containing 0.1% w/v hydrolyzed Casein (Sigma). 100 nl of peptide is dispensed into 10 μ l of assay media in a 384 well plate and then 10 μ l of cells in assay media are added to give 5000 cells per well. Plates are incubated for 90 minutes in a 37°C/5% CO₂ incubator and 10 μ l of PathHunter detection reagent is added (DiscoverX) and plates are incubated at room temperature for 60 minutes. Luminescence signal is measured. Peptide concentration-response curves fit to a four-parameter logistic model to calculate potency as an EC₅₀. Data normalization to % stimulation is performed using DMSO and GLP-1(7-36) as minimum and maximum controls (Campbell *et al.*, Assay Guidance Manual 2017).

The potency of a sample peptide to stimulate GLP-1R induced β -arrestin recruitment is reported in Table 10. The assay results identify whether a peptide is a partial and biased agonist on the GLP-1R with respect to β -arrestin-2 recruitment.

Table 10.

Compound or Example Tested	hGLP1R β -arrestin Rel EC ₅₀ , μ M	% Stimulation Max
hGLP-1 7-36 amide	0.00223	102
Semaglutide	0.00468	99.6
Tirzepatide	>10	10.5
1	>10	17.3

2	>10	12.3
3	>10	16.5
4	0.0232	15.8
5	>10	18.4
288	0.0163	18
289	0.00596	47.5
294	0.0277	35.3
293	0.0119	54.6
290	0.00394	83.5
295	0.0164	44.1
296	0.014	55.2
297	0.0602	33.5
298	0.00329	86.4
300	0.0157	40.3
302	0.0112	56.6
304	0.00921	47.8
301	0.0132	59.1
307	0.00986	70.8
305	0.0233	58.3
311	0.0192	39.6
308	0.0169	41.4
309	0.00672	47.2
315	0.00376	29.7
321	0.00878	90.1
323	0.0108	44
329	0.00611	74.5

Cell based *in vitro* permeability (Papp) assay

Intestinal organoid from Göttingen minipig jejunum tissue and its 2D monolayer are generated using the protocol previously described (van der Hee, B.; Loonen, L. M. P.; Taverne, N.; Taverne-Thiele, J. J.; Smidt, H.; Wells, J. M., Optimized procedures for generating an enhanced, near physiological 2D culture system from porcine intestinal organoids. *Stem Cell Res* **2018**, 28, 165-171). After 7 days of culture, organoids are dissociated into single cells by TrypLE (Gibco), and the single cell suspension is added in 24-well transparent transwell inserts (0.3 cm², Falcon, BD). When the transepithelial electrical resistance reached > 600 $\Omega \cdot \text{cm}^2$, the peptide permeability is examined in the presence of 10 or 20 mM C10. Samples from the basal compartment are collected at 20 min in the presence of C10. Peptide concentrations in the apical and basal compartments are

measured by LC/MS, and the apparent permeability coefficient (P_{app}) is calculated as previously described (Twarog, C.; Liu, K.; O'Brien, P. J.; Dawson, K. A.; Fattal, E.; Illel, B.; Brayden, D. J., A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C10). *Eur J Pharm Biopharm* 2020, 152, 95-107).

The P_{app} values for exemplary polypeptides are reported in Table 11.

Table 11.

Compound or Example Tested	Relative Papp (Compared to internal standard)	
	with 10 mM C10	with 20 mM C10
Semaglutide	0.35	
Amycretin	0.18	0.22
Example 406	0.90	0.59
Example 475	0.79	0.73
Example 62		0.03
Example 94		0.02
Example 119	0.15	
Example 121	0.08	
Example 130		0.06
Example 134	0.07	
Example 135	0.04	
Example 137	0.04	
Example 361	0.10	
Example 154	0.12	
Example 155	0.07	
Example 165	0.09	
Example 169	0.12	
Example 174	0.12	
Example 182	0.12	
Example 184	0.09	

Example 186	0.10	
Example 187	0.48	
Example 188	0.46	
Example 189	0.17	
Example 193	0.17	
Example 198	0.12	
Example 204	0.16	
Example 208	0.29	
Example 209	0.08	
Example 210	0.06	
Example 211	0.06	
Example 212	0.22	
Example 213	0.26	
Example 214	0.07	
Example 223	0.29	
Example 224	0.35	
Example 225	0.48	
Example 226	0.36	
Example 227	0.42	
Example 231	0.06	
Example 232	0.13	
Example 233	0.21	
Example 238	0.06	
Example 241	0.10	
Example 242	0.07	
Example 249	0.04	
Example 250	0.11	
Example 255	0.23	
Example 784		0.16
Example 808		0.29
Example 552		0.53

Example 1033		0.14
Example 595		0.55
Example 666		0.85
Example 670		0.46
Example 673		0.59
Example 675		0.36
Example 686		0.60
Example 694		0.60
Example 696		0.77
Example 699		0.51
Example 700		0.29
Example 710		0.35
Example 712		0.60
Example 737		0.69
Example 741		0.73
Example 743		0.56
Example 761		0.53

In vivo Ileum (distal loop) absorption assay

Ileum absorption of the exemplary polypeptides in the presence of C10 in rats is evaluated using a previously reported intestinal closed loop model (Lawrence, S. A.; Blankenship, R.; Brown, R.; Estwick, S.; Ellis, B.; Thangaraju, A.; Datta-Mannan, A.,
5 Influence of FcRn binding properties on the gastrointestinal absorption and exposure profile of Fc molecules. *Bioorg Med Chem* **2021**, 32, 115942).

Overnight fasted Sprague Dawley rats with body weights between 250-280 grams are anesthetized by inhaling isoflurane and placed on a warm surgical table maintained by circulating water at 37°C. The surgical area is shaved, and the skin is disinfected with
10 betadine scrub followed by 70% isopropyl alcohol. An approximately 2 cm ventral midline incision is made to expose intestine, and 10 cm of an ileum segment is tied off. The peptides are formulated with 100 mM C10 in Tris buffer (pH 8.0, 50 mM) at a final concentration of 300 µM. The formulations are administered directly into the ileum loop. Blood samples

(0.2 mL) are collected from tail vein before peptide dosing and 10, 20, 40, 60 minutes post dosing. Blood samples are collected into tubes containing K₃EDTA (5%) and processed to plasma for subsequent analyses. Peptide concentrations in the plasma are determined by LC/MS.

5 **Table 12.**

Example No.	0-1h IL AUC, nM*hr	10min IL plasma concentration, nM	20min IL plasma concentration, nM	40min IL plasma concentration, nM	60min IL plasma concentration, nM
62	9078	116	169	200	197
93	11118	143	188	242	274
94	9441	106	164	212	220
121	23626	247	359	498	704
125	6772	102	125	148	143
126	14074	162	256	299	344
129	11525	151	191	262	267
130	5339	67	93	116	128
132	17358	214	270	410	403
134	15907	207	287	355	346
151	5314	69	95	115	124
183	21763	241	372	471	556
204	24673	235	399	551	650
213	16102	175	258	362	412
224	15934	237	311	331	346
226	26272	333	454	618	545
227	35445	513	656	779	746
232	12128	186	235	255	256

PROTEOLYTIC STABILITY

10 A pepsin stability assay is utilized to determine the relative stability of Example polypeptides in a simulated gastric proteolytic environment. Pepsin A is dissolved in simulated gastric fluid (SGF) with Example polypeptides or comparators and the solution is sampled and quenched at T0, 15, 30, and 60 minutes. Comparators are semaglutide and example compound number 4 from US Patent Application 2020/0024322 (“Cmpd 4”). The relative amount of intact peptide is quantified by mass spectrometry (MS).

Proteolytic stability of example polypeptides relative to comparators was performed in simulated gastric fluid (SGF 2g/L NaCl, pH 1.2). The examples were dissolved in 50 mM Tris buffer pH 8.0 at a concentration of 10 mg/mL as a stock solution. Pepsin A was reconstituted in SGF at 10 mg/mL. A reaction was prepared by diluting peptide in SGF and spiking in the Pepsin A to have final concentration of example polypeptide at 0.4 mg/mL and 1 mg/mL of pepsin. The example peptide and pepsin solutions were then incubated at 37 °C in a shaking incubator set at 100 rpm. Samples (25 µL) were withdrawn at different time intervals and quenched with 100 mM ammonium bicarbonate pH 9 (50 µL) to stop proteolytic activity. All samples were centrifuged, and the supernatants were analyzed by LC/MS to determine the remaining intact peptide.

Results are provided in Tables 12-14 below:

Table 12. Stability in 0.1mg/mL pepsin A solution.

Test Article	% Intact (SD)			
	0 min	15 min	30 min	60 min
Cmpd 4	100 (0)	101.9 (8.7)	96.0 (12.1)	107.9 (25.5)
Example 677	100 (0)	90.8 (9.6)	91.3 (3.0)	102.7 (11.1)
Example 685	100 (0)	85.1 (7.6)	95.2 (11.6)	94.6 (6.7)
Example 686	100 (0)	99.2 (18.5)	103.8 (26.2)	103.8 (24.5)
Example 688	100 (0)	97.6 (10.0)	95.6 (6.1)	89.9 (8.8)
Example 694	100 (0)	100.9 (8.6)	101.1 (8.0)	113.4 (6.4)
Example 696	100 (0)	101.9 (9.3)	106.6 (5.8)	116.9 (2.2)
Example 699	100 (0)	121.4 (0.8)	115.6 (7.5)	111.9 (5.3)
Example 711	100 (0)	95.0 (12.3)	91.6 (18.0)	91.9 (13.8)
Example 712	100 (0)	92.4 (7.0)	91.4 (1.3)	93.5 (6.2)
Example 714	100 (0)	99.2 (10.8)	102.5 (10.2)	96.9 (5.5)
Example 718	100 (0)	102.7 (3.9)	101.2(11.1)	112.5(16.9)
Example 733	100 (0)	108.8(10.6)	106.6 (6.9)	129.5(12.8)
Example 741	100 (0)	132.4(49.9)	103.9 (6.6)	105.2 (9.3)
Example 742	100 (0)	100.5(10.1)	112.6 (17.9)	103.3(13.8)
Example 700	100 (0)	89.9 (17.8)	105.5 (7.6)	98.9 (20.3)

Table 13. Stability in 1mg/mL pepsin A solution.

Test Article	% Intact (SD)			
	0 min	15 min	30 min	60 min
Cmpd 4	100 (0)	78.2 (8.7)	50.9 (1.6)	26.2 (0.8)
Example 677	100 (0)	58.3 (6.9)	39.2 (4.7)	15.5 (2.0)
Example 685	100 (0)	59.9 (7.2)	39.7 (1.6)	15.0 (0.8)
Example 686	100 (0)	66.27 (3.7)	37.3 (4.4)	18.1 (6.7)
Example 688	100 (0)	67.9 (3.5)	42.4 (1.6)	17.9 (1.3)
Example 694	100 (0)	87.9 (4.1)	77.8 (1.5)	76.9 (3.1)

Example 696	100 (0)	91.0 (4.5)	91.1 (2.5)	77.6 (5.5)
Example 699	100 (0)	97.9 (4.2)	91.8 (6.2)	83.9 (6.1)
Example 711	100 (0)	98.8 (6.7)	97.2 (6.2)	89.7 (8.6)
Example 712	100 (0)	104.2 (6.2)	103.7 (7.1)	91.6 (5.2)
Example 714	100 (0)	106.5 (18.8)	111.9 (8.1)	79.7 (3)
Example 718	100 (0)	108.6 (5.0)	95.9 (2.2)	80.6 (3.9)
Example 733	100 (0)	97.3 (20.1)	118.9 (17.8)	109.5 (23.3)
Example 741	100 (0)	111.3 (9.4)	100.0 (18.1)	113.7 (14.7)
Example 742	100 (0)	87.5 (5.9)	98.0 (10.1)	101.7 (10.7)
Example 700	100 (0)	95.8 (13.0)	102.5 (30.0)	115.2 (24.7)

Table 14. Stability in 1mg/mL pepsin A solution.

Test Article	% Intact (SD)			
	0 min	15 min	30 min	60 min
Cmpd 4	100 (0)	61.7 (5.2)	70.2 (1.8)	55.9 (7.4)
Semaglutide	100 (0)	0 (0)	0 (0)	0 (0)
Example 403	100 (0)	155.4 (70.4)	143.3 (48.0)	365.6 (353.2)
Example 457	100 (0)	78.8 (6.0)	68.9 (48.0)	60.1 (3.5)
Example 499	100 (0)	117.4 (8.8)	118.1 (3.8)	115.0 (8.5)
Example 500	100 (0)	10.6 (1.2)	1.0 (0.1)	0 (0)
Example 505	100 (0)	91.6 (1.2)	78.9 (1.4)	53.5 (2.2)
Example 1235	100 (0)	1.4 (0.1)	0 (0)	0 (0)

The data in Tables 12-14 support improvements in stability for certain Example polypeptides.

SequencesSEQ ID NO:1 – Human GIP amideYAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ-NH₂5 SEQ ID NO:2 – Human GLP-1 (7-36) amideHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH₂SEQ ID NO:3 – Human glucagon

HSQGTFTSDYSKYLDSRRAQDFVQWLMNT

10

SEQ ID NO:4 – Polypeptide of Formula ISEQ ID NO:5 – Polypeptide of Formula II15 SEQ ID NO:6 – Polypeptide of Formula IIISEQ ID NO:7-1242 – Polypeptides of Examples 1-1236SEQ ID NO:1243 – Polypeptide of Formula I'

20

SEQ ID NO:1244 – Polypeptide of Formula II'SEQ ID NO:1245 – Polypeptide of Formula III'

25

CLAIMS

The invention claimed is:

1. A polypeptide comprising:
- 5 $X_1X_2QX_4TX_6TSDX_{10}X_{11}X_{12}X_{13}LX_{15}X_{16}X_{17}AX_{19}X_{20}X_{21}FX_{23}X_{24}X_{25}LX_{27}X_{28}X_{29}GX_{31}X_{32}$
 $SX_{34}X_{35}PX_{37}PX_{39}X_{40}X_{41}X_{42}X_{43}X_{44}X_{45}X_{46}$,
wherein
 X_1 is Y, NMeY or H,
 X_2 is Aib,
10 X_4 is G or D-Ala,
 X_6 is F, α MeF or α MeF(2F),
 X_{10} is F, 3-Pal, 4-Pal, F(4CN), F(4NO₂) or Y,
 X_{11} is S or α MeS,
 X_{12} is Orn, K, R, Q, Dap, S, E or I,
15 X_{13} is α MeL, I or L,
 X_{15} is D or E,
 X_{16} is K, Orn, A or E,
 X_{17} is any amino acid with a functional group available for conjugation to a fatty
acid, A, I or Q or Orn,
20 X_{19} is A or Q,
 X_{20} is any amino acid with a functional group available for conjugation to a fatty
acid, Aib, Q, R or α Me-4-Pal,
 X_{21} is A, Aad, Aib, S, N, Q, E, T or Orn,
 X_{23} is I or V,
25 X_{24} is any amino acid with a functional group available for conjugation to a fatty
acid E, D-Glu, Q, N or D-Gln,
 X_{25} is W, Y, F, 4-Pal, α MeY or α Me-4-Pal,
 X_{27} is L, I, E, V, A, Aad, T, Q or S,
 X_{28} is any amino acid with a functional group available for conjugation to a fatty
30 acid, E or A,

- X_{29} is G, Aib, T, D-Ala or A,
 X_{31} is P or E,
 X_{32} is S or P
 X_{34} is G or Aib,
5 X_{35} is A, D or E,
 X_{37} is P or E,
 X_{39} is E, S, G, A, T or Orn,
 X_{40} is absent or G, E, S, A or T,
wherein if X_{40} is G, E, S, A, T or D-Glu, then X_{41} is absent or is E, S, D, G, Q, T,
10 A, γ E or D-Glu,
wherein if X_{41} is E, S, D, G, Q, T, A, γ E or D-Glu, then X_{42} is absent or G, E, D-Glu, or γ E,
wherein if X_{42} is G, E, D-Glu or γ E, then X_{43} is absent or E, γ E, or D-Glu,
wherein if X_{43} is E, γ E, or D-Glu, then X_{44} is absent or E,
15 wherein if X_{44} is E then X_{45} is absent or E,
wherein if X_{45} is E then X_{46} is absent or E,
wherein if X_{40} is absent, then X_{41} through X_{46} are also absent,
wherein if X_{41} is absent, then X_{42} , through X_{46} are also absent,
wherein if X_{42} is absent, then X_{43} through X_{46} are also absent,
20 wherein if X_{43} is absent, then X_{44} through X_{46} are also absent,
wherein if X_{44} is absent, then X_{45} and X_{46} are also absent,
wherein if X_{45} is absent then X_{46} is also absent,
wherein the polypeptide comprises at least one of the following: X_6 is α MeF or α MeF(2F); X_{10} is F, 3-Pal, 4-Pal, F(4CN) or F(4NO₂); X_{11} is α MeS; X_{13} is α MeL; X_{24} is D-Glu; and/or X_{25} is α MeY;
25 wherein if X_{10} is F, 3-Pal, 4-Pal, F(4CN), or F(4NO₂), then X_{12} is I,
and wherein at least one of X_{17} , X_{20} , X_{24} or X_{28} is an amino acid with a functional group available for conjugation to a fatty acid,

wherein the C-terminal amino acid is optionally amidated; or a pharmaceutically acceptable salt thereof.

2. The polypeptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein the polypeptide comprises at least two of the following: X₁₀ is F, 3-Pal, 4-Pal, 5 F(4CN) or F(4NO₂); X₁₁ is αMeS; X₁₃ is αMeL; X₁₆ is Orn; X₂₄ is D-Glu; and/or X₂₅ is αMeY.

3. The polypeptide of either of claims 1 or 2, or a pharmaceutically acceptable salt thereof, wherein the polypeptide comprises at least three of the following: X₁₀ is F, 3-Pal, 4-Pal, F(4CN) or F(4NO₂); X₁₁ is αMeS; X₁₃ is αMeL; X₁₆ is Orn; X₂₄ is D-Glu; and/or 10 X₂₅ is αMeY.

4. The polypeptide of any of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein: X₁₀ is F, 3-Pal, 4-Pal, F(4CN) or F(4NO₂).

5. The polypeptide of any of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein: X₁ is Y; X₄ is G; X₆ is αMeF(2F); X₁₀ is 4-Pal; X₁₂ is I; X₁₃ is αMeL; X₁₅ 15 is D; X₁₆ is Orn; X₁₉ is Q; X₂₀ is αMe-4-Pal; X₂₁ is E or Orn; X₂₃ is I; X₂₄ is D-Glu; X₂₅ is αMeY; X₂₇ is I or V; X₂₈ is E; X₂₉ is G; X₃₁ is P; X₃₄ is G; X₃₅ is A or E; X₃₇ is P; X₃₉ is E or S; X₄₀ is G or T; X₄₁ is E, S, or G; and X₄₂ is absent.

6. The polypeptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein: X₁₁ is S, X₂₁ is Orn, X₂₇ is I, X₃₅ is E, X₃₉ is E, X₄₀ is T and X₄₁ is E.

20 7. The polypeptide of any of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein: X₁₁ is αMeS, X₂₁ is E, X₂₇ is V, X₃₅ is A, X₃₉ is S, X₄₀ is G and X₄₁ is S.

8. The polypeptide of any of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein: X₁₁ is αMeS, X₂₁ is E, X₂₇ is I, X₃₅ is A, X₃₉ is S, X₄₀ is G and X₄₁ is S.

9. The polypeptide of any of claims 1-5, or a pharmaceutically acceptable salt 25 thereof, wherein: X₁₁ is αMeS, X₂₁ is E, X₂₇ is I, X₃₅ is A, X₃₉ is S, X₄₀ is G and X₄₁ is G.

10. The polypeptide of any of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein: X_{17} is K and is conjugated to a C_{16} - C_{22} fatty acid via a linker between the amino acid and the C_{16} - C_{22} fatty acid.

11. The polypeptide of claim 10, or a pharmaceutically acceptable salt thereof,
5 wherein the linker comprises one to four amino acids.

12. The polypeptide of claim 11, or a pharmaceutically acceptable salt thereof, wherein the amino acids comprised in the linker are Glu, γ Glu or a combination thereof.

13. The polypeptide of any of claims 10-12, or a pharmaceutically acceptable salt thereof, wherein the linker comprises one to four (2-[2-(2-amino-ethoxy)-ethoxy]-
10 acetyl) moieties.

14. The polypeptide of claim 13, or a pharmaceutically acceptable salt thereof, wherein the linker comprises a structure of $(\gamma\text{Glu})_a$ -(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl) $_b$ -(γGlu) $_c$ -CO-(CH $_2$) $_p$ -CO $_2$ H, wherein a is 0 or 1, b is 0, 1 or 2, c is 1, 2 or 3, and p is an integer between 14 to 20.

15. 15. The polypeptide of claim 14, or a pharmaceutically acceptable salt thereof, wherein a is 0, b is 1 and c is 1.

16. A polypeptide selected from the group consisting of SEQ ID NO's: 294-775, 1146-1240, or a pharmaceutically acceptable salt thereof.

17. A polypeptide comprising a a sequence identity of more than 90% to the
20 polypeptide of any of SEQ ID NO's: 692, 700, 702, 705, 706, 716, 718, 743, 747, 749, 767.

18. The polypeptide of claim 17, or a pharmaceutically acceptable salt thereof, selected from the group consisting of: SEQ ID NO's: 692, 700, 705, 718 and 747.

19. The polypeptide of claim 18 consisting of SEQ ID NO. 692, or a
25 pharmaceutically acceptable salt thereof.

20. The polypeptide of claim 18 consisting of SEQ ID NO. 700, or a pharmaceutically acceptable salt thereof.

21. The polypeptide of claim 18 consisting of SEQ ID NO. 705, or a pharmaceutically acceptable salt thereof.

22. The polypeptide of claim 18 consisting of SEQ ID NO. 718, or a pharmaceutically acceptable salt thereof.

5 23. The polypeptide of claim 18 consisting of SEQ ID NO. 747, or a pharmaceutically acceptable salt thereof.

24. The polypeptide of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein the C-terminal is amidated.

10 25. The polypeptide of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable salt is selected from sodium, potassium, trifluoroacetate, hydrochloride or acetate.

26. The polypeptide of any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein one or more hydrogen atoms are replaced by deuterium.

15 27. The polypeptide of any of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein the polypeptide has greater potency at each of the glucagon, GIP and GLP-1 receptors as compared to native glucagon (SEQ ID NO:3), GIP (SEQ ID NO:1) and GLP-1₇₋₃₆ (SEQ ID NO:2).

20 28. A pharmaceutical composition comprising the polypeptide or a pharmaceutically acceptable salt thereof, of any one of claims 1 to 23 and at least one pharmaceutically acceptable carrier, diluent, or excipient.

29. The pharmaceutical composition of claim 28, wherein the composition is formulated for oral administration.

30. The pharmaceutical composition of claim 28, wherein the composition is formulated for subcutaneous administration.

25 31. A method of treating a disease or condition selected from the group consisting of diabetes mellitus, obesity, chronic weight management, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), dyslipidemia, metabolic

syndrome, chronic kidney disease (CKD), osteoarthritis (OA), obesity-related sleep apnea (OSA) polycystic ovary syndrome (PCOS), Parkinson's disease and Alzheimer's disease, the method comprising a step of: administering to an individual in need thereof an effective amount of a polypeptide, or a pharmaceutically acceptable salt thereof, of any one of claims 5 1 to 23.

32. The polypeptide, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 23 for use in therapy.

33. A polypeptide, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 23 for use in treating a disease or condition selected from the group 10 consisting of diabetes mellitus, obesity, chronic weight management, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), dyslipidemia, metabolic syndrome, chronic kidney disease (CKD), osteoarthritis (OA), obesity-related sleep apnea (OSA) and polycystic ovary syndrome (PCOS).

34. Use of a polypeptide, or a pharmaceutically acceptable salt thereof, as 15 claimed by any one of Claims 1 to 23 in the manufacture of a medicament for treating a disease or condition selected from the group consisting of diabetes mellitus, obesity, chronic weight management, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), dyslipidemia, metabolic syndrome, chronic kidney disease (CKD), osteoarthritis (OA), obesity-related sleep apnea (OSA) and polycystic ovary syndrome 20 (PCOS).